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Abstract 
One promising HIV-1 vaccine target is the membrane-proximal external region 
(MPER) of viral gp41. MPER is poorly immunogenic, however, the two rare neutralizing 
antibodies (NAbs), 2F5 and 4E10, bind to MPER with great neutralizing ability. 
Although their neutralizing mechanism represents a promising framework for the 
design of new HIV-1 liposomal vaccine candidates, this mechanism remains poorly 
understood. It is known that 2F5 and 4E10 are required to first associate with HIV-1 
lipids before binding to the target MPER antigen, however, little is known about how 
lipid membranes contribute to NAb-antigen binding. To this end we have developed 
model membrane systems to study NAb and antigen lipid interactions.  
We first created a surface plasmon resonance (SPR) spectroscopy based assay 
that monitors antibody binding to thiol monolayers that mimic the surface-chemical 
properties of lipid membranes. Next, we focused on recreating the lipid phase 
organization (i.e., domain formation) of native membranes by using supported lipid 
bilayers (SLBs). We used simple SLB compositions to model the liquid-disordered (Ld) 
and gel phases. To create the HIV-1 envelope, we used a complex SLB composition that 
contains an Ld and liquid-ordered (Lo) phase. To reliably create model HIV-1 SLBs, we 
developed an SLB formation technique that uses amphipathic, α-helical peptides as a 
catalyst to generate complex SLBs that have a high cholesterol content and contain 
 v 
multiple lipid types. We used atomic force microscopy (AFM) to visualize membrane 
domains, antigen presentation, and antibody-membrane interactions on all SLB surfaces. 
Results from experiments using thiol monolayers showed that binding of NAb to 
hydrophobic functional groups was significantly greater than that of control monoclonal 
antibodies. This supports the hypothesis that these NAbs embed into the hydrophobic 
membrane core. Our experiments on SLBs demonstrate that 2F5/4E10 do not interact 
with the highly ordered gel and Lo domains in the SLB but exclusively bind to the Ld 
phase. This suggests that 2F5/4E10 require low membrane order and weak lateral lipid-
lipid interactions to insert into the hydrophobic membrane interior. Thus, vaccine 
liposomes that primarily contain an Ld phase are more likely to elicit the production of 
lipid reactive, 2F5- and 4E10-like antibodies, compared to liposomes that contain an Lo or 
gel phase. In the context of liposomal antigen presentation, our results show that the 
presence of the MPER656 antigen can severely limit the Ld area available for antibody 
interactions. Subsequently, this reduces the amount of MPER656 that is accessible for 
2F5/4E10 binding, since MPER656 preferentially localizes to the Ld area. If Ld forming lipid 
components are used in vaccine liposomes, it is important to ensure that the presence of 
antigen does not inhibit large-scale Ld formation.       
 
 
 
 
 vi 
Dedication 
This dissertation is dedicated to my parents for providing the inspiration and 
support to pursue the great moments in life.  
 vii 
Contents 
Abstract ......................................................................................................................................... iv 
List of Tables ................................................................................................................................ xii 
List of Figures ............................................................................................................................ xiii 
List of Abbreviations ................................................................................................................. xix 
Acknowledgements .................................................................................................................... xx 
Chapter 1. Background Information .......................................................................................... 1 
1.1 Introduction ....................................................................................................................... 2 
1.2 Human Immunodeficiency Virus Vaccine Design ...................................................... 3 
1.3 NAb Neutralizing Mechanism ....................................................................................... 5 
1.4 Polyreactivity and Immune Tolerance .......................................................................... 6 
1.5 Membrane Properties Influencing Antibody-Lipid Interactions ............................... 8 
1.6 Membrane Organization and Lipid Domains ............................................................ 10 
1.7 Model Membrane Systems ............................................................................................ 13 
1.8 Biophysical Tools Applied to SLB Research Platform ............................................... 15 
1.8.1 Quartz Crystal Microbalance with Dissipation Monitoring ........................... 15 
1.8.2 Surface Plasmon Resonance ................................................................................ 18 
1.8.3 Atomic Force Microscopy .................................................................................... 19 
1.8.4 Neutron Reflectivity ............................................................................................. 21 
Chapter 2. Screening the Interactions between HIV-1 Neutralizing Antibodies and 
Model Lipid Surfaces .................................................................................................................. 24 
2.1 Introduction ..................................................................................................................... 25 
2.2 Background ..................................................................................................................... 26 
 viii 
2.3 Results and Discussion .................................................................................................. 29 
2.3.1 Antibody Screening on Thiol Surfaces ............................................................... 30 
2.3.2 Antibody Binding on Lipid versus Thiol Model Surfaces .............................. 33 
2.4 Conclusions ..................................................................................................................... 35 
2.5 Materials and Methods .................................................................................................. 37 
2.5.1 Antibodies .............................................................................................................. 37 
2.5.2 Lipid Preparation .................................................................................................. 38 
2.5.3 Model Surface Preparation .................................................................................. 38 
2.5.4 Surface Plasmon Resonance ................................................................................ 39 
Chapter 3. Techniques to Form Complex Biomimetic Supported Lipid Bilayers via 
Vesicle Fusion .............................................................................................................................. 40 
3.1 Introduction ..................................................................................................................... 41 
3.2 Background ..................................................................................................................... 42 
3.3 Mechanism of Vesicle Fusion........................................................................................ 45 
3.4 Experimental Optimization Techniques to Achieve Vesicle Fusion ....................... 47 
3.4.1 Effect of Temperature ........................................................................................... 48 
3.4.2 Effect of pH ............................................................................................................ 50 
3.4.3 Effect of Ionic Strength and Ion Type ................................................................ 53 
3.4.4 Effect of Osmotic Stress ........................................................................................ 56 
3.5 Amphipathic α-Helical (AH) Peptide-Induced Vesicle Fusion ............................... 57 
3.5.1 Mechanism of AH Peptide-Induced Vesicle Fusion ........................................ 60 
3.5.2 SLB Applications of the NS5A-Derived AH Peptide ....................................... 62 
3.6 Creating SLBs on Non-Siliceous Surfaces ................................................................... 64 
 ix 
3.7 Vesicle Fusion Considerations ...................................................................................... 66 
3.8. Conclusions .................................................................................................................... 68 
Chapter 4. Biomimetic Supported Lipid Bilayers with High Cholesterol Content Formed 
by α-Helical Peptide-Induced Vesicle Fusion ......................................................................... 70 
4.1 Introduction ..................................................................................................................... 71 
4.2 Background ..................................................................................................................... 71 
4.3 Results and Discussion .................................................................................................. 74 
4.3.1 AH Peptide-Induced Vesicle Fusion Observed by QCM-D ........................... 74 
4.3.2 SLB Characterization by Neutron Reflectivity.................................................. 79 
4.3.3 AFM Visualization of the Model HIV SLB. ....................................................... 81 
4.4 Conclusions ..................................................................................................................... 86 
4.5 Materials and Methods .................................................................................................. 87 
4.5.1 Vesicle Preparation ............................................................................................... 87 
4.5.2 AH Peptide-Induced Vesicle Fusion .................................................................. 87 
4.5.3 Quartz Crystal Microbalance with Dissipation Monitoring ........................... 88 
4.5.4 Neutron Reflectivity ............................................................................................. 89 
4.5.5 Atomic Force Microscopy .................................................................................... 90 
Chapter 5. HIV-1 Antibodies and Vaccine Antigen Selectively Interact with Lipid 
Domains ....................................................................................................................................... 92 
5.1 Introduction ..................................................................................................................... 93 
5.2 Background ..................................................................................................................... 93 
5.2.1 Domain Formation and 2F5/4E10’s Lipid Reactivity ....................................... 95 
5.2.2 Model Membrane Research Platform ................................................................ 97 
 x 
5.3 Results .............................................................................................................................. 97 
5.3.1 Antibody and Antigen Interactions with Liquid-Disordered SLBs ............... 97 
5.3.2 Antibody/Antigen Interactions with Gel/Liquid-Disordered SLBs ............. 101 
5.3.3 NAb and Antigen Interactions with Complex, HIV-1 Mimetic SLB ........... 104 
5.4 Discussion ...................................................................................................................... 110 
5.4.1 NAb Interactions with SLBs .............................................................................. 110 
5.4.2 Antigen/NAb interactions with SLBs ............................................................... 112 
5.5 Conclusion ..................................................................................................................... 114 
5.6 Materials and Methods ................................................................................................ 115 
5.6.1 Antibodies and Antigen ..................................................................................... 115 
5.6.2 Lipid Preparation ................................................................................................ 115 
5.6.3 Atomic Force Microscopy .................................................................................. 116 
5.6.4 Surface Plasmon Resonance .............................................................................. 117 
Chapter 6. Conclusions and Future Research ....................................................................... 119 
6.1 Conclusions ................................................................................................................... 120 
6.2 Future Research ............................................................................................................ 122 
6.2.1 Application and Characterization of the SLB Model Lipid System ............. 122 
6.2.2 Continued HIV-1 Related Research ................................................................. 124 
Appendix A. Membrane Screening Platforms Fabricated by Dip-Pen Nanolithography
 ..................................................................................................................................................... 128 
A.1 Introduction.................................................................................................................. 129 
A.2 Background .................................................................................................................. 130 
A.3 Results and Discussion ............................................................................................... 135 
 xi 
A.3.1 Optimization of Lipid DPN Parameters ......................................................... 136 
A.3.2 AFM Characterization of Lipid DPN in Air ................................................... 137 
A.3.3 AFM Characterization of Lipid DPN in Liquid ............................................. 141 
A.4 Conclusions .................................................................................................................. 156 
A.5 Materials and Methods ............................................................................................... 157 
Appendix B. Protocols .............................................................................................................. 158 
B.1 AFM Parameters for Imaging Lipids Bilayers ......................................................... 159 
B.2 AFM Fluid Cell and Sample Preparation ................................................................. 160 
B.3 Quartz Crystal Cleaning ............................................................................................. 161 
B.4 Lipid Film and Vesicle Preparation ........................................................................... 162 
References .................................................................................................................................. 164 
Biography ................................................................................................................................... 187 
 
 xii 
List of Tables 
Table 2.1: Panel of screened antibodies and their properties. .............................................. 29 
Table 4.1:2QCM-D data showing mean and SE of Δf and ΔD at the maximum and final 
values for SLB formation from model HIV vesicles (formed by AH peptide-induced 
vesicle fusion) and from POPC vesicles (formed by spontaneous vesicle fusion). ........... 79 
Table 5.1:3Average percent surface coverage of Ld area and NAb binding for all SLBs 
tested (calculated from AFM topographical images). (--) indicates NAb coverage was 
unable to be determined. ......................................................................................................... 100 
 
 
 xiii 
List of Figures 
Figure 1.1: Schematic of the envelope spike of HIV-1 showing the location of 
neutralizing antibody epitopes. gp120 is shown in grey, pale green, and pale blue. gp41 
is shown in pink. Carbohydrate chains are shown in yellow. The approximate epitope 
locations for broadly neutralizing antibodies are indicated. Adapted with permission 
from reference [22]. Copyright (2005) National Academy of Sciences. ................................. 6 
Figure 1.2: Schematic representations of lipid organization. (A) Gel domain (dark green) 
surrounded by Ld phase (light green). (B) Lo domains consisting of sphingomyelin (red) 
and cholesterol (yellow) in an Ld phase (light green). ........................................................... 11 
Figure 1.3: POPC:PSM:CH phase diagram at 37 °C. Circles are experimental points, the 
red triangle indicates the expected location of the model HIV SLB composition. Adapted 
with permission from reference [53]. Copyright (2003) Biophysical Journal. .................... 13 
Figure 1.4: Schematic of a 11-mercaptoundecanoic acid (MUA) thiol SAM on a gold 
coated SPR sensor chip. .............................................................................................................. 14 
Figure 1.5: Schematic of a supported lipid bilayer (SLB) interacting with protein. SLB is 
submerged in liquid (not shown). ............................................................................................ 15 
Figure 1.6: QCM-D frequency (solid line) and dissipation (dashed line) response plotted 
as a function of time for SLB formation from pure POPC vesicles via vesicle fusion. (*) 
indicates the critical concentration of vesicle surface coverage (θc). ................................... 17 
Figure 1.7: Schematic of AFM cantilever scanning SLB surface. For clarity, the fluid cell 
is omitted. SLB is a 3D rendering of POPC:POPE (1:1) resulting in taller, gel domains in 
a lower, Ld phase. ........................................................................................................................ 20 
Figure 1.8: AFM height image of SLB domains consisting of POPC:POPE (1:1). The taller 
(brighter) domain consists mainly of POPE in the gel phase. The lower (darker) domain 
consists mainly of POPC in the liquid-disordered phase. A 700 nm cross-section at the 
interface of the two domains (white line on image) reveals a height different of about 6 
Å. ................................................................................................................................................... 21 
Figure 2.1: Model thiol SPR system. (A) Typical membrane phospholipids, except for 
cardiolipin. Cardiolipin is most often found in the mitochondria of cells, however, NAbs 
have been shown to bind cardiolipin. For simplicity, the acyl chain for all lipids is shown 
saturated with an abbreviated chain length. (B) ω-substituted alkane thiols used to 
mimic membrane phospholipids. At pH 7.4 thiol monolayers were negatively charged 
 xiv 
MUA, positively charged AUT, polar MUD, and nonpolar ODT. (C) Schematic of MUA 
surface on a gold coated SPR sensor chip................................................................................ 28 
Figure 2.2:  Antibody-thiol SPR binding curves. (A-C) Representative SPR response 
curves for 4E10, 2F5, and 13H11 to model surfaces. .............................................................. 32 
Figure 2.3: Mean RU value from each antibody grouped for each of the four thiols used 
(n=3). * Signifies statistically significant (p<0.05) when compared to 4E10. † Signifies 
statistically significant (p<0.05) when compared to 2F5. The negative amount of bound 
antibody is due to RU levels below 13H11 background, which was attributed to 
nonspecific interactions and subtracted from all RU values. ............................................... 33 
Figure 2.4: 4E10, 2F5, IS1, and IS4 binding on standard lipid surfaces versus thiol model 
surfaces. (A) Representative SPR response curves for antibodies on negative POPS. (B) 
Representative SPR response curves for antibodies on negative MUA. (C) Kinetic 
properties of antibodies binding on lipid (POPS) and thiol (MUA) model surfaces. 
Analysis for 2F5 was not performed due to below background binding. .......................... 35 
Figure 3.1: Stages of SLB formation: (A) adhesion, (B) crowding, (C-E) rupture and 
spreading of bilayer patches that can expose either leaflet by mechanism 1 or 2, (F, G) 
coalescence of high energy edges and release of water/excess lipid, and (H) completed 
SLB. Additional vesicle adsorption to the SLB is typically weak and does not lead to 
their rupture or spreading. Experimental conditions and techniques that generally have 
the most pronounce effect on respective stages of SLB formation are listed to the right of 
the figure. Substrate type and chemical surface modifications are omitted from 
classification since these conditions generally affect the entire SLB formation process. 
Adapted with permission from reference [112]. Copyright (2009) American Chemical 
Society. .......................................................................................................................................... 46 
Figure 3.2: Vesicle fusion phase diagrams for egg PC vesicles containing: (A) 1 mol% of 
negatively charged lipid probe and (B) 1 mol% of positively charged membrane probe. 
Regions of vesicle instability and incomplete SLB formation are indicated by the 
crosshatched area in (A). The regions with vertical stripes in the lower right corner of 
both diagrams indicate conditions where buffer formation was not possible. Reprinted 
with permission from reference [123]. Copyright (1999) American Chemical Society. .... 56 
Figure 3.3: Membrane activity of the NS5A amphipathic α-helix (AH) peptide. (A) 
Potential mechanism of AH-peptide induced vesicle fusion on gold. (B) Expected 
positioning of the average structure of amphipathic α-helix membrane anchor domain of 
NS5A (PDB entry 1R7E) at the interface between phospholipid polar head groups and 
hydrophobic tails. The phospholipid bilayer was drawn using the 
 xv 
phosphatidylethanolamine (PE) models reported in the Protein Data Bank entry 1BCC. 
Molecules are colored according to atom types (N, blue; O, red; P, yellow; C, H, gray). 
(C) Top view of AH peptide embedded in a model phospholipid membrane. Adapted 
with permission from reference [136] and [137]. Copyright (2009 and 2004) from the 
American Chemical Society and The American Society for Biochemistry and Molecular 
Biology, respectively. .................................................................................................................. 60 
Figure 4.1: Chemical structures of membrane components used in this study. Biomimetic 
HIV-1 SLBs were formed from vesicles containing a lipid composition of 
POPC:POPE:POPS:SM:CH (9.35 : 19.25 : 8.25 : 18.15 : 45.00).[60] Reproduced by 
permission of The Royal Society of Chemistry. ...................................................................... 73 
Figure 4.2: Representative QCM-D plots. Energy dissipation (dashed) and third overtone 
frequency (solid) plotted versus time. (A) SLB formation of 100% POPC by spontaneous 
vesicle fusion. (B) Failure of model HIV vesicles to undergo spontaneous vesicle fusion. 
(C) Successful model HIV SLB formation by AH peptide-induced vesicle fusion. (D) AH 
peptides create a SLB from a partially formed bilayer amongst un-fused vesicles.[60] 
Reproduced by permission of The Royal Society of Chemistry. .......................................... 76 
Figure 4.3: Neutron reflectivity curves, best-fits, and best-fit nSLD profiles for the 
measurements of the model HIV SLB. Inset: Best-fit nSLD profiles of reflectivity 
curves.[60] Reproduced by permission of The Royal Society of Chemistry. ..................... 81 
Figure 4.4: AFM height image of model HIV SLB on mica (imaged in buffer, 18° C, ± 1.6 
nm height scale). (A) 1.8 x 1.6 µm image showing SLB topography before AH peptides 
were washed from the surface. Height cross-section was taken along the three domains 
indicated by the position of the dashed line. The three domains labeled in the height 
cross-section correspond to the numbers labeled on the AFM height image. (B) 1.8 x 1.6 
µm image showing SLB topography after AH peptides were washed from the surface. 
(C) Height image demonstrating a complete, defect free SLB over a larger, 8 x 8 µm, 
area.[60] Reproduced by permission of The Royal Society of Chemistry. .......................... 85 
Figure 5.1: Schematic representations of NAbs, antigen, and lipid organization in SLBs. 
(A) Proposed SLB environment interacting with NAbs (green) and MPER656 (yellow). 
NAbs and MPER656 only interact with the Ld phase (blue) and avoid Lo and gel 
domains (represented collectively in red). (B) Lipid organization expected from the 
POPC:POPE SLB. Gel domain (dark green) surrounded by Ld phase (light green). (C) 
Lipid organization expected from the model HIV SLB. Lo domains consisting of 
sphingomyelin (red) and cholesterol (yellow) in a Ld phase (light green). ....................... 96 
 xvi 
Figure 5.2: AFM height images of the POPC and POPC:MPER656 SLBs with and without 
antibody addition (imaged in liquid at 24 °C). Height cross-section given for select 
images. (A) POPC SLB. (B-D) 2F5, 4E10 and 13H11 added to the POPC SLB, respectively. 
(E) POPC:MPER656 SLB. (F-H) 2F5, 4E10, and 13H11 added to the POPC:MPER656 SLB, 
respectively. ............................................................................................................................... 101 
Figure 5.3: AFM height images of the POPC:POPE and POPC:POPE:MPER656 SLBs with 
and without antibody addition (imaged in liquid at 18-20 °C). Height cross-section given 
for select images. (A) POPC:POPE SLB. The bright area is the taller, gel domain, while 
the darker area is the lower, Ld phase. (B-D) 2F5, 4E10, and 13H11 added to the 
POPC:POPE SLB, respectively. (E) POPC:POPE:MPER656 SLB. Inset: 250 x 250 nm height 
image from a replicate sample showing MPER656 in the Ld phase. (F) 2F5 added to the 
POPC:POPE:MPER656 SLB. Inset: 250 x 250 nm image from a replicate sample (G) Image 
(F) with a second addition of 2F5 (4.0 µM). (H,I) Repeated conditions from image (F,G) 
with 4E10. (M) 13H11 added to POPC:POPE:MPER656 SLB. ............................................... 104 
Figure 5.4: AFM height images of the model HIV and model HIV:MPER656 SLB with and 
without antibody addition. Height cross-section of SLBs given below select images. 
(A,B) Model HIV SLB imaged at 18 °C and 37 °C, respectively. (C,D) 2F5 added to the 
model HIV SLB at 18 °C and 37 °C, respectively. (E,H) 4E10 and 13H11 added to the 
model HIV SLB at 37 °C, respectively (G) Model HIV:MPER656 SLB at 37 °C. (H-J) 2F5, 
4E10, and 13H11 added to the model HIV SLB:MPER656, respectively (at 37 °C). ........... 108 
Figure 5.5: Surface plasmon resonance (SPR) curves of NAbs and 13H11 interacting with 
POPC and model-HIV membranes (with and without MPER656). Antibodies added at 0 
sec and washed from surface at 120 sec (resulting in response spike). (A-C) Antibodies 
interacting with POPC:MPER656 (solid line) and POPC (dashed line) membranes. (D-F) 
Antibodies interacting with model HIV:MPER656 (solid line) and model HIV (dashed 
line) membranes. ....................................................................................................................... 109 
Figure A.1: Conventional dip-pen nanolithography. An AFM cantilever tip is coated 
with molecules in solution. As the tip travels across a substrate molecules are deposited 
through the fluid meniscus. Adapted with permission from reference [221]. Copyright 
(1999) Science. ............................................................................................................................ 131 
Figure A.2: Images of lipid stack structures in air with 20 mol % admixing of DNP Cap 
PE to DOPC as carrier ink obtained by AFM, FM, and SEEC microscopy (left to right, 
respectively). Scale bars = 20 µm. Adapted with permission from reference [233]. 
Copyright (2011) American Chemical Society. ..................................................................... 134 
 xvii 
Figure A.3: Structural model for lipid membrane stacking. The three-layer membrane 
stack consists of a single monolayer as wetting layer and two bilayers. Adapted with 
permission from reference [233]. Copyright (2011) American Chemical Society. ........... 134 
Figure A.4: Lipid ink well (lower half of image) and dip pen nanolithography cantilever 
array (upper half of image). ..................................................................................................... 136 
Figure A.5: AFM height images of lipid DPN islands in air. DOPC:SM:CH (51.75 : 18.25 : 
30.00) written at 60% humidity. .............................................................................................. 138 
Figure A.6: AFM height image showing the height elevation on outer edge of DPN 
islands and patches of elevated lipids within the interior of DPN island. Height cross-
section given below the image. ............................................................................................... 139 
Figure A.7: AFM height (A,B,D) and phase images (C,E), in air of lipid DPN islands 
demonstrating the halo effect. ................................................................................................. 140 
Figure A.8: AFM height images of DPN islands consisting of 30, 5, and 0 molar % of 
cholesterol (A,B, and C respectively). As the molar ratio of cholesterol increases, the lipid 
ink transfer from tip to the substrate decreases. All lipid compositions were written at 
60% humidity, on glass. ........................................................................................................... 141 
Figure A.9: (A,B) AFM height images from a fresh tip, imaging fresh glass in buffer 
(tapping mode). (C,D) AFM height images from a heavily used tip, imaging fresh glass 
in buffer (tapping mode). ......................................................................................................... 143 
Figure A.10: Fluorescent images of lipid DPN islands, DOPC:SM:CH (63.50 : 18.25 : 
18.25) with Rho-PE dye, taken at 63 x in liquid. The red arrows indicated islands that 
have been imaged by AFM tapping mode which results in lipid smearing. Lipids are 
transferred from the main DPN island to the surrounding glass substrate by the AFM 
tip................................................................................................................................................. 144 
Figure A.11: (A) AFM height images showing regular arrangement of dimples on DPN 
island surfaces (DOPC:DOPE 1:1). (B) Height image of dimples after introduction and 
wash of AH fusion peptide. ..................................................................................................... 145 
Figure A.12: AFM height image of lipid DPN islands in buffer. DOPC:SM:CH (51.75 : 
18.25 : 30.00), 60% writing humidity.  Before and after images of AH fusion peptide 
addition from the zoomed in region from B. The corresponding height profiles are given 
below the height images. DOPC:SM:CH (51.75 : 18.25 : 30.00) .......................................... 147 
 xviii 
Figure A.13: AFM height images before (A) and after (B) introduction of AH fusion 
peptide. ....................................................................................................................................... 148 
Figure A.14: (A-D) AFM height image of DPN islands in liquid after addition of AH 
fusion peptide, DOPC:SM:CH (51.75 : 18.25 : 30.00). ........................................................... 149 
Figure A.15: AFM height images of lipid DPN islands in liquid. Height cross-section 
given below image. ................................................................................................................... 150 
Figure A.16: (A) AFM height image, and (B) phase image of lipid DPN islands that have 
been blocked with 5% bovine serum albumin (BSA). .......................................................... 151 
Figure A.17: AFM height images showing the result of AH fusion addition (A to B) and 
antibody, 4E10, addition. (C) one dose of 4E10 (0.3 mg/mL), and (D) after  three doses of 
4E10 (0.3 mg/mL). Each scan is about 15 minutes apart. Scan takes 8:30 minutes to 
complete, with about 7 minutes for the addition of antibody, incubation, and AFM setup 
to scan again.  DOPC:SM:CH (51.75 : 18.25 : 30.00), written at 70% humidity................. 153 
Figure A.18: Height image of the interior of DPN island before and after addition of 
antibody 4E10. Topography comparison of SLB created from vesicle fusion (left image) 
with lipid island created from DPN (Right image). Both techniques used a lipid 
composition of DOPC:SM:CH (63.50 : 18.25 : 18.25). Antibody was added in four dosages 
of 0.6 mg/mL each. The difference in color of the taller patches between the before and 
after image is due to a decreased set point (harder tapping force) when the “after” image 
was taken. ................................................................................................................................... 154 
 
 xix 
List of Abbreviations   
POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
POPE 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine 
POPS 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine 
ODT 1-octadecanethiol 
MUD 11-mercapto-1-undecanol     
AUT 11-amino-1-undecanethiol 
MUA 11-mercaptoundecanoic acid 
AFM Atomic force microscopy 
AH Alpha-helical 
BCD Bubble collapse deposition 
CDR Complementary determining region  
CH Cholesterol  
θc Critical concentration of vesicle surface coverage 
∆D Damping oscillation change 
DPN Dip-pen nanolithography 
HIV Human immunodeficiency virus 
Ld Liquid-disordered  
Lo Liquid-ordered 
Rmax Maximum SPR binding capacity  
MPER Membrane-proximal external-region 
mAb Monoclonal antibody 
NAb Neutralizing antibody 
NR Neutron reflectivity 
PBS Phosphate buffered saline 
QCM-D Quartz crystal microbalance with dissipation monitoring 
∆f Resonance frequency change 
nSLD Scattering length density  
SAM Self-assembled monolayer 
SM Sphingomyelin (brain) 
SLB Supported lipid bilayer 
SPR Surface plasmon resonance 
Tm Transition temperature (melting) 
 xx 
Acknowledgements 
I would like to acknowledge and thank my advisor, Professor Stefan Zauscher 
for being an exceptional mentor. He has provided invaluable insight, guidance, and 
patience at all the right moments.  For their steady support and expertise, I am thankful 
for my committee members: Professors Munir Alam, Thomas McIntosh, Joe Shapter, and 
Piotr Marszalek. Thank you to Dr. Dr. Michael Hirtz for hosting my research in 
Karlsruhe and for sharing his nano-fabrication expertise. I am especially grateful to 
Professor Joe Shapter for hosting my apprenticeship in his lab. This experience was one 
of the highlights of my graduate career and provided me with the research skills that 
would prove to be the foundation of my dissertation.   
There are many other people that have helped me arrive at the completion of my 
PhD and enriched the experience along the way. Thank you to Elizabeth Hanlon, Tim 
Hanlon, Trisha Boulware, Aditee Kurane, Rahul Nayak, Kara Anasti, Jaclyn Lautz, R.P. 
Czekay, Robert Gerszten, Carla Sturdivant, Kathy Parrish, Aven Garms, Mathew Lee, 
Robert Ferris, the entire Zauscher Lab, Chad Gibbs, Elise Corwin, Monty Reichert, Tyler 
Thornton, and my parents, Tom and Teresa Hardy.   
Finally, I would like to acknowledge financial and training support from the 
Center for Biomolecular and Tissue Engineering (CBTE) and the Structural Biology and 
Biophysics (SBB) program (Duke University), grant funding from the National Institutes 
of Health (NIH) and the Duke University Center for AIDS Research (CFAR), and visiting 
 xxi 
scholarship funding from the East Asia and Pacific Summer Institutes program, 
Australian Academy of Science, Burroughs Wellcome Fund, and the Karlsruhe House of 
Young Scientists (Karlsruhe Institute of Technology).  
     
  
 1 
Chapter 1. Background Information  
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1.1 Introduction 
This dissertation is focused on studying protein-membrane interactions in the 
context of HIV-1 vaccine designs. Model membrane systems that reflect the native HIV-1 
lipid envelope will be used to study protein-membrane interactions using HIV-1 
neutralizing antibodies (2F5 and 4E10) and recombinant HIV-1 vaccine antigen 
(MPER656).   
Chapter 1 presents background information on the mechanism of 2F5/4E10 HIV-
1 neutralizing antibodies (including lipid membrane contributions), model lipid 
systems, and the major biophysical tools utilized in this research. Chapter 2 presents a 
surface plasmon resonance (SPR) spectroscopy based assay that monitors antibody 
binding to thiol monolayers, which mimic chemical properties of lipid membranes. 
While thiol monolayers have the advantage of easily modeling the chemistry of common 
lipid head groups, they fail to capture the dynamic lipid mobility and complex lipid 
organization found in native membranes. Thus, Chapter 3 introduces techniques to 
model this complex lipid environment using supported lipid bilayers (SLBs).  
For simple, binary or tertiary lipid compositions, there are many established SLB 
formation methods. However, to form SLBs that contain a more complex, biomimetic 
lipid composition (i.e., many lipid types with high cholesterol content) there are 
obstacles for SLB formation for which there are few reliable solutions. Chapter 4 
addresses this problem by presenting a novel technique to easily and reliably overcome 
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obstacles for creating complex SLBs that more accurately mimic the native HIV-1 lipid 
envelope. Chapter 5 describes how this SLB research platform is used to visualize 
membrane domains, antigen presentation, and antibody-membrane interactions. Taken 
together, the results provide progress towards the development of model membrane 
research platforms and important information for HIV-1 vaccine design, specifically for 
the design of liposomes that attempt to optimize antigen presentation and elicit 
membrane dependent neutralizing antibodies. Chapter 6 summarizes major conclusions 
and outlines future work that builds off these results to help further shape next-
generation vaccine designs.  Finally, Appendix A presents progress towards a 
membrane screening platform fabricated by dip-pen nanolithography and Appendix B 
contains detailed protocols essential to this research.  
 
1.2 Human Immunodeficiency Virus Vaccine Design 
Induction of broadly neutralizing antibodies against HIV-1 remains an 
unprecedented challenge.[1, 2] One promising vaccine target is the membrane-proximal 
external region (MPER) of viral gp41, which is a highly conserved region across diverse 
HIV-1 strains. When bound by an antibody, its transient epitopes effectively prevent 
viral fusion with the host cell membrane.[3] Nevertheless, MPER is poorly immunogenic 
due to its transient structure and poor sterics, limiting accessibility for immune 
recognition. In part, these limitations help explain why membrane-proximal neutralizing 
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antibodies (NAbs) have only rarely been isolated during natural HIV-1 infection.[4] Two 
such NAbs that bind to MPER with great strain breadth and neutralizing ability are 2F5 
and 4E10. Their neutralizing mechanism represents a promising framework for the 
design of new HIV-1 liposomal vaccine candidates, yet this mechanism is only poorly 
understood.  
Although antigens embedded in liposomes facilitate high affinity interactions 
that are selective for NAbs, it was shown that it is not sufficient to simply induce 
antibodies that bind MPER antigens to achieve neutralization.[5-7] In order to mimic 
2F5/4E10’s neutralizing ability, immunogens must elicit antibodies that also react with 
the HIV-1 lipid envelope. However, these gp41 MPER polyreactive antibodies are likely 
subjected to immunological tolerance[8, 9] and are thus rarely induced by either 
infection or immunization. Nevertheless, some level of polyreactivity can be tolerated 
and can even confer an advantage in binding of certain pathogens.[10-12] In fact, high 
affinity gp140 antibodies from HIV-1 are more frequently polyreactive[13, 14] and such a 
trait is observed in the case of both neutralizing and non-neutralizing gp41 
antibodies.[15] Thus, a certain level of polyreactivity may be permissible for several 
HIV-1 NAbs and developing a SLB research platform for studying the nature of these 
interactions is critical for understanding the human antibody responses against HIV-1. 
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1.3 NAb Neutralizing Mechanism 
In vitro studies have shown that 2F5 and 4E10 successfully inhibit the fusion 
process of HIV-1 by binding the MPER of gp41 during a two-stage mechanism: the 
NAbs first interact nonspecifically with the viral lipid membrane and then with the 
target MPER antigen.[16, 17] One explanation for this two-stage interaction is that NAb-
membrane interactions likely direct high NAb concentrations toward the viral surface, 
where the NAb’s ability to diffuse within the viral membrane could better position it to 
encounter and extract its sparse MPER epitope from within the lipid bilayer.[18] Figure 
1.1 shows the location of 2F5 and 4E10’s MPER epitope relative to the viral envelope and 
other broadly neutralizing antibodies. Besides binding kinetics, there is very little 
experimental evidence detailing this lipid reactivity in HIV-1 neutralization. The recent 
literature on 2F5/4E10-membrane reactivity simply states that reactivity exists, and that 
neutralization is dependent on membrane reactive CDR H3 loops.[19] Mechanistic 
details of how membrane properties influence NAb-lipid and NAb-antigen interactions 
remain unknown.  
This unexpected interaction between lipids and 2F5/4E10 is potentially mediated 
by their long complementary determining region (CDR) H3 loop.[20] CDR H3 contains 
unusually large numbers of hydrophobic and membrane-reactive residues that can 
embed in the viral membrane.[18, 21] CDR H3 regions mediate a reversible attachment 
to the viral membrane; which is a required first step for neutralization.[19] This 
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phenomenon may explain why simple peptide immunogens that mimic neutralizing 
epitopes on gp41 do not elicit NAbs in vivo,[5-7] and it is clear that gp41 MPER is not the 
sole determinant of neutralizing ability.[19] In order to mimic 2F5 and 4E10’s in vitro 
neutralizing ability, in vivo immunogens must elicit antibodies that also react with the 
HIV-1 lipid envelope. How to design immunogens to do this remains largely 
unknown.[7] 
  
 
Figure 1.1: Schematic of the envelope spike of HIV-1 showing the location of 
neutralizing antibody epitopes. gp120 is shown in grey, pale green, and pale blue. gp41 
is shown in pink. Carbohydrate chains are shown in yellow. The approximate epitope 
locations for broadly neutralizing antibodies are indicated. Adapted with permission 
from reference [22]. Copyright (2005) National Academy of Sciences. 
 
1.4 Polyreactivity and Immune Tolerance 
There is much evidence indicating that B cells that express self-reactive receptors 
are subjected to negative selection[23], which results in significant purging of 
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polyreactivity in the mature B cell population.[24] However, a predominant population 
(~70%) of memory B cells against HIV-1 gp120 and gp41 are polyreactive.[12, 13, 17, 25, 
26] This suggests that polyreactivity is conserved despite negative selection mechanisms. 
Furthermore, the detection of such polyreactive responses in both elite controllers and 
clade A non-controllers suggested that this is a general phenomenon associated with 
human antibody responses to HIV-1 envelope[13] and that not all polyreactive B cells 
are subjected to tolerance. The enhancement of binding avidity due to heteroligation is 
one plausible explanation for the positive selection of such polyreactive B cells.[12] 
Several, more recently described antibodies have acquired ability to interact with 
glycans, a self-antigen, in addition to HIV-1 epitopes on gp120, V1V2.[10, 11, 27] 
Together these results suggest that the evolution of the above polyreactive antibodies 
involved a fine-tuning of self-reactivity below a threshold level that is permissible. Thus, 
small subsets of mature naïve B-cells (between 5-20%) are capable of escaping immune 
tolerance while maintaining poly or self-reactivity[28, 29] and B cells can also re-acquire 
poly or self-reactivity during the germinal center reaction.[30]   
In the case of gp41 MPER monoclonal antibodies, results from 2F5 knock-in mice 
suggested that HIV-1 MPER antigen reactivity was under more stringent tolerance 
control than lipid reactivity per se.[9, 24] Furthermore, the unmutated ancestor (putative 
germline) of 2F5 binds more strongly to lipids than the mature 2F5 mAb,[31] and thus 
suggests that lipid reactivity might be fine-tuned and antigen affinity enhanced during 
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antibody maturation. A corollary to the above is that lipid binding per se is not totally 
prohibitive and in the mature antibody both self and antigen reactivity may be 
conserved. The polyreactive trait is also not limited to NAb and non-neutralizing gp41 
antibodies that show substantial binding to lipids and protein autoantigens.[15] In fact, 
humans do naturally produce antibodies that can bind to many lipid types, including 
phospholipids[32, 33], cholesterol[34, 35] and squalene.[36] Furthermore, during phase 1 
clinical trials, passive administration of 2F5/4E10 to HIV-1 patients resulted in no 
deleterious autoimmune response, indicating that pathogenicity is not a concern for 
induction of such antibodies.[37-39] However, how to design immunogens and 
adjuvants that allow targeting of B cells that can make antibodies that bind to both gp41 
MPER and lipids is not sufficiently understood.      
  
1.5 Membrane Properties Influencing Antibody-Lipid Interactions 
Understanding membrane properties that influence antibody-lipid interactions 
are essential to the design of next-generation HIV-1 vaccines. For example, lipid 
compositions conducive to eliciting NAbs can be selected for the assembly of vaccine 
liposomes. Liposomes are currently a common vehicle for delivering vaccine packages, 
consisting of antigens, immunogenic lipids, and adjuvants. When designing liposomal 
vaccines, immunologists are largely focused on antigen sequence, the presented 
conformation of the membrane integrated antigen, and the adjuvant used to initiate the 
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body’s immune response. Given the importance of 2F5/4E10’s lipid reactivity, we argue 
that the lipid composition of the liposome must not be overlooked and is an essential 
component of the vaccine package that can influence B cell receptor recognition (and 
thus dictate antibody production). It is clear that lipid composition affects the liposomal 
membrane properties, and membrane properties directly influence antibody 
interactions. Thus, by studying how membrane properties contribute to lipid-antibody 
interactions, we will identify lipid compositions that will elicit favorable antibody-lipid 
interactions.  
To determine the driving factors dictating adsorption of antibodies to the HIV-1 
envelope, it is necessary to understand common forces governing protein adsorption. 
The adsorption of soluble proteins onto the surface of lipid membranes is often driven 
by hydrophobic interactions. Proteins interacting with a solid hydrophobic surface in 
solution (i.e., gold) are known to adsorb to the surface by re-folding to position their 
hydrophobic core to contact the hydrophobic surface. This adsorption is driven by an 
effort to minimize entropic energy. Protein adsorption onto lipid bilayers can also be 
driven by the same hydrophobic effect. Hydrophobic regions of a protein may insert 
into the hydrophobic core of the lipid bilayer to achieve a more favorable entropic 
organization in its solvent. Thus, it is hypothesized that 2F5/4E10’s CDR H3 
hydrophobic loop may insert into the hydrophobic core of the bilayer. 
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1.6 Membrane Organization and Lipid Domains 
Currently it is believed that membranes, including the HIV-1 envelope, organize 
into distinct lipid regions or domains (Fig. 1.2), and that these lipid regions might act as 
binding sites for neutralizing antibody interactions and control antigen presentation in 
vaccine liposomes. The HIV-1 envelope contains a lipid composition that differs from 
that of host cell membranes[40] as HIV-1 acquires its membrane envelope by budding 
from isolated islands of membrane lipids enriched in cholesterol and sphingomyelin. 
Thus, major differences include elevated levels of cholesterol and sphingomyelin in 
addition to anionic lipids,[41] all of which have been shown to contribute to 
heterogeneous lipid domain formation.[42-45] Cholesterol’s preference for saturated 
lipid tails drives this phase separation. These membrane domains are characterized by 
distinct lipid/lipid interactions and packaging from the surrounding medium. As a 
result, these membrane domains also have different physico-chemical properties, such 
as fluidity, thickness, and head-group chemistry, which could be exploited by an 
immune response in order to generate lipid-reactive, broadly neutralizing antibodies to 
HIV-1. It is likely that lipid domains drive protein-membrane interactions and control 
conformations of transmembrane and membrane associated peptides.[46] Yet, the size, 
physical properties, and dynamics of such lipid domains are poorly characterized for the 
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HIV-1 lipid envelope, and it is still unknown how lipid domains contribute to NAb-
membrane interactions and antigen presentation.  
Due to packing characteristics of phospholipids, two main domain types form: (i) 
liquid-disordered (Ld), and (ii) gel domains (Fig. 1.2A). The transition temperature (Tm) 
(i.e., melting temperature) of the lipid will determine at what temperature the lipid will 
melt from the gel to the Ld domain. Furthermore, cholesterol and sphingolipids have a 
tendency to self-associate within the Ld domain and to phase separate into highly 
ordered, tightly packed islands, known as liquid ordered (Lo) domains or lipid rafts (Fig. 
1.2B).[47, 48] Cholesterol’s strong interaction with sphingomyelin is believed to result 
from cholesterol’s ability to interact along the entire length of sphingomyelin’s saturated 
acyl chains.[49] 
 
 
Figure 1.2: Schematic representations of lipid organization. (A) Gel domain (dark green) 
surrounded by Ld phase (light green). (B) Lo domains consisting of sphingomyelin (red) 
and cholesterol (yellow) in an Ld phase (light green).  
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The lipid diffusivity between the Lo and Ld phase differs by a factor of 2-10, 
depending on experimental details/systems.[50-52] Such diffusivity differences are 
important because the ability of NAbs to insert into the lipid bilayer may be related to 
lipid diffusivity in the domains. It is hypothesized that areas of high lipid diffusivity are 
easier to penetrate then areas of low lipid diffusivity, which will have stronger lateral 
lipid-lipid interactions and thus, be more difficult for antibodies to overcome the 
activation energy required to penetrate into the hydrophobic core. How these areas of 
different diffusivities dictate antibody-membrane interactions remains to be explored.   
Given the presence of high concentrations of cholesterol and sphingomyelin in 
the HIV-1 membrane, it is likely that lipid domains/rafts populate the membrane 
surface. We modeled the native HIV-1 lipid envelope with a lipid composition of 
POPC:POPE:POPS:sphingomyelin:cholesterol  (9.35 : 19.25 : 8.25 : 18.15 : 45.00) and 
observed phase separated bilayers at 37 °C (Chapter 4), that contained Lo domains 
within an Ld phase. The observed domain formation in the model HIV-1 membrane 
agrees with the phase diagram of POPC, PSM, and cholesterol at 37 °C (Fig. 1.3).[53] The 
expected location of the model HIV-1 SLB within the phase diagram is indicated by the 
red triangle.  
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Figure 1.3: POPC:PSM:CH phase diagram at 37 °C. Circles are experimental points, the 
red triangle indicates the expected location of the model HIV SLB composition. Adapted 
with permission from reference [53]. Copyright (2003) Biophysical Journal.  
 
1.7 Model Membrane Systems 
We first use simple, self-assembled thiol monolayers (SAMs), whose head groups 
mimic the chemistry of viral and host membrane lipids, to characterize and better 
understand antibody-lipid interactions. Antibody screening was performed by 
anchoring the self-assembled thiol monolayers on custom surface plasmon resonance 
(SPR) sensor chips (Fig. 1.4). Our thiol monolayers exhibited a range of chemical 
functionalities (i.e., variations in hydrophobicity and surface charge) that also occur in 
the phospholipid head-groups of both the native host CD4+ cells and the HIV-1 virion. 
The details and results from this screening platform are presented in Chapter 2.  
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Figure 1.4: Schematic of a 11-mercaptoundecanoic acid (MUA) thiol SAM on a gold 
coated SPR sensor chip.    
 
While thiol SAMs on gold allow the use of SPR to characterize NAb-SAM 
interactions, they fail to capture the fluidity and complex lipid organization found in 
native membranes. Thus, we have expanded our model membrane platform to include 
supported lipid bilayers (SLBs). Briefly, SLBs contain a single lipid bilayer supported on 
a substrate, with a thin (1-2 nm) hydration layer between the bilayer and the substrate 
surface (Fig. 1.5). Although the SLB is stable and confined in two dimensions to the 
substrate surface, it can recapitulate the lateral lipid diffusivity and lipid organization of 
native cell membranes. Furthermore, the planar orientation of SLBs allows the use of 
many quantitative surface characterization techniques that are able to provide unique 
insights into membrane functions and protein-membrane interactions. Details of SLB 
formation techniques are discussed in Chapter 3, while Chapter 4 presents a novel SLB 
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formation technique to reliably create SLBs that more accurately mimic native 
membrane compositions.  
 
 
Figure 1.5: Schematic of a supported lipid bilayer (SLB) interacting with protein. SLB is 
submerged in liquid (not shown). 
 
1.8 Biophysical Tools Applied to SLB Research Platform 
While SLBs lend themselves to study by a number of biophysical tools, in the 
research discussed here we will largely utilize the following: (i) quartz crystal 
microbalance with dissipation monitoring (QCM-D), (ii) surface plasmon resonance 
(SPR), (iii) atomic force microscopy (AFM), and (iv) neutron reflectivity (NR).  
 
1.8.1 Quartz Crystal Microbalance with Dissipation Monitoring  
Quartz Crystal Microbalance with Dissipation Monitoring (QCM-D) measures, in 
real-time, mass adsorbed and desorbed from a substrate by monitoring the resonance 
frequency change (∆f) of an oscillating quartz crystal. In the limit of thin, elastic layers, 
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the relationship between a quartz crystal’s resonance frequency change and the mass of 
the adlayer is linear, and described by the Sauerbrey equation.[54] Viscoelasticity of the 
adlayer can also be detected by monitoring the damping of the crystal’s oscillation (∆D), 
which can give insight into the conformational changes occurring during vesicle fusion 
and peptide-lipid interactions. Figure 1.6 shows frequency and dissipation plotted as a 
function of time during SLB formation via vesicle fusion from zwitterionic 
phosphatidylcholine vesicles. First, vesicles are sparsely adsorbed onto the silica surface, 
resulting in a large frequency drop due to the increase in associated mass from the 
buffer trapped within and between the intact vesicles. Concurrently, the adsorbed 
vesicles contribute to an increase in dissipation due to their viscoelastic properties. Once 
the vesicle surface coverage reaches a critical concentration (θc, indicated by the * in Fig. 
1.6), the vesicles spontaneously rupture and fuse to form a continuous SLB.[55-58] The 
frequency increase is due to SLB displacement of adsorbed vesicles and the buffer 
released from within the vesicle interior. Thus, for vesicles composed of 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC), a complete bilayer is characterized by a dip 
in ∆f and peak ∆D with time, resulting in a final ∆f of ~ –26 Hz and a ∆D of ~ 0.2 x 10-6 
(Fig. 1.6).[59]  
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Figure 1.6: QCM-D frequency (solid line) and dissipation (dashed line) response plotted 
as a function of time for SLB formation from pure POPC vesicles via vesicle fusion. (*) 
indicates the critical concentration of vesicle surface coverage (θc). 
 
While QCM-D serves as a reliable method to confirm bilayer formation on the 
meso- and macroscales, it is limited in the detection of minor bilayer defects and in 
characterizing details in the physical properties of SLBs. Past QCM-D studies have 
found that for different vesicle compositions, final ∆f and ∆D values can differ 
substantially, e.g., up to 30% for ∆f.[60, 61] The interpretation of such differences is 
difficult, given that ∆f represents an averaged, surface-associated mass, and does not 
differentiate between mass contributions from the lipids, the associated buffer, or the 
hydration layer. Furthermore, ∆D provides qualitative insights into the structure of 
surface-associated mass and cannot quantitatively identify structural properties such as 
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bilayer thickness, defects, or lipid packing density. Thus, QCM-D should be used in 
combination with other techniques, such as neutron reflectivity, ellipsometry, surface 
plasmon resonance, fluorescence recovery after photo-bleaching, and atomic force 
microscopy to confirm details of SLB formation and to quantify SLB properties.  
 
1.8.2 Surface Plasmon Resonance 
Surface plasmon resonance (SPR) is a technique that is used to monitor the 
change in dielectric properties and the corresponding change in refractive index above a 
plasmon-producing, metal-liquid interface.[62] When incident light is shone through a 
prism onto the backside of a metallic layer, an evanescent electromagnetic field can be 
produced at the liquid-solid interface. The angle of reflection is dependent on the 
refractive index of the thin layer adjacent to the metallic surface. Adsorption of 
molecules (e.g., antibodies) to the metallic surface will result in a shift in the intensity 
minimum. This shift indicates a change in refractive index, and correspondingly, a 
change in adsorbed mass. For immunological-based experiments, SPR is often used to 
interrogate antibody-ligand interactions by determining association/dissociation rates 
and the binding constant (KD). A review of how SPR is used to advance HIV-1 vaccine 
efforts and other viral vaccines can be found in reference [63].  
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1.8.3 Atomic Force Microscopy 
Atomic force microscopy (AFM) is a type of high-resolution scanning probe 
microscopy technique, with resolution on the order of fractions of a nanometer; i.e., 
significantly higher than the optical diffraction limit used in traditional light 
microscopy.[64] An AFM obtains high-resolution images by scanning the surface with a 
cantilever that contains a sharp tip at its end. Forces between the tip and the sample lead 
to a deflection of the cantilever. The deflection is measured using a laser spot reflected 
from the top surface of the cantilever onto a photosensitive detector (Fig. 1.7). For the 
research presented here, intermittent contact mode (Tapping Mode) will be the primary 
mode of operation for the AFM. In tapping mode, the cantilever is oscillated close to its 
resonance frequency. The oscillation amplitude, phase, and resonance frequency are 
modified by tip-sample interaction forces. These changes in oscillation provide 
information about the sample's surface characteristics. Tapping mode is gentle enough 
to preserve the integrity of supported lipid bilayers and membrane associated 
proteins.[55, 65] 
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Figure 1.7: Schematic of AFM cantilever scanning SLB surface. For clarity, the fluid cell 
is omitted. SLB is a 3D rendering of POPC:POPE (1:1) resulting in taller, gel domains in 
a lower, Ld phase.   
 
The AFM is an essential tool for imaging, measuring, and manipulating matter at 
the nanoscale and provides sufficiently high, lateral imaging resolution to identify 
membrane nano-domains and single antibody-antigen complexes.[47] Using AFM we 
can obtain topography images to visualize antibody-membrane binding at antibody 
concentrations a factor of 10 less than those typically used in SPR measurements. SPR-
based analyses have been a large driving force behind advances in immunogen design. 
However, there is still a large gap in understanding the lipid reactivity of 2F5/4E10. 
AFM can complement SPR measurements by resolving how antibodies spatially interact 
with the viral membrane. AFM is used to reveal complex membrane topography of lipid 
domains and associated proteins with Ångstrom vertical resolution and approximately 
5-10 nm lateral resolution. Here, we have optimized our SLB systems to resolve both 
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antibody and antigen interactions with domain separated SLBs. Figure 1.8 shows an 
example AFM height image of a POPC:POPE SLB that contains the gel and Ld phase. 
The domain height difference is approximately 6 Å.  
 
 
Figure 1.8: AFM height image of SLB domains consisting of POPC:POPE (1:1). The taller 
(brighter) domain consists mainly of POPE in the gel phase. The lower (darker) domain 
consists mainly of POPC in the liquid-disordered phase. A 700 nm cross-section at the 
interface of the two domains (white line on image) reveals a height different of about 6 
Å. 
 
1.8.4 Neutron Reflectivity 
While AFM can provide high lateral resolution (in-plane) of our SLB platform, it 
cannot provide information on buried interfaces in the Z, or out-of-plane direction. Thus 
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we complement AFM imaging with neutron reflectivity (NR) measurements, to provide 
information on the out-of-plane composition and organization of SLBs and SLB/protein 
assemblies, with atomic resolution. NR is a surface-sensitive technique that provides 
molecular-scale information about the structure of interfacial layers perpendicular to an 
interface.[66] The technique involves shining a highly collimated beam of neutrons onto 
SLBs and measuring the intensity of reflected radiation as a function of angle or neutron 
wavelength. The exact shape of the reflectivity profile provides detailed information 
about the structure, vertical position, and orientation of chemical constituents of the SLB 
and associated antigens and antibodies.  
Applied to SLBs, NR measurements provide additional information compared 
with traditional reflectivity measurements employing X-rays, for example. Since neutron 
reflectivity probes nuclear contr3ast, rather than electron density, it is more sensitive 
than X-ray diffraction for measuring lighter elements found abundantly in biological 
samples (such as hydrogen, carbon, nitrogen, and oxygen).[67] Isotope sensitivity also 
allows contrast to be selectively controlled and greatly enhanced to detect antigens and 
antibodies that contain isotopic labeling.[68] Neutrons are also highly penetrating yet 
non-perturbing to delicate biological samples such as lipid bilayers and membrane-
associated proteins. To gain Ångstrom resolution of biological structures immunologist 
have typically used X-ray crystallography.[69] Yet membrane proteins have been proven 
to be extremely difficult to crystallize in their native context of lipid membranes. Thus, a 
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significant advantage of neutron reflectivity over X-ray crystallography is its ability to 
gain Ångstrom vertical resolution and conformational details of membrane bound 
proteins, including weak membrane-associated proteins. 
Neutron reflectivity data from SLBs are predominantly analyzed by fitting 
models of simulated reflectivity profiles to experimental data. The reflectivity simulation 
relies on modeling the contributions from different parts of the experimental scattering 
length density profile in a way that describes their distribution along the surface normal 
direction.[70] The most common and simplest models include layered box models and 
the optical matrix method,[71] or the Parratt recursion algorithm.[72]   
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Chapter 2. Screening the Interactions between HIV-1 
Neutralizing Antibodies and Model Lipid Surfaces 
 
 
This research was performed in collaboration with Dr. Yee Lam (Mechanical 
Engineering and Materials Science) who assisted with experimental design. Shelley 
Stewart and Kara Anasti (Duke Human Vaccine Institute) performed the SPR 
experiments.    
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2.1 Introduction 
Despite the significance of 2F5/4E10 lipid reactivity there is little experimental 
evidence detailing these NAb-membrane interactions. Simple and efficient screening 
assays are needed to further define these and understand NAb neutralization and 
autoreactivity, specifically in the context of how exposed chemical groups from lipid 
membranes help drive antibody interactions. To this end we have developed a surface 
plasmon resonance (SPR) spectroscopy based assay that monitors antibody binding to 
thiol monolayers, which mimic salient surface chemical properties of lipid membranes. 
Specifically, we probed the relative importance of charge and hydrophobicity on 
antibody-surface interactions. We found that NAb binding to hydrophobic thiol surfaces 
was significantly greater than that of control monoclonal antibodies (mAbs). 
Furthermore, we confirmed the importance of charge mediated antibody surface 
interactions, originally suggested by results from mAb interactions with conventional 
lipid vesicle/bilayer surfaces. Our approach thus provides an efficient and useful tool to 
screen interactions of mAbs and lipid-reactive NAbs with a broad range of biologically 
relevant surface chemistries. The research within Chapter 2 is published in the Journal of 
Immunological Methods.[73]  
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2.2 Background 
In this work, we present a simple screening platform to characterize antibody 
interactions with chemical mimics of viral and host membrane lipids to better 
understand antibody-lipid interactions. We employ thiol self-assembled monolayers 
(SAMs) that exhibit a range of chemical functionalities (namely variations in 
hydrophobicity and surface charge) presented on common membrane phospholipids of 
both the native host CD4+ cells and the HIV-1 virion (Fig. 2.1). These thiol SAMs (Fig. 
2.1B) present polar (11-mercapto-1-undecanol (MUD)), nonpolar (1-octadecanethiol 
(ODT)), positively charged (11-amino-1-undecanethiol (AUT)), and negatively charged 
(11-mercaptoundecanoic acid (MUA)) end-functionality, serving as simple chemical 
mimics for corresponding lipid head-groups (Fig. 2.1A). Antibody screening was 
performed by anchoring the thiol SAMs on custom surface plasmon resonance (SPR) 
sensor chips (depicted in Fig. 2.1C).  
It is an important and difficult challenge to develop membrane reactive NAbs 
that selectively target viral lipids and avoid native host cells. Used with SPR and other 
biophysical diagnostic tools, our thiol surfaces may provide insight on required 
chemical structures that could be mimicked on non-human immunogens. Immunogens 
comprised with non-human components, such as plant lipids, can potentially present 
chemical groups that will elicit antibodies with similar 2F5/4E10-membrance reactivity, 
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but yet be different enough in structure to avoid autoreactivity with host cell 
membranes.  
There are many biosensors that effectively probe antibody-membrane 
interactions. These sensors make use of calorimetry, acoustic (e.g., quartz crystal 
microbalance), and near-field optical (e.g., SPR) assays.[74] SPR is one of the most 
powerful sensing assays in that it can provide information on the specificity, kinetics, 
and affinity of antibody interactions in a label-free environment. This avoids expensive 
reagents such as fluorescently labelled compounds and secondary antibodies used in 
standard ELISAs. Recently, significant progress has been made in developing lipid 
bilayer systems to be used in biosensor assays, including SPR. These model systems 
include supported lipid monolayers, tethered lipid bilayers,[75] pore-spanning 
bilayers,[76] and polymer supported lipid bilayers, which have all been engineered to 
screen protein interactions. However, preparation of these planar lipid systems is not 
always straightforward. For example, the morphology of model membranes formed on 
surfaces such as the commonly used SPR Biacore L1 chip, can vary between intact 
vesicles, a planar lipid bilayer, and even the exposed underlying polymer surface.[74] 
This variety arises from the complex interplay of the variables that determine whether 
vesicles rupture to form the desired planar lipid bilayer. Important variables include the 
temperature, pH, ionic strength and buffer composition, size of the lipid vesicles, lipid 
transition temperatures, degree of acyl chain saturation, and the presence of cholesterol. 
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Figure 2.1: Model thiol SPR system. (A) Typical membrane phospholipids, except for 
cardiolipin. Cardiolipin is most often found in the mitochondria of cells, however, NAbs 
have been shown to bind cardiolipin. For simplicity, the acyl chain for all lipids is shown 
saturated with an abbreviated chain length. (B) ω-substituted alkane thiols used to 
mimic membrane phospholipids. At pH 7.4 thiol monolayers were negatively charged 
MUA, positively charged AUT, polar MUD, and nonpolar ODT. (C) Schematic of MUA 
surface on a gold coated SPR sensor chip.    
 
The thiol monolayers prepared here offer a simple alternative to planar lipid 
bilayers for screening antibody interactions. Thiol surfaces remain stable for months 
when stored in thiol solution and are economical to produce with high reliability in a 
large range of screening conditions. Furthermore, the chemical versatility and the well-
characterized nature of thiol monolayers also allow distinct chemical groups to be 
isolated during antibody screening. Our screening platform thus provides an efficient 
and useful tool not only to study a required step in the mechanism of HIV-1 
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neutralization, but also to study antibody autoreactivity, especially for newly generated 
antibodies.  
 
2.3 Results and Discussion 
Using SPR spectroscopy, we investigated the binding behavior of a panel of 
neutralizing (4E10, 2F5), lipid reactive (4E10, 2F5, IS4, IS1, P1), and non-lipid reactive 
nor neutralizing (A32, 13H11) antibodies (Table 2-1). Antibodies were tested on four 
model surfaces: negatively charged MUA (contact angle of 33 ± 3˚), polar MUD (contact 
angle of 21 ± 3˚), positively charged AUT (contact angle of 60 ± 4˚), and nonpolar ODT 
(contact angle of 104 ± 3˚) (Fig. 2.2).  
 
Table 2.1: Panel of screened antibodies and their properties. 
 
Antibody Description Lipid Reactivity 
Neutralizing 
Ability 
4E10 
Human anti-cardiolipin IgG, binds 
gp41 in MPER 
CL, PS, PE, PC, SM [26]  Broad, potent 
A32 Human IgG binds gp120 None None 
2F5 
Human anti-cardiolipin IgG, binds 
gp41 in MPER 
CL [26] Broad, potent 
13H11 
Murine mAb binds gp41 in 
overlapping region of MPER with 
2F5. Blocks 2F5. 
None None, control 
IS4 
Human anti-phospholipid 
syndrome IgG, 
CL [77]  None 
IS1 Human anti-phospholipid antibody CL, POPS [78] Unpublished 
P1 Human anti-cardiolipin IgG 
CL (personal 
communication,  S. Alam) 
Unpublished 
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2.3.1 Antibody Screening on Thiol Surfaces  
Representative SPR curves, in which response units (RU) are plotted as a 
function of time, are shown in Figures 2.2A-C. The low levels of 13H11 binding on all 
surfaces, seen in representative SPR curves (Fig. 2.2C), was attributed to nonspecific 
interactions. Although 13H11 shares an epitope on viral envelope protein gp41 with 2F5, 
it is not known to be lipid reactive. Thus, the binding response of 13H11 was subtracted 
as background from all experiments. The average amount of all antibodies which 
remained bound following one injection cycle is shown for each of the four model 
surfaces (Fig. 2.3). These data demonstrate that our simple and versatile model surfaces 
are able to differentiate between NAb binding and binding of other mAbs. 
Both 2F5 and 4E10 bound at highest levels to hydrophobic ODT surfaces and had 
significantly higher binding compared to all other antibodies tested (Figs. 2.2A-B, and 
Fig. 2.3). These results are supported by structural information which shows that the 
CDR3 region on NAbs 4E10 (EGTTGWGWLGKPIGAFAH)[79] and 2F5 
(RRGPTTLFGVPIARGPVNAMDV)[80] contain unusually large numbers of 
hydrophobic and membrane reactive residues (underlined). 4E10’s CDR3 contains 
zwitterionic tryptophan residues that not only interact with polar head groups but can 
also embed into the hydrophobic bilayer.[81] 2F5 bound significantly less on 
hydrophobic ODT than 4E10, but binding was still significantly elevated relative to all 
other antibodies. This result was expected as 2F5’s lipid reactivity is less, relative to that 
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of 4E10.[26] The relative binding levels of 2F5 versus 4E10 on ODT were also similar to 
binding levels on cardiolipin seen in previous ELISA studies (roughly 1:2).[26]    
The SPR screening of NAb 4E10 showed strongest binding on hydrophobic ODT 
surfaces (Fig. 2.3A) followed by positive AUT (Fig. 2.3D), then negative MUA (Fig. 2.3B). 
This suggests that if 4E10 is able to penetrate into the membrane bilayer, hydrophobic 
interactions may dominate its membrane interactions. Furthermore, these results 
indicate that charge interactions likely contribute to lipid binding as well. 4E10’s high 
affinity to anionic cardiolipin demonstrates this potential charge effect.[26] 
Human mAb A32 binds a site far from the lipid membrane on viral envelope 
protein gp120, and is not known to be lipid reactive. A32 had weak binding to all thiol 
surfaces, with no particular preference for any one model surface. The lipid reactive 
CDR3 in IS4 contains positively charged arginine residues,[77] and during IS4 screening, 
the highest binding response occurred on negatively charged MUA thiols (Fig. 2.3B). 
Furthermore, mAb IS1 is known to interact with cardiolipin and (1-palmitoyl-2-oleoyl-
sn-glycero-3-phospho-L-serine) POPS, which are both negatively charged. This apparent 
preference for negatively charged lipids is recapitulated by IS1 binding most strongly to 
negative MUA thiols. mAb P1 interacts with negatively charged cardiolipin, which is 
also recapitulated by comparable levels of binding to negatively charged thiols. These 
antibody-binding observations are consistent with a charge based interaction 
mechanism.   
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These results demonstrate that simple, well-characterized self-assembled thiol 
monolayers on gold present a surface capable of distinguishing between broadly 
neutralizing and control antibodies as well as discern the salient aspects of antibody-
lipid interactions. 
 
 
Figure 2.2:  Antibody-thiol SPR binding curves. (A-C) Representative SPR response 
curves for 4E10, 2F5, and 13H11 to model surfaces.  
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Figure 2.3: Mean RU value from each antibody grouped for each of the four thiols used 
(n=3). * Signifies statistically significant (p<0.05) when compared to 4E10. † Signifies 
statistically significant (p<0.05) when compared to 2F5. The negative amount of bound 
antibody is due to RU levels below 13H11 background, which was attributed to 
nonspecific interactions and subtracted from all RU values.    
 
2.3.2 Antibody Binding on Lipid versus Thiol Model Surfaces 
To further investigate the binding behavior of our antibodies, we prepared lipid 
surfaces using POPS liposomes on a commercially available L1 chip (Biacore, Sweden). 
Notably the topography of these lipid surfaces is not clearly defined, possibly presenting 
a vesicular surface and/or planar lipid bilayer.[74] We monitored binding of 4E10, 2F5, 
IS4, and IS1 to this more physiologically relevant POPS lipid surface (Fig. 2.4A) to 
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compare with the binding behavior on the model MUA thiol surface (Fig. 2.4B). All 
kinetic data (Fig. 2.4C) was fitted using a bivalent analyte model to incorporate the 
bivalent nature of antibody binding. 2F5 binding to POPS was below baseline behavior 
(similar to A32 and 13H11 binding) preventing the accurate calculation of kinetic data.   
The MUA surface packing density is approximately three times greater than that 
of POPS surfaces due to the tightly packed thiol groups.[82, 83] We thus expect that 
densely packed thiol surfaces also exhibit a higher surface charge density compared to 
that of the lipid surfaces. Specifically, a charge-based interaction is likely for mAbs IS1 
and IS4, which have a positively charged membrane-reactive region, and could thus 
explain why MUA surfaces had overall slightly higher antibody binding compared with 
the lipid surfaces. Importantly, however, the binding order of IS1, IS4, and 2F5 was 
consistent between the thiol and lipid surfaces, with IS1 binding the highest followed by 
IS4 and 2F5, respectively. Furthermore, the half-life of IS1 and IS4 correlated well 
between the POPS and MUA surface. These results are consistent with known antibody 
properties. For example, IS1 and IS4 bind strongly to negatively charged cardiolipin. 
Additionally, 2F5 is known to interact only weakly with POPS,[26] and bound at lowest 
levels on both POPS and MUA surfaces. On MUA, 4E10 bound at relatively higher levels 
than IS1. While 4E10 and IS1 reached an equivalent average steady state association on 
POPS, 4E10 exhibited much larger variability on the MUA surface (Fig. 2.3B). Taken 
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together, these observations suggest that the interaction characteristics of mAbs with 
both the thiol and lipid surfaces are largely conserved. 
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Figure 2.4: 4E10, 2F5, IS1, and IS4 binding on standard lipid surfaces versus thiol model 
surfaces. (A) Representative SPR response curves for antibodies on negative POPS. (B) 
Representative SPR response curves for antibodies on negative MUA. (C) Kinetic 
properties of antibodies binding on lipid (POPS) and thiol (MUA) model surfaces. 
Analysis for 2F5 was not performed due to below background binding.  
 
2.4 Conclusions  
The model surfaces used here admittedly lack many characteristics of the 
complex lipid bilayer including, membrane proteins, lipid heterogeneity, and membrane 
mobility. Nevertheless, by simply mimicking lipid chemistry these thiol substrates 
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allowed us to isolate and distinguish chemical groups that could potentially contribute 
to specific antibody-lipid interactions. Our results showed that only 2F5 and 4E10 bound 
strongly to hydrophobic thiols. This observation correlates with findings that suggest 
that 2F5 and 4E10 embed into the hydrophobic membrane core. This NAb-lipid 
interaction could then facilitate NAb’s ability to diffuse within the viral membrane, 
positioning the NAb to more likely encounter its sparse MPER antigen. We note, 
however, that the NAb’s high affinity for hydrophobic ODT could be attributed to 
structural conformations (denaturation) of the NAb, which may not occur at the 
membrane interface. Regardless, this information translates to vaccine design by 
suggesting that immunogens designed to elicit 2F5/4E10-like antibodies may require an 
accessible hydrophobic component available for B-cell receptor recognition.  
The hydrophobic ODT surface clearly distinguished between neutralizing and 
non-neutralizing antibodies, both lipid reactive and non-lipid reactive, and thus, is 
promising as a proficient screening platform for broadly neutralizing mAbs that are 
designed to replicate 2F5 and 4E10’s neutralizing breadth and efficacy. If these 
antibodies have similar binding interaction to ODT thiol surfaces as 2F5/4E10, then they 
may also possess the same broadly neutralizing ability as 4E10/2F5. In order to 
determine if specific chemical groups have cooperative effects, the complexity of the 
model system can be increased by creating mixed monolayer systems or by introducing 
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different end-functionalized thiols. Peptides specific for 4E10 or 2F5 could also be 
incorporated into the model surface system via covalent attachment.  
In conclusion, the surface chemical diversity that can be achieved with thiol 
SAMs provides a useful and simple platform for screening a wide variety of monoclonal 
antibodies for 2F5/4E10-like lipid reactivity. These model surfaces also provide a method 
to infer the importance of different chemical functionalities on NAb-lipid interactions. 
Such information may contribute to a more complete mechanistic understanding of 
HIV-1 neutralization as provided by 2F5 and 4E10, and ultimately help guide vaccine 
design efforts.  
 
2.5 Materials and Methods 
2.5.1 Antibodies  
Human mAb A32 against HIV-1 envelope gp120 was the generous gift of James 
Robinson, Tulane University, New Orleans, LA and was purified as previously 
described.[84] Anti-HIV-1 gp41 (anti-membrane proximal) NAbs 4E10 and 2F5 were 
purchased from Polymun, Inc., Vienna, Austria. Anti-cardiolipin mAbs IS4 and IS1 were 
provided by Pojen Chen, University of California, Los Angeles and were derived from 
an APS patient. Hybridomas were generated as previously described.[85] Mouse mAb 
13H11 was produced from splenocytes from a mouse immunized with HIV-1 envelope 
oligomer CON-S[86], as described.[84] P1 was purified using Protein A / Protein G 
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immunoaffinity. All mAbs were purified by affinity chromatography on anti-
immunoglobulin columns.[87] 
 
2.5.2 Lipid Preparation  
Palmitoyl oleoyl phosphatidyl serine (POPS) in chloroform (Avanti Polar Lipids) 
was brought to room temperature for one hour, dried under nitrogen for five minutes, 
and then dried under vacuum for three hours. The lipid film was reconstituted in 37 °C 
PBS without Ca2+ and Mg2+, pH 7.4 (Gibco Invitrogen, Grand Island, NY), vortexed, 
sonicated, and extruded 11 times through first a 0.4 μm filter (Whatman, Florham Park, 
NJ), and then through a 0.1 μm filter (Whatman).[88] The concentrated lipid solution 
was then diluted to 0.1 mg/ml in PBS w/o Ca2+ and Mg2+ and vortexed immediately 
before use. Lipid solutions were used within eight hours after extrusion. 
 
2.5.3 Model Surface Preparation 
Glass cover slips (VWR) were first cleaned for 30 minutes using a “Piranha” 
solution (1:3 H2SO4: H2O2) and then rinsed copiously with deionized water and dried 
under nitrogen. Finally, 5 nm chromium and 45 nm gold were evaporated onto their 
surface. The coated glass cover slips were sonicated in ethanol before being incubated in 
1 mM solutions of mercaptoundecanoic acid (Sigma), mercaptoundecane thiol (Sigma), 
aminoundecanethiol (Dojindo), or octadecanethiol (Sigma) for at least 12 hours, and up 
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to one month. Before each experiment, slides were sonicated in thiol solution, rinsed 
with ethanol, and dried with nitrogen. They were then immediately mounted into 
BIAcore cassettes (BIAcore Inc.), and placed in a BIAcore 3000 or 1000 instrument for 
SPR measurements.   
 
2.5.4 Surface Plasmon Resonance 
Surface plasmon resonance (SPR) measurements were performed on a BIAcore 
3000 or 1000 (BIAcore Inc., Uppsala, Sweden) instrument. BIAevaluation 3.0 software 
(BIAcore Inc.) was used to evaluate the data assuming a bivalent analyte model. For 
model surfaces, binding of proteins was monitored in real-time at 25oC with a 
continuous flow of PBS, pH 7.4 (Gibco Invitrogen, Grand Island, NY) at 5 μl/min. For 
lipid surfaces, POPS liposomes were incubated on a BIAcore SPR L1 chip. A blank in-
line reference surface was used to determine non-specific or bulk responses. Bound 
protein was removed from the liposome sensor surfaces following each cycle of mAb 
binding by octyl β-D glucopyranoside, and 5 s injections each of 5 mM HCl then 5 mM 
NaOH. 
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Chapter 3. Techniques to Form Complex Biomimetic 
Supported Lipid Bilayers via Vesicle Fusion 
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3.1 Introduction 
Vesicle fusion has long provided an easy and reliable method to form supported 
lipid bilayers (SLBs) from simple, zwitterionic vesicles on siliceous substrates. However, 
for complex compositions, such as vesicles with high cholesterol content and multiple 
lipid types, the energy barrier for the vesicle-to-bilayer transition is increased or the 
required vesicle-vesicle and vesicle-substrate interactions are diminished. Thus, for 
vesicle compositions that more accurately mimic native membranes, vesicle fusion often 
fails to form SLBs. In Chapter 3 we review two approaches to overcome these barriers to 
form complex, biomimetic SLBs via vesicle fusion: (i) optimization of experimental 
conditions (e.g., temperature, buffer ionic strength, osmotic stress, cation valency, and 
buffer pH), and (ii) α-helical (AH) peptide-induced vesicle fusion. Collectively, this 
chapter introduces vesicle fusion techniques that can be generalized for many 
biomimetic vesicle compositions and many substrate types, and thus will aid efforts to 
reliably create complex SLB platforms on a range of substrates. The information within 
Chapter 3 is published in Current Opinion in Colloid and Interface Science.[89] 
.  
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3.2 Background  
Native plasma membranes contain a complex, heterogeneous distribution of 
lipids and membrane proteins which interact to create important biological functions. To 
investigate this complex membrane environment significant progress has been made to 
model native membranes. The most common systems include lipid monolayers, lipid 
vesicles, and supported lipid bilayers (SLBs). While each system has its advantages, 
SLBs are particularly valuable due to their ease of formation and their lipid 
arrangement. SLBs constitute a single lipid bilayer on a solid substrate, typically glass, 
silica, or mica. The hydrophilic head groups of one lipid leaflet face the substrate where 
they are separated by a thin hydration layer. Their hydrophobic acyl chains interact with 
the acyl chains of the second lipid leaflet, whose hydrophilic head groups face the bulk 
solution and are available to interact with analytes (proteins, cells, nanoparticles, etc.). 
The SLB is stable and confined in two dimensions to the substrate surface, yet it can 
recapitulate the lateral lipid diffusivity of native cell membranes. Furthermore, the 
planar orientation of SLBs allows the use of many quantitative surface characterization 
techniques that are able to provide unique insights into membrane functions.  
 There are many techniques to create SLBs, including Langmuir-Blodgett/Schäfer 
deposition,[90] spin coating,[91] microcontact printing,[92] solvent-exchange 
deposition,[93] lipid-surfactant micelles,[94] evaporation induced assembly,[95] bubble 
collapse deposition,[96] lipid dip-pen nanolithography,[97] and vesicle fusion.[98] 
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Langmuir-Blodgett/Schäfer (LB/LS) deposition and vesicle fusion are perhaps the most 
commonly used techniques to form SLBs. Briefly, LB/LS deposition is achieved by 
transferring a lipid monolayer contained at an air-liquid interface to a solid substrate. 
The substrate is passed through the lipid monolayer a second time to assemble the final 
SLB. SLB formation via vesicle fusion typically occurs by adsorption of lipid vesicles to a 
substrate, followed by vesicle rupture, fusion, and bilayer spreading. Of these 
techniques, vesicle fusion is the most simple, versatile, and widely accessible since it 
does not require sophisticated equipment to produce high quality SLBs. These 
advantages position vesicle fusion to play an important role in advancing SLB research 
platforms, particularly in regards to creating complex, multi-component SLBs that more 
accurately mimic native cell membranes. Thus, this chapter will focus on vesicle fusion 
techniques to form complex SLBs. Other SLB forming techniques and model lipid 
systems are discussed in recent review articles.[99, 100]   
SLBs that contain one or two zwitterionic lipid types, and are supported on 
siliceous substrates (e.g., glass, silicon oxide, or mica), have long provided the 
foundation of model SLB systems.[101] These simple SLBs have been exceptionally 
successful at mimicking the basic structure and dynamics of the plasma membrane; 
however, they fail to capture the highly complex lipid environment that often 
determines native biological functions. For example, there are about 100 lipid species in 
the simple red blood cell alone, and more than 600 lipid species in most plasma 
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membranes.[102] Considering this extensive membrane diversity, SLBs with one or two 
lipid types can be inadequate when attempting to accurately model native cell 
membranes. 
Successful SLB formation via vesicle fusion largely depends on the lipid 
components of the vesicles being used. In attempts to increase SLB complexity, such as 
by incorporating cholesterol, charged lipids, or phase separating lipid compositions, 
complete SLB formation may no longer occur.[60, 61] This restricts the utility of SLBs 
created from vesicle fusion by limiting their compositional complexity to simple binary 
or tertiary lipid compositions containing little or no cholesterol. Cholesterol is often 
neglected or underrepresented in biomimetic SLBs because it can prevent vesicle fusion 
and subsequent SLB formation by increasing vesicle rigidity.[60] However, cholesterol is 
an essential component of plasma membranes, ranging from 15-50% of total lipid 
composition.[102] In native plasma membranes, cholesterol provides an important 
structural role by condensing acyl chains of unsaturated lipids in fluid lipid phases, and 
fluidizing saturated lipids that would otherwise form solid-like gel phases. Regions of 
cholesterol- and sphingolipid-enriched domains, termed lipid rafts,[103] are also 
believed to exist in plasma membranes, where they contribute to compartmentalizing 
cellular processes. Lipid rafts are associated with the function of many membrane 
proteins and are directly linked to important pathologies including those of the central 
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nervous system,[104, 105] viral infections,[106, 107] cardiovascular disease,[108] and 
certain types of cancer.[109] 
Despite the difficulties in forming complex SLB systems, several vesicle fusion 
approaches have the capability to create SLBs with multiple lipid types and high 
cholesterol content on a range of substrates. In this chapter, we summarize two 
approaches to induce complex SLB formation: (i) optimizing experimental conditions, 
including temperature and buffer selection and (ii) the use of α-helical (AH) peptides 
acting as a vesicle fusion catalyst. These approaches were selected due to their potential 
to advance the use of biomimetic SLB platforms by easily achieving SLB formation on a 
range of substrates and under conditions that would otherwise be unfavorable.  
 
3.3 Mechanism of Vesicle Fusion 
The mechanism of vesicle fusion will be briefly discussed to understand the 
barriers to SLB formation and how they can be overcome. Although not completely 
understood, the mechanism of vesicle fusion is believed to be a two-step process that 
relies on membrane tension, vesicle-vesicle and vesicle-substrate interactions, as shown 
in Figure 3.1.[59, 110] Small unilamellar vesicles are first adsorbed to a substrate surface. 
Vesicle crowding ensues and after a critical concentration (θc) of surface-adhered 
vesicles is reached, vesicles will rupture and fuse with each other, forming SLB patches 
on the substrate. The energetically unfavorable edge of SLB patches can spread on the 
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surface and induce rupture of adsorbed vesicles to form a complete SLB (Fig. 3.1). 
Although one-step SLB formation by direct vesicle rupture is possible for certain 
combinations of vesicles, buffers, and substrates,[111] the surface-induced stress alone is 
often insufficient for vesicle rupture.  
 
 
Figure 3.1: Stages of SLB formation: (A) adhesion, (B) crowding, (C-E) rupture and 
spreading of bilayer patches that can expose either leaflet by mechanism 1 or 2, (F, G) 
coalescence of high energy edges and release of water/excess lipid, and (H) completed 
SLB. Additional vesicle adsorption to the SLB is typically weak and does not lead to 
their rupture or spreading. Experimental conditions and techniques that generally have 
the most pronounce effect on respective stages of SLB formation are listed to the right of 
the figure. Substrate type and chemical surface modifications are omitted from 
classification since these conditions generally affect the entire SLB formation process. 
Adapted with permission from reference [112]. Copyright (2009) American Chemical 
Society. 
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The transition from vesicles to a SLB is most commonly observed with quartz 
crystal microbalance with dissipation monitoring (QCM-D).[113] In this chapter, QCM-
D results will be used to discuss the effectiveness of vesicle fusion techniques. 
Additional mechanistic detail and description of the vesicle to SLB transformation can 
be found in Chapter 1, section 1.8.1.  
 
3.4 Experimental Optimization Techniques to Achieve Vesicle 
Fusion   
Although SLB formation via vesicle fusion is a reliable and easy technique for 
many vesicle compositions, it is still a complex, dynamic, and highly sensitive process. 
As researchers attempt to increase complexity of SLB platforms, additional steps or 
alternative techniques become necessary to induce SLB formation. Favorable SLB 
formation by conventional vesicle fusion largely depends on the substrate type and lipid 
composition of the vesicles, where lipid charge, polarity, head group size, acyl chain 
length, and degree of unsaturation ultimately all contribute to the ease of vesicle fusion 
and subsequent SLB formation. However, for researchers attempting to use SLBs to 
model native membranes the compositional ratios and lipid types of a vesicle are largely 
fixed. Yet, the experimental conditions in which vesicle fusion takes place can often be 
optimized to achieve SLB formation for a wide range of vesicle compositions. 
Conditions that are commonly manipulated include vesicle size,[57] vesicle 
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concentration,[101] temperature,[114] pH,[115] flow conditions (batch or flow 
system),[116] exposure to buffers of different ionic strengths,[117] the type of substrate 
material,[116] and chemical surface modifications.[59] It is commonly observed that 
experimental conditions that work for one vesicle composition, may fail to work as well 
for that of another vesicle composition. However, there are a few variables that are 
generally more important than others since they can be successfully applied to a wide 
range of vesicle compositions to promote vesicle fusion. These include temperature, 
buffer pH, buffer ionic strength, ion type, and osmotic stress. 
            
3.4.1 Effect of Temperature 
The critical surface coverage of vesicles required for SLB formation has been 
shown to be temperature dependent, thus indicating that vesicle rupture is a thermally 
activated process.[114] For example, Reimhult et al. have shown that a decrease in 
temperature requires a higher critical coverage (θc) of surface adhered vesicles (i.e., an 
increase in vesicle-vesicle interactions) to induce fusion, and increases the time to 
transition from intact vesicles to SLBs.[98] Furthermore, temperature also affects the 
lipid phase, which can play a critical role for vesicle fusion. A phase change into a more 
fluid vesicle can promote SLB formation, especially when the temperature change 
involves passing through a chain melting temperature (Tm) of one of the lipid 
components.[101] The chain melting temperature defines the transition of a lipid from 
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one phase to another i.e., from the gel to the liquid-disordered (Ld) phase. Vesicles with 
lipids in the gel phase contain higher order compared to the Ld phase and are believed to 
resist vesicle fusion due to decreased lipid mobility and vesicle-vesicle interactions. 
Thus, using vesicles in the liquid phase by raising the temperature approximately 15 °C 
above the highest lipid Tm is a common and successful strategy for achieving reliable 
SLB formation.[98, 114]  
In addition to lipid structure, the presence of cholesterol and sphingolipids can 
also result in vesicle phase separations as they have the tendency to self-associate within 
the Ld phase to form highly ordered, tightly packed islands, known as liquid-ordered 
(Lo) domains or lipid rafts.[118] For instance, POPC:cholesterol (55:45) undergoes a 
phase transition in the temperature range between 15-35 °C.[53] At 15 °C the lipid 
bilayer is completely in the Lo phase while between 25-35 °C the Lo and Ld phases co-
exist. With increasing temperature the Ld phase increases, resulting in shorter times to 
reach θc, peak ∆f and ∆D amplitudes decrease, and final ∆f and ∆D values approach 
those of pure POPC vesicles.[61] Thus, a temperature increase has been successful in 
achieving SLB formation from vesicles containing as much as 50 mol% cholesterol.[119] 
Without heating, vesicles may fail to consistently form SLBs when containing cholesterol 
compositions above 33 mol%.[120] Therefore, for vesicles containing cholesterol, raising 
the temperature to increase the Ld phase may assist in achieving reliable SLB formation.  
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Using elevated temperature to prepare SLBs via vesicle fusion is one of the most 
frequently used techniques. However, depending on the vesicle composition, the use of 
temperature alone can be insufficient to induce vesicle fusion. Furthermore, this 
technique is not appropriate when using temperature sensitive membrane components, 
such as membrane embedded proteins. In such instances, researchers are referred to 
alternative techniques discussed below.      
 
3.4.2 Effect of pH 
Initial vesicle-substrate interactions are often the limiting factor in determining 
whether successful SLB formation occurs. Whether these interactions are sufficient for 
SLB formation largely depends on electrostatic forces between the lipid vesicles and 
substrate surface.[111] Generally, to readily achieve vesicle fusion, electrostatic 
attraction between vesicles and the substrate surface should be enhanced. If attractive 
electrostatic interactions are not possible, then repulsive electrostatic forces should be 
minimized. This can allow van der Waals, steric, and hydration forces to dominate 
surface interactions which can be sufficient to promote bilayer formation.  
Electrostatic forces play an important role in creating biomimetic SLBs because 
most native cell membranes contain negatively charged lipids (yielding a surface charge 
of ~ –0.05 C/m2)[121] and SLBs are most commonly formed on negatively charged mica 
and silica substrates. This repulsive electrostatic interaction results in an increase in θc 
 51 
required for vesicle rupture and, depending on the concentration of negatively charged 
lipid, may prevent SLB formation entirely.[116] An effective technique for tuning the 
electrostatic interactions between vesicles and the substrate surface is to adjust the buffer 
pH (under constant ionic strength). The buffer pH influences the state of lipid charge by 
affecting the degree of ionization, reflected in the lipid’s pKa. This pKa is largely 
determined by the lipid head group acid-base chemistry.  
Here, we present a general guideline for using buffer pH (with ionic strength ≈ 
100 mM NaCl) to minimize the negative charge of common lipid types.[122] For 
example, common negatively charged lipid head groups include phosphatidylserine 
(PS), phosphatidylinositol (PI), phosphatidic acid (PA), and phosphatidylglycerol (PG). 
PS has pKas at 2.6, 5.5, and 11.5, requiring a pH < 6 to diminish its charge of –1 and at pH 
< 4, PS will begin to have a net positive charge. PI, PA, and PG have a pKa at 2.5, 3.0, and 
3.5, respectively. Thus, each lipid type will begin to diminish its charge of –1 at pH < 4. 
Furthermore, common zwitterionic lipids include those with a phosphatidylcholine (PC) 
or phosphatidylethanolamine (PE) head group. PE has pKas at ~1.7 and 9.8, resulting in a 
neutral charge between pH ≈ 3–9. PC has one pKa at ~1.0 and will be neutral for any pH 
> ~3.[122] Positively charged lipids (at pH = 7) are not commonly used to model native 
cell membranes; however, when using negatively charged surfaces (e.g., silica or mica) 
vesicle-substrate interactions can be enhanced by strategically incorporating positively 
charged membrane components (e.g., peptides, lipids, or fluorescent probes) within the 
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vesicles. As little as 1 mol% of positively charged membrane probe can be effective at 
inducing SLB formation.[123]    
Buffer pH can also affect the ionization of hydroxyl groups that exist on surface 
oxides commonly used for SLB formation (e.g., mica, silica, and titanium oxide). At a 
certain pH, known as the point of zero charge (pzc), the surface charge is approximately 
zero. At a pH above its pzc value, a surface is generally negatively charged, while at a 
pH below the pzc the surface is generally positively charged. For silica and mica 
surfaces, the pzc is ~1.5 – 3.5, while the pzc of titanium oxide is ~6.5.[124] Thus, using a 
pH at or below the pzc value, can diminish repulsive vesicle-substrate interactions and 
enhance vesicle adsorption and subsequent SLB formation for negatively charged 
vesicles. 
Cho et al. demonstrates how oxide surfaces are affected by pH and ultimately 
control successful vesicle fusion. SLB formation was monitored in various buffer pH 
(with 200 mM NaCl) using zwitterionic POPC vesicles on silicon and titanium oxide 
surfaces.[115] For POPC vesicles on silicon oxide at a pH ≥ 10.0 an irreversibly adsorbed 
vesicle monolayer is formed, with no subsequent vesicle fusion. At pH = 7.5, however, a 
SLB is formed, as expected, in two successive steps. At a pH ≤ 6.0, SLB formation 
approaches one-step behavior, indicating a decreasing role of vesicle-vesicle interactions 
required for rupture. POPC vesicles on titanium oxide, which showed weaker vesicle-
substrate interactions than silicon oxide, form an irreversibly adsorbed vesicle 
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monolayer already at pH = 7.5, again with no subsequent vesicle fusion. However, at pH 
= 4.0 the vesicle-substrate interactions are strong enough to generate isolated SLB 
patches mixed with adsorbed vesicles, and at pH = 2.5, a complete bilayer finally forms. 
These results demonstrate that stronger vesicle-substrate interactions often occur at low 
pH and that oxide surfaces have titratable OH groups that control the surface charge 
density, which plays an important role in the adsorption and fusion of vesicles.    
 
3.4.3 Effect of Ionic Strength and Ion Type  
Closely linked to surface charge is the surface potential, which also needs to be 
considered when evaluating vesicle fusion interactions. The lipid surface potential is 
best approximated by the ζ potential, which describes the charge seen at a distance from 
the surface, where the Stern layer and diffuse layer meet. The ionic strength of the buffer 
plays an essential in role in determining the ζ potential and is likely the major reason 
why zwitterionic vesicles fail to adsorb to and fuse on substrates in deionized water. For 
example, Anderson et al. demonstrated that adhesion and fusion of DMPC vesicles on 
silica decreased with decreasing ionic strength, and below a critical ionic strength of 
about 1.5 mM no longer formed SLBs.[101] Even though DMPC is theoretically 
zwitterionic over a broad range of pH values, due to head group orientation[125] and 
hydration layers surrounding the head group surface,[126] PC has a negative ζ potential 
of ~ –12 mV in deionized water.[127] As the ionic strength increases, the ζ potential 
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increases because cations adsorb to the surface of the polar lipid head group. At a high 
ionic strength, the ζ potential of PC becomes positive and vesicles readily adsorb and 
fuse on negatively charged substrates.[127]   
Presence of divalent ions can also influence the formation of SLBs, especially for 
vesicle compositions containing charged lipid head groups or charged membrane 
embedded peptides. Divalent cations stabilize vesicle-substrate interactions between the 
negatively charged lipid head groups and negatively charged substrates by charge 
bridging.[128] For example, calcium (Ca2+) and magnesium (Mg2+) ions are common 
divalent cations used to promote SLB formation with negatively charged vesicles.[117, 
129, 130] Already at concentrations as low as 25 µM, Ca2+ ions contribute significantly to 
vesicle fusion.[123] It is important to introduce divalent cations only during the vesicle-
substrate adsorption step. If introduced earlier, divalent cations can inhibit SLB 
formation by promoting vesicle-vesicle interactions, which leads to vesicle aggregation 
and an increase in vesicle polydispersity.  
An example of how ionic strength and pH have a pronounced effect on SLB 
formation is given by Cremer and Boxer.[123] Using positively and negatively charged 
vesicles on borosilicate, SLB formation was monitored while varying the pH and ionic 
strength of a sodium phosphate buffer. For negatively charged vesicles, they observed 
that SLB formation occurred at high ionic strengths and low pH, but was inhibited at 
low ionic strength and high pH (Fig. 3.2A).[123] The low pH likely reduced negative 
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charge density of the substrate and the high ionic strength likely shielded repulsive 
vesicle-vesicle and vesicle-substrate electrostatic interactions. As the pH of the buffer is 
raised (or the ionic strength is lowered) electrostatic repulsion increases and eventually 
overcomes the attractive forces, thus inhibiting SLB formation.  
However, SLBs formed from positively charged vesicles readily form on 
negatively charged substrates, often regardless of the pH and ionic strength used. 
Cremer and Boxer showed that positively charged vesicles formed SLBs at all pH values 
and ionic strengths measured (Fig. 3.2B).[123] Furthermore, with attractive electrostatic 
interactions, SLB formation can occur in one step, as the vesicle-substrate interaction 
alone can be sufficient to cause vesicle rupture.[58] 
When using pH and ionic strength conditions conducive to vesicle fusion, it is 
important to realize that once a SLB has been formed, the buffer can be changed to one 
that more accurately mimics physiological conditions. This does not adversely affect 
bilayer adhesion or stability.[123] Thus, inducing vesicle fusion under low pH and high 
ionic strength conditions with a subsequent buffer change represents a practical 
technique to promote vesicle fusion. 
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Figure 3.2: Vesicle fusion phase diagrams for egg PC vesicles containing: (A) 1 mol% of 
negatively charged lipid probe and (B) 1 mol% of positively charged membrane probe. 
Regions of vesicle instability and incomplete SLB formation are indicated by the 
crosshatched area in (A). The regions with vertical stripes in the lower right corner of 
both diagrams indicate conditions where buffer formation was not possible. Reprinted 
with permission from reference [123]. Copyright (1999) American Chemical Society. 
 
3.4.4 Effect of Osmotic Stress 
Increasing vesicle membrane tension is an important factor that can promote 
rupture of adsorbed vesicles. It is likely that the activation barrier against vesicle rupture 
is lowered for vesicles under high membrane tension. In addition to using small 
diameter vesicles between 50-100 nm (which can be controlled through vesicle 
extrusion), membrane tension can also be increased by creating a gradient in ionic 
strength across the vesicle membrane. The resulting osmotic pressure difference causes 
an osmotic stress that changes the volume of the vesicle, and thus creates membrane 
tension leading to rupture.[117] Reimhult et al. found that SLBs created from egg PC 
vesicles, with a fixed interior ionic strength of 150 mM, formed at all solution ionic 
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strengths tested (115–300 mM).[98] However, the θc decreased when the vesicles were 
osmotically stressed, i.e., when the ionic strength of the buffer differed from that of the 
vesicle interior. This was also evident in the decrease of the ∆f and ∆D peaks in QCM-D 
measurements, indicating that SLB formation occurred more quickly and required less 
surface adsorbed vesicles to induce vesicle rupture. For successful vesicle rupture via 
osmostic stress, it is thus common practice to introduce vesicles to substrates in buffers 
with ionic strengths between 150-500 mM NaCl (to maximize vesicle adsorption as 
discussed above) and to then induce an osmotic shock after their adsorption, by 
exchanging the buffer with deionized water. Once the SLB is formed, the deionized 
water can be replaced with standard buffer to maintain SLB stability.[131, 132]  
 
3.5 Amphipathic α-Helical (AH) Peptide-Induced Vesicle Fusion 
While adjusting experimental conditions provides a successful strategy for 
creating complex SLBs, the approach can be tedious since conditions are chosen based 
on the substrate type and vesicle composition. As substrates and lipid mixtures increase 
in complexity it can be difficult to anticipate which optimization techniques will 
promote vesicle fusion. To reliably create SLBs, it is likely that multiple experimental 
conditions will have to be optimized, including those not discussed above (e.g., vesicle 
concentration, flow conditions, and chemical surface modifications). Furthermore, 
experimental optimization techniques can fail or become inconsistent when the vesicle 
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cholesterol content exceeds 30 mol%. To overcome these limitations, we summarize an 
alternative approach that uses amphipathic, α-helical (AH) peptides as a catalyst to 
promote vesicle fusion and that generates complex SLBs containing as much as 45 mol% 
cholesterol. While this approach can be used in combination with the optimization 
techniques discussed above, a unique and major advantage of AH peptide-induced 
vesicle fusion is that is sufficient to form SLBs independently of optimizing experimental 
conditions. With sufficient vesicle-substrate adsorption, it is generally recommended to 
introduce AH peptides under standard experimental conditions (room temperature, pH 
= 7, ionic strength ≈ 150 mM) regardless of the substrate and vesicle composition. 
AH peptide is derived from hepatitis C virus’s (HCV) nonstructural protein 5A 
(NS5A), which interacts with host cell membranes and is required for HCV replication. 
NS5A’s membrane association is mediated by its N-terminal amphipathic α-helix, 
termed the AH peptide (Fig. 3.3B,C).[133] After realizing the AH peptide’s ability to 
rupture intact adsorbed vesicles, Cho et al. created SLBs from simple POPC vesicles 
adsorbed on gold substrates (Fig. 3.3A).[134, 135] Without the use of AH peptide, gold 
substrates are limited to vesicle adsorption and do not induce vesicle rupture.[59] 
Previously, SLB formation from vesicle fusion was mainly limited to hydrophilic 
substrates (e.g., mica, glass, and silicon oxide). This work thus established a technique 
that expanded the type of substrates amenable to easy SLB formation by vesicle fusion. 
Recently, our group has extended the value of AH peptide-induced vesicle fusion by 
 59 
demonstrating a reliable and easy way to form SLBs that contain high cholesterol 
content (45 mol%) and multiple lipid types.[60] For the first time, this vesicle fusion 
technique enables researchers to form SLBs with complex lipid compositions and high 
cholesterol content, without the need to optimize experimental conditions such as 
temperature, pH, and ionic strength.  
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Figure 3.3: Membrane activity of the NS5A amphipathic α-helix (AH) peptide. (A) 
Potential mechanism of AH-peptide induced vesicle fusion on gold. (B) Expected 
positioning of the average structure of amphipathic α-helix membrane anchor domain of 
NS5A (PDB entry 1R7E) at the interface between phospholipid polar head groups and 
hydrophobic tails. The phospholipid bilayer was drawn using the 
phosphatidylethanolamine (PE) models reported in the Protein Data Bank entry 1BCC. 
Molecules are colored according to atom types (N, blue; O, red; P, yellow; C, H, gray). 
(C) Top view of AH peptide embedded in a model phospholipid membrane. Adapted 
with permission from reference [136] and [137]. Copyright (2009 and 2004) from the 
American Chemical Society and The American Society for Biochemistry and Molecular 
Biology, respectively.   
 
3.5.1 Mechanism of AH Peptide-Induced Vesicle Fusion  
The mechanism of AH peptide-induced vesicle fusion is not yet fully 
understood. It has been hypothesized that AH peptide membrane integration may cause 
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the vesicle membrane to swell and greatly expand, possibly into microvilli folds.[134, 
138, 139] This hypothesis is supported by findings from Cho et al. who showed that the 
interaction of AH fusion peptides with POPC vesicles (~60 nm in diameter) on gold 
substrates caused vesicle swelling, which in turn enhanced vesicle-vesicle interactions 
and led to vesicle fusion and SLB formation.[138] However, this vesicle fusion activity 
was diminished for vesicles greater than 100 nm in diameter.[140, 141] Furthermore, at 
AH peptide concentrations that rupture vesicles, no peptide binding to planar bilayers 
was observed.[142] This functional dependence on vesicle diameter/membrane 
curvature is unique and suggests that the mechanism of AH peptide-induced vesicle 
fusion is not analogous to that of other membrane disruptive peptides interacting with 
large diameter membranes (e.g., cells, bacteria, and giant unilamellar vesicles). For these 
other membrane disruptive peptides, membrane disruption often occurs via pore 
formation by barrel-stave or toroidal pore mechanisms.[143-145]   
To study the unique fusion mechanism of AH-peptide, Jackman and Cho studied 
the initial binding of the AH peptide to vesicles and found that binding saturation 
occurred before completion of vesicle swelling.[142] This lag time suggests that 
membrane association alone is insufficient to directly cause complete vesicle swelling. It 
is likely that associated peptides may first rearrange to achieve pore formation, which 
leads to solvent uptake and subsequent vesicle deformation and SLB formation. It was 
also observed that the onset of pore formation is almost a factor of 10 slower for larger 
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vesicles (~200 nm in diameter) compared to that of smaller vesicles (~70 nm in diameter), 
however, the rate of peptide binding had no significant dependence on the vesicle 
diameters studied.[140] Typically, pore formation increases with vesicle diameter due to 
an increase in the number of bound peptides per vesicle (given a constant peptide/lipid 
(P/L) ratio).[146] However, this is not the case for the AH peptide which suggests that 
pore formation, rather than the rate of peptide binding, is dependent on high membrane 
curvature.[140]  
To investigate how AH peptide action depends on nanoscale membrane 
curvature, Tabaei et al. observed the release of encapsulated vesicle content, induced by 
AH peptide pore formation and membrane disruption.[140] They found that as little as 
four AH peptides per vesicle were required to cause pore formation, which translates 
into an unusually low effective P/L ratio of ~1/1000.[140] Furthermore, their results 
suggest that the inability of AH peptides to rupture large vesicles and planar bilayers is 
due to insufficient line tension, related to reduced or nonexistent membrane curvature. 
They also suggest that AH peptide’s pore formation process may be facilitated by 
curvature-induced defects in lipid packing.  
      
3.5.2 SLB Applications of the NS5A-Derived AH Peptide 
While Cho and others are focused on realizing antiviral clinical benefits of this 
AH peptide[140, 141, 147, 148], our group is focused on promoting the use of AH 
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peptides to create SLB platforms under conditions that are generally unfavorable for 
vesicle fusion. Examples of such conditions include vesicles containing high amounts of 
cholesterol, the presence of membrane-embedded proteins, strong lipid-substrate 
interactions, and formation of SLBs on hydrophobic or irregular/patterned substrate 
surfaces. The extent to which AH peptides can overcome these and other barriers 
limiting SLB formation are subject to current investigation. 
Using AH peptides, we report in Chapter 4 the formation of complex biomimetic 
SLBs that contain cholesterol concentrations of up to 45 mol% on mica and silica 
substrates.[60] Our chosen SLB system is a five-component lipid bilayer that models the 
native lipid envelope of human immunodeficiency virus-1 (HIV-1).[40] We chose to 
model this lipid envelope due to the membrane’s significance in viral infection and its 
potential use as a target in next-generation vaccine designs.[17, 19, 73, 149] Furthermore, 
the native viral envelope is of interest as it contains a unique composition of 
heterogeneous membrane components that likely represents a mosaic of lipid rafts,[41] 
protein and antigen clustering,[150] and various gradients of lipid diffusivity.[151] 
Generating a complex SLB that models the native HIV-1 envelope also provides a proof-
of-concept for modeling other complex native biological membranes. Complete details 
of this work are presented in Chapter 4. 
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3.6 Creating SLBs on Non-Siliceous Surfaces 
In addition to the lipid composition of vesicles, the substrate also plays a crucial 
role in creating SLBs via vesicle fusion. Vesicle fusion is typically dominated by surface 
adhesion energy between vesicles and the substrate. Traditional substrates used for 
vesicle fusion include hydrophilic silica, glass, mica, and quartz. These siliceous 
substrates are commonly used because they provide the necessary balance between 
adhesion, repulsion, and hydration forces that results in vesicle rupture and a hydration 
layer between the substrate and SLB. This hydration layer allows SLBs to mimic the 
lateral fluidity of native cell membranes. However, as applications of SLBs continue to 
evolve, there is a need to create SLBs on a wider range of surfaces. Progress has been 
made to form SLBs on many solid non-siliceous surfaces including chrome,[152] indium 
tin oxide,[153] gold,[134] titanium oxide,[154] and alumina.[155]  In many cases these 
surfaces have vesicle-substrate interactions that do not enable conventional vesicle 
fusion, and thus surface-specific techniques must be used to promote SLB formation.  
Although optimization techniques, including surface functionalization[156, 157] 
and the use of charged lipids,[158] have been successfully applied to create SLBs on 
solid non-siliceous surfaces, these techniques are often specific to a particular substrate 
and not universally applicable. AH peptide-induced vesicle fusion may overcome this 
limitation as it can offer SLB formation on a broad range of substrates. For example, AH 
peptide-induced vesicle fusion was successfully used on gold and titanium oxide 
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surfaces.[134] Furthermore, our group is currently using AH peptides to create SLBs on 
chromium and experimenting with its use on a polymeric, Nafion surface.       
While AH peptide-induced vesicle fusion may be harnessed to form SLBs under 
a range of conditions on a variety of substrates, it requires vesicle-substrate interactions 
that are strong enough to (i) form a monolayer of vesicles on the surface, and (ii) resist 
vesicle desorption upon a buffer wash. A vesicle monolayer is required to provide 
sufficient vesicle-vesicle interactions, while a buffer wash is required to remove excess 
vesicles from the surface and the bulk solution. Excess vesicles need to be removed from 
the system before AH peptide is introduced, so that it can interact exclusively with the 
surface adsorbed vesicles. For surfaces with especially weak vesicle-substrate 
interactions these requirements may not be met, and AH peptides may fail to form a 
complete SLB. In this case, the so-called bubble-collapse deposition (BCD) technique 
may overcome this limitation.[96]  
BCD provides an innovative approach that requires a lower vesicle-substrate 
adhesion energy then traditional vesicle fusion. For example, Mager et al. use this 
technique to form a POPC SLB on alumina; a substrate which usually does not provide 
sufficient vesicle adhesion to induce fusion.[155]  BCD uses an air bubble that is blown 
underwater at the end of a needle. This bubble is “inked” with a lipid monolayer by 
contacting it with a previously formed sacrificial bilayer. The bubble is then brought into 
contact with the substrate at the desired deposition site. The needle then withdraws air 
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from the bubble causing the bubble to shrink until the surface-supported monolayer 
folds back on itself, forming a bilayer patch on the substrate surface.  
To date, BCD can form a SLB with simple lipid composition on substrates that 
otherwise are unable to induce vesicle rupture due to weak vesicle-substrate 
interactions. It is thus conceivable that if a complex SLB, created by one of the 
techniques discusses above, is used as the sacrificial inking bilayer, then BCD may be 
able to form SLBs with complex lipid composition on substrates that have weak vesicle 
interactions.  
 
3.7 Vesicle Fusion Considerations  
Many questions exist concerning how preparation methods affect properties of 
SLBs, and to what extent these properties accurately mimic native cell membranes. For 
the techniques discussed above, the conditions that are manipulated to induce vesicle 
fusion (e.g., temperature, buffer type, fusion peptides, etc.) can be replaced with the 
desired experimental conditions once the SLB has formed. However, after the conditions 
have been changed, it is important to take into consideration the possibility of residual 
effects on SLB properties that originate from the SLB preparation conditions. For 
example, zwitterionic lateral lipid-lipid interactions are believe to be promoted by ions 
bound into the membrane. Strong interaction between Na+ and Ca2+ ions and the 
carbonyl oxygens of the lipids form tight ion-lipid complexes.[127] This increases 
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membrane organization and can affect bilayer cohesion and lipid diffusivities. Thus, 
using high ionic strength for SLB formation, and then changing to a physiological ionic 
strength may have a lasting effect on lateral lipid-lipid interactions. Furthermore, 
temperature changes are known to affect the ζ potential and orientation of lipid head 
groups[126] and it is unclear if the resulting effects, both direct and indirect, are 
reversible.  
Compositional asymmetry between the leaflets of the SLB must also be taken 
into consideration. Bilayer asymmetry is a common property in native cell membranes 
and is believed to contribute to many biological functions by mediating membrane 
protein distribution and functionality.[159] Thus, there is a large focus on controlling 
and characterizing asymmetry in deposited bilayers.[160, 161] Typically, Langmuir-
Blodgett/Schäfer deposition offers the most control of SLB asymmetry since each leaflet 
can be deposited independently, allowing lipid selection of each initial leaflet 
composition. Asymmetry is harder to control with vesicle fusion techniques since it 
must originate from the vesicle or occur from lipid re-arrangement once the SLB has 
formed. However, it is possible to achieve and control bilayer asymmetry using vesicle 
fusion. Studies have suggested that the solid support can induce preferential 
distribution of certain lipid types. In the presence of Ca2+ ions, it has been observed that 
negatively charged DOPS preferentially resides in the leaflet closest to mica and 
titanium oxide surfaces.[128, 162] This suggests that lipid head group chemistry leads to 
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membrane asymmetry.[163] SLBs have also shown leaflet organizational asymmetry 
between gel- and fluid-phases[164] and with cholesterol induced domain 
formations.[165] Furthermore, it has been shown that SLB leaflet asymmetry can be 
controlled by vesicle deposition temperature and the salt concentration of the vesicle 
solution.[161]  
This brief discussion is meant to demonstrate that details in preparation methods 
can affect SLB properties, and emphasizes that such details need to be considered and 
perhaps accounted for in experimental design and data interpretation. 
 
3.8. Conclusions   
Common criticism against SLB formation via vesicle fusion states that it is 
limited to few select surfaces and vesicle compositions. In this chapter, we have 
attempted to prove this criticism to be outdated by summarizing vesicle fusion 
techniques that are able to readily form SLBs with multiple lipid types, high cholesterol 
content, and on non-siliceous substrates. These techniques are simple and reliable, and 
thus maintain the major advantage of forming SLBs via vesicle fusion.       
In the past, optimization of experimental conditions has been widely used to 
induce vesicle fusion and has provided a successful strategy for creating simple SLBs. 
With increasing SLB complexity and emerging applications for SLBs, such optimization 
techniques will play an even more important role for their formation. Here, we have 
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summarized the strategies that are used to tune the most important conditions to make 
vesicle fusion applicable to a larger range of SLB compositions and substrates. Important 
strategies include elevating the temperature, increasing buffer ionic strength, adding 
divalent cations, and lowering buffer pH. By optimizing these conditions it is possible to 
create SLBs from vesicles that ordinarily resist vesicle fusion, and to access substrates 
that are generally not amenable to SLB formation. 
In cases where such optimization strategies fail to provide easy SLB formation, 
the optimization efforts can be supplemented with a novel vesicle fusion technique, AH 
peptide-induced vesicle fusion. Finally, bubble collapse deposition can be combined 
with these vesicle fusion techniques to create complex SLBs on surfaces with especially 
weak vesicle-substrate interactions. Together, these techniques allow researchers to 
easily create SLBs that contain high cholesterol content and multiple lipid types on a 
wide range of substrates. Thus, SLB formation via vesicle fusion is no longer restricted to 
a few select surfaces and a limited range of lipid compositions.   
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Chapter 4. Biomimetic Supported Lipid Bilayers with 
High Cholesterol Content Formed by α-Helical Peptide-
Induced Vesicle Fusion 
 
 
This research was performed in collaboration with Dr. Frank Heinrich (Carnegie Mellon 
University, NIST Center for Neutron Research) who analyzed and modeled the NR data.  
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4.1 Introduction  
Chapter 4 presents a technique to create a complex, high cholesterol-containing 
supported lipid bilayers (SLBs) using α-helical (AH) peptide-induced vesicle fusion. 
Vesicles consisting of  POPC:POPE:POPS:SM:CH  (9.35 : 19.25 : 8.25 : 18.15 : 45.00) were 
used to form a SLB that models the native composition of the HIV-1 lipid envelope. In 
the absence of AH peptides, these biomimetic vesicles fail to form a complete SLB. We 
verified and characterized AH peptide-induced vesicle fusion by quartz crystal 
microbalance with dissipation monitoring, neutron reflectivity, and atomic force 
microscopy. Completion of this research was essential for establishing the basis of our 
SLB research platform and enabling the progression and utilization of this platform 
detailed in Chapter 5. The research presented within this chapter is published in the 
Journal of Materials Chemistry.[60]   
 
4.2 Background 
AH peptide is derived from hepatitis C virus’s nonstructural protein 5A (NS5A). 
This AH segment within NS5A is responsible for the association between the hepatitis C 
virus and host cell membranes during viral infection.[166, 167] Using AH peptides we 
established SLB formation of complex biomimetic SLBs that contain concentrations of 
45% cholesterol on mica and silica. Our chosen SLB system is a five-component lipid 
bilayer that models the native lipid envelope of human immunodeficiency virus-1 (HIV-
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1).[40] The model HIV SLB consists of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1-palmitoyl-2-
oleoyl-sn-glycero-3-phospho-L-serine (POPS), brain sphingomyelin (SM), and 
cholesterol (CH) (Fig. 4.1) in a molar ratio of 9.35 : 19.25 : 8.25 : 18.15 : 45.00. SLB 
formation from vesicles modeling the HIV-1 lipid envelope does not occur by 
conventional spontaneous vesicle fusion. In part, this is due to the highly ordered model 
HIV vesicles. The high order arises from the high cholesterol content and presence of 
sphingomyelin. Furthermore, the negatively charged POPS and negatively charged 
silica give rise to repulsive lipid-substrate interactions that resist vesicle fusion. The use 
of AH peptide-induced vesicle fusion allows us to overcome these obstacles and to more 
accurately recapitulate the composition of the HIV-1 lipid envelope compared to 
simpler, lower cholesterol SLBs consisting of POPC:SM:CH (3 : 3 : 2).[168] To verify and 
characterize AH peptide-induced vesicle fusion of our model system, we used quartz 
crystal microbalance with dissipation monitoring (QCM-D), neutron reflectivity (NR), 
and atomic force microscopy (AFM) imaging.  
The known mechanistic details of AH peptide-induced vesicle fusion is 
presented in Chapter 3, section 3.5. Cho and colleagues offer additional information on 
the proposed mechanism in previous publications.[137, 166, 169] Briefly, AH peptides 
first bind to a monolayer of intact vesicles on a substrate, creating a physical instability 
on the outer vesicle leaflet. This initial interaction leads to vesicle swelling and possibly 
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formation of microvilli-like extensions on the vesicle, which are believed to facilitate 
lateral vesicle-vesicle interactions.[137] Vesicles then start to rupture and spread on the 
substrate similar to that observed in the classical spontaneous vesicle fusion model. We 
note however, that the fusion mechanism for complex vesicles containing high 
concentrations of cholesterol with several lipid types has not been studied and the 
mechanism may differ from that observed from simple vesicles on gold. 
 
 
Figure 4.1: Chemical structures of membrane components used in this study. Biomimetic 
HIV-1 SLBs were formed from vesicles containing a lipid composition of 
POPC:POPE:POPS:SM:CH (9.35 : 19.25 : 8.25 : 18.15 : 45.00).[60] Reproduced by 
permission of The Royal Society of Chemistry. 
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4.3 Results and Discussion  
 
4.3.1 AH Peptide-Induced Vesicle Fusion Observed by QCM-D.  
We used quartz crystal microbalance with dissipation monitoring (QCM-D) to 
observe the characteristics of AH peptide-induced vesicle fusion and lipid bilayer 
formation. Figure 4.2A shows SLB formation from POPC vesicles by spontaneous vesicle 
fusion. This is a two-step process that relies on membrane tension,[110, 170] vesicle-
vesicle, and vesicle-substrate interactions.[170] First, POPC vesicles are sparsely 
adsorbed onto the silica surface, resulting in a large frequency drop due to the increase 
in associated mass from the large amount of solvent trapped within and between the 
intact vesicles. Concurrently, the adsorbed vesicles contribute to an increase in 
dissipation due to their viscoelastic properties. Once the vesicle surface coverage reaches 
a critical concentration, the vesicles spontaneously rupture and fuse to form a 
continuous SLB.[55-58] The frequency increases due to released solvent from within the 
vesicle interior. Consistent with previous literature,[98] our final Δf and ΔD values for 
homogenous POPC SLBs are -27.1 ± 0.1 Hz and 0.19 x 10-6, respectively (Table 4.1).   
However, when vesicles were used that reflect the high cholesterol content and 
complex membrane of the HIV-1 envelope, complete spontaneous vesicle fusion does 
not occur (Fig. 4.2B). As the model HIV vesicles are added, vesicles adsorb to the silica 
surface resulting in a monolayer of un-ruptured vesicles. The leveled-off frequency 
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response (Δf = -150 Hz) demonstrates that vesicles adsorb until a vesicle monolayer is 
reached, as there is no vesicle fusion, which would provide a release of associated 
solvent. The frequency response here closely resembles that of a POPC vesicle 
monolayer on a gold substrate.[137]            
Figure 4.2C demonstrates the ability of AH peptides to induce SLB formation 
from a monolayer of model HIV vesicles (as shown in Fig. 4.2B). Vesicles are first added 
to achieve monolayer saturation, then excess vesicles in the QCM-D chamber are 
removed by three successive buffer washes. AH peptides (15 µM) are then added and 
cause vesicle fusion, which is reflected in the increase in frequency. After the frequency 
becomes stable, the peptide is washed away from the bilayer leaving behind the final 
SLB. Since the wash step of a complete SLB formed by spontaneous vesicle fusion does 
not remove surface-associated mass, we conjecture that when using AH peptide-
induced vesicle fusion, the observed frequency rise after the final wash step is due to 
decoupled mass associated with the removal of AH peptides from the SLB. The 
associated mass removed after the AH peptide wash was calculated to be 346.0 ± 22 ng 
cm-2 (n=5), using the Sauerbrey equation. 
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Figure 4.2: Representative QCM-D plots. Energy dissipation (dashed) and third 
overtone frequency (solid) plotted versus time. (A) SLB formation of 100% POPC by 
spontaneous vesicle fusion. (B) Failure of model HIV vesicles to undergo spontaneous 
vesicle fusion. (C) Successful model HIV SLB formation by AH peptide-induced vesicle 
fusion. (D) AH peptides create a SLB from a partially formed bilayer amongst un-fused 
vesicles.[60] Reproduced by permission of The Royal Society of Chemistry. 
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In most experiments, there was no spontaneous vesicle fusion when using model 
HIV vesicles (Figs. 4.2B,C). However, as seen in Figure 4.2D, there were instances when 
partial spontaneous vesicle fusion occurred. Figure 4.2D shows that even when AH 
peptides are added to a partially formed bilayer amongst un-fused vesicles, complete 
SLB formation is still achieved. This suggests that AH peptides are able to integrate 
preformed SLB areas with areas of intact vesicles to form a complete SLB with minimal 
defects. This is further corroborated by the close agreement in the final Δf value for SLBs 
formed from different starting conditions and shows that variations in the starting 
condition do not compromise the ability of AH peptides to form complete SLBs. 
The final Δf of the model HIV SLB was -35.4 ± 0.8 Hz with a ΔD of 1.91 ± 0.23 x 
10-6. These values are significantly larger than the final Δf and ΔD values of SLBs formed 
by spontaneous vesicle fusion using 100% POPC vesicles (Table 4.1). The frequency 
difference between these SLBs corresponds to about a 32% apparent mass increase for 
the model HIV SLB. It is unclear, however, if this apparent mass increase arises from an 
increase in lipid packing density due to the presence of cholesterol and sphingomyelin, 
or from an increase in SLB-associated solvent, or from an incomplete bilayer with areas 
of intact vesicles. Our NR and AFM data suggest, however, that our SLB is complete 
with no intact vesicles remaining on the surface. The SLB preparation for NR and AFM 
experiments is not identical to that for the QCM-D experiments, and thus, we cannot 
 78 
definitively conclude that our final Δf value reflects a 100% complete SLB. Our QCM-D 
results agree closely, however, with a previous publication that reports the final Δf and 
ΔD of a POPC:CH (55:45) SLB formed at 25 °C on silica to be 32 ± 0.7 Hz and 2.00 ± 0.4 x 
10-6, respectively.[30] Although the SLB lipid composition is simpler compared to the 
model HIV SLB, the cholesterol content is identical and the final Δf and ΔD values 
closely agree. Therefore, we speculate that the increase in lipid packing density due to 
high cholesterol concentration is likely a factor contributing to the observed mass 
increase of the model HIV SLB.  
However, there is also an increase in the final dissipation value compared to the 
POPC bilayer formed by spontaneous vesicle fusion. This suggests that the model HIV 
SLB is more viscoelastic, which is contrary to a more rigid and denser SLB. Thus, it is 
unlikely that the increased packing density accounts for the entire increase in mass. The 
higher final Δf and ΔD could indicate that there are intact vesicles on the surface. There 
is also a possibility that upon AH peptide-induced vesicle fusion, the amount of 
liposomes present on the surface before the introduction of the AH fusion peptide, 
exceeds the lipid content necessary to form a planar SLB. This could give rise to small 
undulations in the SLB, which would contribute to higher final Δf and ΔD values. 
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Table 4.1:2QCM-D data showing mean and SE of Δf and ΔD at the maximum and final 
values for SLB formation from model HIV vesicles (formed by AH peptide-induced 
vesicle fusion) and from POPC vesicles (formed by spontaneous vesicle fusion).   
Vesicle Composition Δfmax,3  3-1 /Hz ΔDmax,3  (10-6) Δffinal,3  3-1 /Hz ΔDfinal,3  (10-6) 
Model HIV SLB (n=6) -172 ± 17 38 ± 8 -35.4 ± 0.8 1.91 ± 0.23 
POPC (n=3) -65 ± 6 5.7 ± 0.7 -27.1 ± 0.1  0.19 ± 0.02 
 
 
4.3.2 SLB Characterization by Neutron Reflectivity  
Neutron reflectivity (NR) is a surface-sensitive technique that provides 
molecular-scale information about the structure of interfacial layers perpendicular to the 
interface.[171] NR measurements were used to characterize the membrane structure (to 
identify membrane defects), to determine SLB thickness, and to determine if there were 
residual AH peptides embedded within or associated with the SLB after washing. Fit 
parameters and 95% confidence intervals were determined using a Monte Carlo re-
sampling analysis of the reflectivity data. The reflectivity curves obtained from NR (Fig. 
4.3) give rise to the modeled NR scattering length density (nSLD) profiles (Fig. 4.3, inset) 
that provide a depth profile of the chemical constituents of the model bilayer with 
Ångstrom resolution. The NR results confirm that the SLB is 100 +0.0-0.1% complete. The 
nSLD value of the hydrocarbon core of the bilayer ρn = 0.42 +0.07-0.07 10-6 Å-2 shows the 
absence of peptide material in this region with an uncertainty of approximately 3 vol%. 
The volume fraction of head group material in the head group layers was 78 +0.1-0.3%. This 
falls, within confidence limits, into the expected range of 40%-60% for a bilayer void of 
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additional peptide material, but the high uncertainties do not permit a quantification of 
residual amounts of peptide in the narrow head group region. However, from the NR 
data the presence of any peptide material beyond the outer lipid head group can be 
excluded. We conclude therefore, that the AH fusion peptides are completely removed 
from the SLB surface after washing, which is in agreement with previous studies.[137, 
172] Finally, the hydration layer between the silicon wafer and the SLB was 4.8 +1.0-1.4 Å, 
the average total bilayer thickness was 49.9 +1.9-1.5 Å. A similar bilayer composition 
(DOPC:SM:CH 1:1:1) measured by X-ray diffraction results in a bilayer thickness of 
approximately 54 Å[46] and is in close agreement to our bilayer thickness of our model 
HIV SLB measured by NR.  The thickness of the inner head group, each hydrocarbon 
leaflet, and outer head groups were 12.3 +0.9-0.8, 14.8 +1.0-0.8, and 8.0 +0.8-0.5 Å, respectively. We 
expected the inner and outer lipid headgroups to have a similar thickness, yet the inner 
head group was measured to be approximately 4.3 Å thicker than the outer headgroup. 
This suggests asymmetric leaflet organization or that there is an error in the 
experimental modeling of the NR curves. To detect asymmetry in our SLBs it is possible 
to use sum frequency generation (SFG) spectroscopy, which is a highly surface sensitive 
characterization method that emits sum frequency light at interfaces.[173] This inherent 
interface specificity can be used to probe the molecular leaflet arrangements in our SLBs 
and can help determine if the lipid headgroup thicknesses of our SLBs were modeled 
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accurately. Deuterated lipids may also be used with NR to more accurately model 
thicknesses of the SLB structure.  
 
 
Figure 4.3: Neutron reflectivity curves, best-fits, and best-fit nSLD profiles for the 
measurements of the model HIV SLB. Inset: Best-fit nSLD profiles of reflectivity 
curves.[60] Reproduced by permission of The Royal Society of Chemistry. 
 
4.3.3 AFM Visualization of the Model HIV SLB.  
We used AFM[174] imaging to visualize lipid domains that are expected to form 
in SLBs with high concentrations of cholesterol and to visualize potential SLB surface 
defects. Due to the packing characteristics of phospholipids, two domain types typically 
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form, (i) gel domains and (ii) liquid-disordered (Ld) domains. Gel domains are 
characterized by tightly packed lipids that have limited lateral mobility compared with 
liquid-disordered domains, in which lipids are more loosely packed and have a higher 
degree of lateral mobility. The phase transition from the gel domain to an Ld domain is 
determined by the Tm of the lipids that constitute the domain. Furthermore, cholesterol 
and sphingolipids have a tendency to associate with lipids to create the Ld domain 
where they stiffen the lipid’s acyl chains into a more upright position. This organization 
facilitates a high lipid packing density, resulting in highly ordered, tightly packed 
islands, known as liquid-ordered (Lo) domains or lipid rafts.[47, 48] A height difference 
between lipids within Lo and Ld domains ensues because lipids are in a more upright 
position within Lo domains compared to lipids within Ld domains. These height 
differences can be visualized using high-resolution AFM imaging (Figs. 4.4A,B).  
Three visually distinct lipid domains can be seen in the model HIV SLB (Figs. 
4.4A,B). Ordered membrane domains are taller and appear brighter compared to the 
more disordered membrane domains which are lower and appear darker. Domain 
height differences were analyzed from several AFM images after a wash step, which 
removed SLB-associated AH peptides (Fig. 4.4B). We also completed experiments where 
SLBs were imaged before and after the final wash step (Fig. 4.4A contrasted with Fig. 
4.4B). Thus, AH peptides are still associated with the SLB in Figure 4.4A as observed 
from QCM-D results (Fig. 4.2). Within the limit of detection, AFM imaging did not 
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reveal the presence of AH peptide aggregates on the membrane surface. Additionally, 
no differences in domain heights were observed before or after AH peptides were 
washed from the SLB.   
The height differences between the lowest and middle domain (i.e. domains 1 
and 2) was 10.3 ± 0.6 Å, and between the middle and tallest domain (i.e. domains 2 and 
3) was 2.4 ± 0.7 Å. The thickness of domains 1, 2, and 3 were 40.9 +1.9-1.6, 51.2 +2.0-1.7, and 
53.7 +2.1-1.8 Å, respectively. These thicknesses were determined using the average 
thickness of the SLB obtained from NR measurements, the relative height differences 
between domains, and the fractional surface area occupied by each domain (obtained 
from several AFM height images). 
Considering the transition temperature of each lipid type, it is likely that the 
most fluid domain (lowest height, domain 1) predominantly contains POPC (Tm = -2 °C) 
and POPS (Tm = 14 °C), while the more ordered domains, 2 and 3, likely contain a 
mixture of POPE (Tm = 25 °C), sphingomyelin (Tm = 37 °C), and cholesterol. Since domain 
3 is the thickest, and thus, the most ordered, cholesterol is likely to be at the highest 
concentration in this domain.   
Furthermore, Figure 4.4C shows a 64 µm2 image, which offers a more global 
view of a complete SLB. Within imaged regions of the bilayer, cross-sections revealed 
that there were neither hole defects (expected to be ~ 5 nm deep i.e., the bilayer 
thickness) nor intact vesicles on the substrate surface (expected to be ~ 100 nm tall). We 
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note that the resolution of AFM imaging depends on many variables including tip size, 
imaging parameters, and tip-substrate interactions. It is therefore possible that there are 
defects on the molecular scale that were not resolved by AFM imaging. Furthermore, it 
is possible that AFM imaging can smooth out membrane undulations, and potentially 
rupture surface-adhered vesicles.[129, 175]  
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Figure 4.4: AFM height image of model HIV SLB on mica (imaged in buffer, 18° C, ± 1.6 
nm height scale). (A) 1.8 x 1.6 µm image showing SLB topography before AH peptides 
were washed from the surface. Height cross-section was taken along the three domains 
indicated by the position of the dashed line. The three domains labeled in the height 
cross-section correspond to the numbers labeled on the AFM height image. (B) 1.8 x 1.6 
µm image showing SLB topography after AH peptides were washed from the surface. 
(C) Height image demonstrating a complete, defect free SLB over a larger, 8 x 8 µm, 
area.[60] Reproduced by permission of The Royal Society of Chemistry. 
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4.4 Conclusions  
This work introduces AH peptide-induced vesicle fusion as a reliable and facile 
technique to form a SLB that contains a high cholesterol content and multiple lipid 
types. The utility of this technique to form biomimetic SLBs was exemplified by forming 
SLBs from vesicles that recapitulate the native HIV-1 envelope. Without the use of AH 
peptides, model HIV vesicles fail to form a complete SLB. The SLB formation was 
characterized by QCM-D and NR measurements, and AFM imaging. AH peptides were 
able to induce SLB formation from adsorbed vesicles, and also from areas of partially 
formed bilayer amongst un-fused vesicles. NR results show that the formation of the 
SLB using AH peptides is complete and that peptides are completely removed from the 
SLB surface after washing. AFM imaging provided a topographical map of the SLB and 
revealed three distinct membrane domains. Furthermore, AFM imaging showed that 
imaged SLB areas did not have major hole defects, did not contain intact vesicles, and 
did not show AH peptide aggregates.  
Given the success reported here and by Cho and coworkers in using AH peptide-
induced vesicle fusion, there is potential for this technique to form SLBs under a range 
of conditions and surfaces that are generally unfavorable for spontaneous vesicle fusion. 
Examples may include, fusion of vesicles that contain large membrane-embedded 
proteins, and SLB formation on polymeric substrates. 
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4.5 Materials and Methods 
4.5.1 Vesicle Preparation 
All lipids used, palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (POPE), 1-palmitoyl-2-oleoyl-sn-
glycero-3-phospho-L-serine (POPS), brain sphingomyelin (SM), and cholesterol (CH), 
were dissolved in chloroform (Avanti Polar Lipids) and brought to room temperature 
for 1 h, dried under nitrogen for 5 min, and then dried under vacuum for 3 h. The lipid 
film was reconstituted in 37 °C PBS without Ca2+ and Mg2+, pH 7.4 (Gibco Invitrogen, 
Grand Island, NY) vortexed, sonicated, and extruded 11 times through a 0.4 μm filter 
and then through a 0.1 μm filter (Whatman, Florham Park, NJ).[176] The concentrated 
lipid solution was then diluted to 0.6 mg/mL in buffer and vortexed immediately before 
use. Lipid solutions were used within 10 h of extrusion. 
 
4.5.2 AH Peptide-Induced Vesicle Fusion  
Amphipathic α-helical (AH) peptide was synthesized by Anaspec Corporation 
(San Jose, CA). The sequence of the AH peptide is H-Ser-Gly-Ser-Trp-Leu-Arg-Asp-Val-
Trp-Asp-Trp-Ile-Cys-Thr-Val-Leu-Thr-Asp-Phe-Lys-Thr-Trp-Leu-Gln-Ser-Lys-Leu-Asp-
Tyr-Lys-Asp-NH2. Peptide powder was dissolved in dimethyl sulfoxide and diluted to 
15 µM in buffer. AH peptide-induced vesicle rupture was achieved by first depositing a 
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solution of 100 nm vesicles on substrates using a fluid cell (for QCM-D and NR 
experiments) or pipetted onto substrates (for AFM experiments). After washing non-
adhered vesicles from solution, AH peptide (15 µM) was added and allowed to incubate 
on the sample between 15-45 min. Finally, samples were washed to remove AH peptides 
and excess lipids unless otherwise noted.   
 
4.5.3 Quartz Crystal Microbalance with Dissipation Monitoring  
Experiments were performed using a D300 Q-Sense QCM-D with silicon oxide 
crystal sensors (Biolin Scientific, Gothenburg, Sweden). Before each QCM-D experiment, 
all crystals were first treated with ultraviolet light and ozone for 5 min and then cleaned 
in 2% sodium dodecyl sulfate (SDS) solution for 30 min, rinsed with ultrapure water, 
and blown dry under N2 flow. The crystals were then treated with ultraviolet light and 
ozone for 10 min before being sonicated in acetone for 3 min. Finally, the crystals were 
rinsed excessively with ultrapure water, blown dry under N2 gas, and immediately 
mounted into the QCM-D chamber. 10 mM Tris, 150 mM NaCl, pH 7.4 was used to 
equilibrate the crystal, and then vesicles in buffer were introduced into the chamber 
until a stable frequency level was obtained. 
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4.5.4 Neutron Reflectivity 
Neutron reflectivity (NR) measurements were performed at the NG1 
reflectometer at the NIST Center for Neutron Research (NCNR)[177] using neutrons of a 
wave length λ = 4.75 ± 0.10 Å. A momentum transfer, qz, range between 0 and 0.35 Å-1 
was used for all measurements. The bilayer sample was measured while being 
immersed subsequently using three distinct solvent isotopic contrasts: aqueous buffer 
prepared from D2O, H2O, and from a 2:1 mixture of D2O and H2O by volume (CM4). For 
each contrast, sufficient counting statistics were obtained after 6-9 h. The NCNR flow 
cell allows for in situ isotopic solvent contrast exchange on the instrument. Therefore, all 
measurements were performed on exactly the same sample area. The entire flow cell 
was maintained at room temperature. 
Analysis of NR data was performed using the GARefl software package.[178] 
Reflectivity is computed from a slab model[179] that represent the scattering length 
density (SLD) profiles using the optical matrix method[180] for computing the 
reflectivity. Optimization of model parameters is achieved by the combined use of a 
genetic algorithm and a simplex amoeba algorithm for efficient searching of parameter 
space and a Levenberg-Marquardt non-linear least square algorithm to refine the fit. All 
reflectivity curves measured on the same wafer during an experiment were fitted 
simultaneously, sharing fit parameters, for example, for the solid substrate. 
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A Monte Carlo error analysis procedure[181] was used to determine the SLD 
confidence limits by multiple generation of synthetic reflectivity consistent with the 
measured data based upon the original data set and the statistical uncertainties of the 
individual data points. Synthetic reflectivities were subsequently fitted to the same 
model. Using a statistic analysis of the obtained set of parameter values, a bias free 
estimate of the uncertainties of the resulting SLD profiles is obtained. 
 
4.5.5 Atomic Force Microscopy 
Visualization of the SLB was performed using a commercial atomic force 
microscope (Nanoscope V, Bruker, Santa Barbara, CA) at room temperature. All images 
were obtained in buffer and imaged in tapping mode using triangular Si3N4 cantilevers 
(Digital Instruments) with a spring constant of 0.06 N m-1 operating at 5% offset from the 
cantilever resonance frequency. Formation of SLBs was achieved by depositing 200 µL 
of 100 nm vesicle solution (10 mM HEPES, 150 mM NaCl, pH 7) on a freshly cleaved 
mica surface taped to a circular Teflon puck. Prepared surfaces were then washed with 
buffer and then incubated with AH peptides (Anaspec, San Jose, CA) at room 
temperature for at least 30 min. Prior to imaging, surfaces were rinsed by successive 50 
µL buffer exchanges 7 times unless otherwise noted. High-resolution (512 x 512 points) 
topographical images were collected. The height differences between lipid domains 
were determined from cross-sectional analysis of six different locations from two 
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different SLB samples. Error propagation was used to calculate the standard error of 
absolute domain thicknesses, which were determined from NR and AFM 
measurements. 
 
 92 
Chapter 5. HIV-1 Antibodies and Vaccine Antigen 
Selectively Interact with Lipid Domains 
 
 
This work was in collaboration with Kara Anasti (Duke Human Vaccine Institute) who 
performed the SPR experiments.  
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5.1 Introduction 
Chapter 5 applies the SLB research platform developed in Chapter 4 to help 
determine how lipid domains contribute to 2F5/4E10 membrane interactions and antigen 
presentation in supported lipid bilayers. To this end, we have engineered biomimetic 
supported lipid bilayers and use atomic force microscopy to visualize membrane 
domains, antigen clustering, and antibody-membrane interactions. Our results 
contribute to vaccine design considerations by determining the optimal lipid phase that 
should be used in vaccine liposomes to elicit 2F5/4E10 membrane-interactions. This 
research is currently under preparation for submission to the Proceeding of the National 
Academy of Sciences.  
 
5.2 Background  
Understanding the role of the lipid membrane in 2F5/4E10’s neutralization 
mechanism can help select important lipid components to be used in the synthesis of 
vaccine liposomes. We posit that vaccine liposomes that contain the MPER antigen and 
an optimized lipid environment are more likely to induce the desired, polyreactive 
NAbs. The research presented here ultimately provides information on lipid selection 
when developing new immunogen designs.  
Several spectroscopy-based techniques have been used to help understand the 
role of lipids in 2F5/4E10 HIV-1 neutralization and vaccine design.[73, 182] Although 
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these established techniques are sensitive, they lack lateral resolution and cannot 
visualize how membrane morphology, such as lipid domains, contribute to NAb- and 
antigen-membrane interactions. Currently, it is believed that the viral envelope will 
organize highly ordered lipid domains (i.e., lipid rafts) and that these lipid domains 
influence lipid-NAb interactions. Due to the high concentration of cholesterol (CH) and 
sphingomyelin (SM) in the native HIV-1 envelope, the Lo domain is expected to 
dominate HIV-1 domain structures. With proper lipid selection, lipid domains can also 
be created in vaccine liposomes and potentially influence antibody binding and antigen 
presentation. To help understand how lipid domains influence NAb- and antigen-
membrane interactions we have created supported lipid bilayers (SLBs) that can phase 
separate into lipid domains (Fig. 5.1A). To visualize NAb- and antigen-membrane 
interactions, we used atomic force microscopy[183] (AFM) to produce high-resolution, 
topographical images of three different types of SLBs: a single-phase SLB, a two-phase 
SLB, and a complex, five-component SLB composition that mimics the lipid composition 
of the native HIV-1 lipid envelope. Unlike many surface-sensitive, spectroscopy 
techniques, AFM can visualize how antibodies and antigens spatially interact with lipid 
domains. We show that AFM reveals the height mismatch between lipid domains and 
surface-associated proteins with Ångstrom vertical resolution and approximately 5-10 
nm lateral resolution.  
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5.2.1 Domain Formation and 2F5/4E10’s Lipid Reactivity 
A comprehensive discussion of domain formation and 2F5/4E10’s lipid-reactivity 
is given in Chapter 1. A brief description will be given here. Generally, lipid domains are 
defined as areas of a membrane that have a different composition from their 
surroundings, i.e., an enrichment or depletion of certain membrane components. Lipid 
domains typically form when there is more than one lipid phase in the same bilayer. 
There are two main phase types: a solid and a liquid phase. The solid or “gel” phase is 
characterized by highly ordered, tightly packed lipids that have limited lateral mobility 
compared with the liquid phase (Fig. 5.1B). The liquid phase can be further divided into 
the liquid-disordered (Ld) and liquid-ordered (Lo) phase (Fig. 5.1C). The Ld phase exists 
when lipids have melted from the gel to liquid phase (defined by the transition 
temperature, Tm) while the Lo typically forms when CH and SM exist in Ld membranes. 
CH and SM will co-localize within the Ld phase resulting in highly ordered, tightly 
packed islands known as Lo domains or lipid rafts.[47, 184].  
The interaction between lipids and 2F5/4E10 is likely mediated by the NAb’s 
unique complementary determining region (CDR) H3 loop.[20] The CDR H3 regions 
contain an unusually large number of hydrophobic and membrane-reactive residues, 
suggesting that they can embed in the viral membrane and position the NAb to 
encounter and bind its antigen.[21, 185] Mutations in these CDR H3 antibody regions 
allow 2F5/4E10 to bind MPER’s linear and conformational epitopes, but prevent the 
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NAb’s lipid reactivity, which results in the inability to bind membrane bound MPER 
antigen.[186] This phenomenon may explain why simple peptide immunogens that 
mimic neutralizing epitopes on gp41 do not elicit NAbs in vivo,[187, 188] and it is clear 
that antigen sequence is not the sole determinant of neutralizing ability. To mimic 2F5 
and 4E10’s in vitro neutralizing ability, in vivo immunogens must elicit antibodies that 
also react with the HIV-1 lipid envelope. How to design immunogens to do this remains 
largely unknown. 
 
 
Figure 5.1: Schematic representations of NAbs, antigen, and lipid organization in SLBs. 
(A) Proposed SLB environment interacting with NAbs (green) and MPER656 (yellow). 
NAbs and MPER656 only interact with the Ld phase (blue) and avoid Lo and gel 
domains (represented collectively in red). (B) Lipid organization expected from the 
POPC:POPE SLB. Gel domain (dark green) surrounded by Ld phase (light green). (C) 
Lipid organization expected from the model HIV SLB. Lo domains consisting of 
sphingomyelin (red) and cholesterol (yellow) in a Ld phase (light green).    
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5.2.2 Model Membrane Research Platform 
The three SLBs tested here contain the Ld, Lo, and gel phase. The POPC SLB 
contains a homogenous Ld phase. POPC:POPE (1:1) SLB contains a gel and Ld phase, and 
the model HIV SLB (POPC:POPE:POPS:SM:CH, 9.35 : 19.25 : 8.25 : 18.15 : 45.00) contains 
an Ld and Lo phase, and depending on the temperature, may also contain a gel phase. To 
reliably create the model HIV SLB, we used amphipathic, α-helical (AH) peptides 
(detailed in Chapter 4) as a catalyst to generate complex SLBs containing high 
cholesterol content with multiple lipid types.[60]  
 
5.3 Results 
5.3.1 Antibody and Antigen Interactions with Liquid-Disordered 
SLBs 
 AFM height images of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC) SLBs are shown in Figures 5.2A-D. In these, and all following AFM height 
images, increasing topographical feature heights are represented by increasing 
brightness. The POPC SLB appears smooth, with no observable height differences in the 
membrane organization (Fig. 5.2A). This smooth topography reflects the presence of a 
homogenous lipid phase with no observable domain formation. Since the Tm of POPC is 
-2 °C, the SLB exists in the Ld phase at room temperature.  
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2F5 and 4E10 were each separately added to the POPC SLBs. After NAb 
addition, the AFM height images (Figs. 5.2B,C) reveal bright spots (i.e., topographical 
peaks) over the entire membrane surface; we attribute these peaks to the presence of 
NAbs that have interacted with the top leaflet of the SLB. The surface-associated NAbs 
cover approximately 3% of the SLB surface (Table 5.1). Based on topographical feature 
size distributions, the surface-associated NAbs are distributed between 0.5-1.5 nm above 
the SLB with few feature counts at 2 nm and greater. Features exceeding 2 nm in height 
likely reflect clusters of antibodies bound to the SLB. In solution, antibodies such as 2F5 
and 4E10 have a radius of gyration of approximately 7 nm.[189] The small heights of the 
topographic peaks suggest that in most instances individual antibodies are bound to the 
SLB surface. We attribute the apparent size difference (i.e., height of NAbs on the SLB 
surface vs. Ab size in solution) to the tapping force exerted by the AFM cantilever during 
imaging. This force compresses the antibody against and possibly into the SLB, which 
results in the smaller observed heights.  
MPER656 consists of a hydrophobic GTH1 membrane anchor tag and the binding 
epitope for both 2F5 and 4E10.[190] While the GTH1 anchor resides within the 
hydrophobic core of the SLB, the NAb binding epitopes are likely positioned parallel 
with the top lipid leaflet, i.e., at the interface of the lipid bilayer and bulk solution.[191] 
Based on the size of the MPER binding epitope (3.3 kDa), the folded length is 
approximately 2 nm. When MPER656 is included in the POPC SLB (Fig. 5.2E), 0.5 nm 
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high topographical peaks appear evenly distributed over the SLB surface. This subtle, 
antigen-induced height difference between the POPC and POPC:MPER656 SLB is further 
confirmed by the root mean squared (RMS) surface roughness. Over a 1 µm2 area, the 
RMS roughness of the POPC:MPER656 SLB is 2.7 ± 0.2 Å, while that of the neat POPC 
bilayer is significantly smaller, with 1.6 ± 0.05 Å. This difference in SLB surface 
roughness can also be seen by comparing the height cross-sections from Figures 5.2A 
and 5.2E, presented below the topography images.  
When NAbs are incubated on these SLB surfaces, they bind preferentially to 
regions that contain MPER656 antigen (Figs. 5.2F,G). NAb binding to the SLB and to 
MPER656 can be seen by the appearance of “bright spots”, i.e., peaks 2-4 nm in height, in 
the SLB height images. The locations of these peaks are evenly distributed across the 
SLB surface, suggesting that MPER656 is also evenly distributed. 2F5’s surface coverage is 
42 ± 6%, while addition of 4E10 results in a surface coverage of 47 ± 5% (Table 5.1).    
A murine monoclonal antibody, 13H11, was incubated on all SLB surfaces as 
control. 13H11 has no lipid reactivity and while it does bind to the soluble form of the 
MPER-antigen peptide, it cannot bind to membrane-embedded MPER.[17] As expected, 
there is little to no 13H11 interactions with the POPC SLB (Fig. 5.2D) nor with POPC SLB 
containing MPER (Fig. 5.2H), thus confirming that NAb-membrane interactions are 
specific to 2F5 and 4E10. 
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Table 5.1:3Average percent surface coverage of Ld area and NAb binding for all SLBs 
tested (calculated from AFM topographical images). (--) indicates NAb coverage was 
unable to be determined. 
SLB Ld coverage (%, n=4) 2F5 coverage  (%, n=3)  4E10 coverage (%, n=3) 
    Ld area Total area Ld area Total area 
POPC  100 ± 0 3 ± 0.3 3.0 ± 0.3 2.7 ± 0.3 2.7 ± 0.3 
POPC:MPER656 100 ± 0 42.0 ± 5.5 42.0 ± 5.5 46.7 ± 4.7 46.7 ± 4.7 
POPC:POPE  41.2 ± 4.1 2.8 ± 0.7 1.1 ± 0.4 3.4 ± 0.3 1.4 ± 0.3 
POPC:POPE:MPER656  38.7 ± 2.3 26.1 ± 7.0 10.1 ± 3.3 19.3 ± 1.9 7.5 ± 1.2 
Model HIV  39.1 ± 3.0 -- 3.7 ± 0.9 -- 1.9 ± 0.2 
Model HIV:MPER656 3.1 ± 0.4 -- 2.1 ± 0.5 -- 1.7 ± 0.1 
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Figure 5.2: AFM height images of the POPC and POPC:MPER656 SLBs with and without 
antibody addition (imaged in liquid at 24 °C). Height cross-section given for select 
images. (A) POPC SLB. (B-D) 2F5, 4E10 and 13H11 added to the POPC SLB, respectively. 
(E) POPC:MPER656 SLB. (F-H) 2F5, 4E10, and 13H11 added to the POPC:MPER656 SLB, 
respectively. 
 
5.3.2 Antibody/Antigen Interactions with Gel/Liquid-Disordered SLBs 
While NAbs and MPER656 are apparently evenly distributed throughout the Ld 
phase of the unary POPC SLB, we next tested their distribution in a binary, phase-
separated SLB, consisting of POPC:1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine (POPE) (1:1). POPC:POPE SLBs, imaged at 18-20 °C (Fig. 5.3A), 
revealed a gel domain consisting of predominantly POPE (Tm = 25 °C) and an Ld phase 
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consisting of predominantly POPC (Tm = -2 °C). Gel domains are taller and appear 
brighter compared to the Ld phase, which is lower and thus appears darker. The taller 
POPE gel domains extend 4.8 ± 0.4 Å above the surrounding POPC Ld phase. When 
NAbs were incubated on this phase-separated SLB surface, they interacted only with the 
Ld phase (Figs. 5.3B,C), resulting in a surface coverage on the Ld phase of 3 ± 1% for 2F5 
and 3 ± 0% for 4E10, respectively (Table 5.1). The tallest NAb peaks were approximately 
1.5 nm above the Ld domain surface.  
 Next, POPC:POPE:MPER656 SLBs were prepared. AFM images (Fig. 5.3E) 
revealed that MPER656 exclusively localized to the Ld domain. While the antigen peak 
heights ranged from about 0.5 nm to 2.0 nm, the peak widths ranged from about 15 to 30 
nm, i.e., much wider than expected for single MPER656 peptides. This observation 
suggests that MPER656 aggregated in the Ld phase.  
When NAbs were added to the POPC:POPE:MPER656 SLB, they bound to the SLB 
and to MPER656, indicated by the presence of 1-2 nm peaks in the AFM images (Figs. 
5.3G,I). These images also show that NAbs only bound to the Ld phase and were 
excluded from the taller, gel phase. 2F5’s Ld surface coverage was 26 ± 1%, while 4E10 
addition resulted in an Ld surface coverage of 19 ± 2% (Table 5.1). A second addition of 
NAbs (4.0 µM) resulted in large clusters (3-7 nm tall) of Ld-localized NAb (Figs. 5.3H,J) 
reaching close to 100% coverage of the Ld phase. No antibody binding peaks were found 
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in the gel domains, which suggest that gel domains are either void of MPER656, or the 
antigen is presented in a conformation that is not accessible to NAb binding.  
As expected, 13H11 showed no interactions with neither the POPC:POPE (Fig. 
5.3D) nor the POPC:POPE:MPER656 SLB (Fig. 5.3F).  
 
 
 
 
 104 
 
Figure 5.3: AFM height images of the POPC:POPE and POPC:POPE:MPER656 SLBs with 
and without antibody addition (imaged in liquid at 18-20 °C). Height cross-section given 
for select images. (A) POPC:POPE SLB. The bright area is the taller, gel domain, while 
the darker area is the lower, Ld phase. (B-D) 2F5, 4E10, and 13H11 added to the 
POPC:POPE SLB, respectively. (E) POPC:POPE:MPER656 SLB. Inset: 250 x 250 nm height 
image from a replicate sample showing MPER656 in the Ld phase. (F) 2F5 added to the 
POPC:POPE:MPER656 SLB. Inset: 250 x 250 nm image from a replicate sample (G) Image 
(F) with a second addition of 2F5 (4.0 µM). (H,I) Repeated conditions from image (F,G) 
with 4E10. (M) 13H11 added to POPC:POPE:MPER656 SLB. 
 
5.3.3 NAb and Antigen Interactions with Complex, HIV-1 Mimetic SLB 
 A common SLB model of the HIV-1 envelope is a ternary composition consisting 
of POPC, SM, and CH.[168, 192] Here we use a more physiologically relevant SLB model 
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of the HIV-1 envelope[193] to study NAb and antigen interactions. Our model HIV SLB 
composition consists of POPC, POPE, 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-
serine (POPS), brain SM, and CH in a molar ratio of 9.35 : 19.25 : 8.25 : 18.15 : 45.00. This 
composition was previously used to make liposomes for SPR binding assays in vaccine 
studies.[12, 186]. To create SLBs with this model HIV composition, we have previously 
developed a vesicle fusion technique that uses amphipathic, α-helical (AH) peptides as a 
catalyst to generate complex SLBs containing high cholesterol content.[194] Here, for the 
first time, we imaged with AFM to visualize NAb and antigen interactions with this 
model HIV SLB.     
Figure 5.4 demonstrates the significant morphological changes that occur in the 
model HIV SLB when imaged at 18 °C compared to 37 °C. At 18 °C there are three 
distinct domains visible (Fig. 5.4A) with a height difference of 10.3 ± 0.6 Å between the 
lowest and medium height domain, and a height difference of 2.4 ± 0.7 Å between the 
medium height and tallest domain. At 37 °C (Fig. 5.4B), however, only two distinct 
phases exist, with a height difference of 8.2 ± 0.4 Å.  
 Regardless of temperature, the addition of 2F5 resulted in 2F5-membrane 
interactions only in the most disordered (i.e., lowest height) lipid phase (Figs. 5.4C,D). 
To mimic physiological conditions, comprehensive measurements were conducted on 
model HIV SLBs at 37 °C. We found that 2F5 had a surface coverage of 4 ± 1%, and that 
4E10 behaved like 2F5, by binding only to the most disordered lipid phase (Fig. 5.4E), 
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reaching a surface coverage of 2 ± 0% (Table 5.1).  
When MPER656 was incorporated in the model HIV SLB (37 °C), the prominent, 
two-phase SLB no longer existed (Figs. 5.4G-J). Rather, a more homogenous lipid phase, 
with small, about 7 Å deep, narrow depressions appeared in the bilayer (Fig. 5.4G). We 
surmise that these depressions consist largely of the Ld phase, likely containing also 
MPER656. The surface coverage of these Ld features is 3 ± 0%, i.e., significantly less than 
the surface coverage of the Ld area on the model HIV SLB without antigen (39 ± 3%). 
Upon addition of NAb, the antibodies only bound to these depressions (Figs. 5.4H,I), 
resulting in a NAb total surface coverage of 2 ± 1% and 2 ± 0% for 2F5 and 4E10, 
respectively (Table 5.1). The taller, homogenous lipid phase is void of any antigen or 
antibody binding. Addition of 13H11 resulted in little to no interactions with the HIV 
SLB in absence (Fig. 5.4F) and presence (Fig. 5.4J) of MPER656.  
Surface plasmon resonance (SPR) experiments (Fig. 5.5) revealed that NAb 
binding was significantly higher on the POPC:MPER656 membrane compared with 
binding on the model HIV:MPER656 membrane (Figs. 5.5A,B vs. 5.5D,E). The Rmax 
(maximum binding capacity) for POPC:MPER656 was 65 ± 9 and 214 ± 10 response units 
(RU) for 4E10 and 2F5, respectively. For the model HIV:MPER656 membrane, the Rmax 
dropped to 9 ± 2 RU for 4E10 while binding of 2F5 was even weaker, and no reliable Rmax 
values could be determined. These results qualitatively agree with our surface coverage 
(i.e., binding) measurements by AFM imaging, which showed NAb coverage to be 
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between 42 and 47% for the POPC:MPER656 SLB compared to only 2 to 4% for the model 
HIV:MPER656 SLB. For the POPC and the model HIV membrane, 4E10 resulted in an Rmax 
of 7 ± 2 and 5 ± 0 RU, respectively, while 2F5 resulted in an undetectable Rmax. SPR 
measurements showed no detectable interactions of 13H11 for all membrane 
compositions tested (Figs. 5.5C,F).  
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Figure 5.4: AFM height images of the model HIV and model HIV:MPER656 SLB with and 
without antibody addition. Height cross-section of SLBs given below select images. 
(A,B) Model HIV SLB imaged at 18 °C and 37 °C, respectively. (C,D) 2F5 added to the 
model HIV SLB at 18 °C and 37 °C, respectively. (E,H) 4E10 and 13H11 added to the 
model HIV SLB at 37 °C, respectively (G) Model HIV:MPER656 SLB at 37 °C. (H-J) 2F5, 
4E10, and 13H11 added to the model HIV SLB:MPER656, respectively (at 37 °C). 
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Figure 5.5: Surface plasmon resonance (SPR) curves of NAbs and 13H11 interacting with 
POPC and model-HIV membranes (with and without MPER656). Antibodies added at 0 
sec and washed from surface at 120 sec (resulting in response spike). (A-C) Antibodies 
interacting with POPC:MPER656 (solid line) and POPC (dashed line) membranes. (D-F) 
Antibodies interacting with model HIV:MPER656 (solid line) and model HIV (dashed 
line) membranes.    
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5.4 Discussion    
5.4.1 NAb Interactions with SLBs 
AFM imaging of NAbs interacting with the POPC and POPC:POPE SLB revealed 
that 2F5 and 4E10 exclusively interacted with the Ld membrane phase. For the POPC 
SLB the Ld phase made up 100% of the SLB area, while for the POPC:POPE SLB, the Ld 
area was 41 ± 4%. Despite the difference in Ld area, NAb binding coverage was about 3% 
on both SLBs. NAb coverage on the Ld area for the model HIV SLB could not be 
determined accurately due to the dispersed nature and small size of the Ld phase. 
Instead, we report NAb coverage relative to the total area of the model HIV SLB (Table 
1). NAb binding on the model HIV SLB was similar to that on the POPC and 
POPC:POPE SLBs. NAbs exclusively interacted with the lipid phase with the lowest 
height and therefore the lowest lipid packing density, the largest membrane disorder, 
and the highest lipid diffusivity.[195-197] This result is in agreement with a previous 
AFM study completed by Franquelim et al.[168] The lipid diffusivity in the Lo phase is 
approximately a factor 2-10 smaller than in the Ld phase, depending on experimental 
details.[50-52] The presence of cholesterol is a major contributor to the physical 
properties of lipid domains. It has been shown that the force required to break the 
intermolecular lipid interactions in a cholesterol-rich Lo phase is greater compared to 
that in a cholesterol-depleted Ld phase.[197] This supports the hypothesis that the high 
order of Lo and gel domains prevented NAb insertion into these SLB areas. 
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Given the overall compositional and structural complexity of the model HIV 
SLB, the detailed lipid compositions of individual domains are unclear, but can be 
estimated considering the Tm values of the lipids. At 18 °C, the domain with the lowest 
height likely contains the highest concentration of POPC (Tm = -2 °C) and POPS (Tm = 14 
°C). The middle and tallest domains likely contain the highest concentration of POPE 
(Tm = 25 °C), SM (Tm = 37 °C), and CH. When the temperature is increased from 18 °C to 
37 °C, the SLB transitions from three to two phases. To create this two-phase system, it is 
likely that CH and SM have redistributed to form discrete Lo–Ld domains. At 37 °C, an 
Lo–Ld forming bilayer of the model HIV SLB agrees with the phase diagram of a similar 
bilayer composition, i.e., POPC:PSM:CH (1:1:1).[53] X-ray diffraction experiments of 
another, similar bilayer composition, i.e., DOPC:SM:CH (1:1:1), confirm the absence of a 
gel phase. This suggests that our model SLB also lacks a gel phase, and thus contains a 
Ld and Lo phase instead.[46] Furthermore, at 37 ºC, our model HIV domain height 
difference is 8.2 ± 0.4 Å, which agrees with expected Lo–Ld height differences. For 
example, Rinia et al. report similar height differences observed by AFM for 
DOPC:SM:CH bilayers that phase separate into Lo–Ld domains.[198] Thus, we believe 
that a Ld phase exists in our model HIV SLB, and since the Ld phase contains the highest 
lipid disorder, that it should reside in the domains of lowest SLB height, i.e., the same 
domains to which NAbs bind. This suggests that NAbs interact exclusively with the Ld 
phase in the model HIV SLB.  
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Collectively, our experiments on the three SLB systems tested, demonstrate that 
NAbs 2F5/4E10 bind exclusively to the Ld phase and do not interact with the ordered gel 
and Lo domains. This also suggests that these NAbs likely target Ld regions on the native 
virus before binding to their MPER antigen on gp41. To elicit antibodies that can 
recognize and interact with the Ld phase, vaccine liposomes likely should also contain 
lipids that organize into a dominant Ld phase. However, as discussed below, vaccine 
antigens may adversely contribute to Ld formation.     
 
5.4.2 Antigen/NAb interactions with SLBs 
On the POPC SLB (Ld), antigen presentation and NAb binding was uniformly 
distributed across the entire SLB surface. This indicates that the Ld phase does not 
restrict or hinder antibody/antigen membrane interactions and facilitates high antibody 
to antigen binding. In the POPC:POPE:MPER656 SLB (gel-Ld), MPER656 resided 
exclusively in the Ld phase. Gel domains not only excluded NAb interactions, but also 
prevented MPER656 membrane integration. The presence of MPER656 also inhibited gel 
domain coalescence. This is seen in Figure 5.3 where, in presence of antigen, smaller gel 
domains still exist (Fig. 5.3E) when compared to the gel domains in absence of antigen 
(Fig. 5.3A). However, the overall Ld area remains relatively constant, i.e., 41 ± 4% without 
and 39 ± 2% with MPER656. The presence of MPER656 in the model HIV SLB, decreased 
the total Ld area substantially. Without MPER656, the model HIV SLB had an Ld coverage 
 113 
of 39 ± 3%, and with MPER656 the Ld area decreased to 3 ± 0%. When comparing the 
morphology between the model HIV SLB without and with MPER656 (Fig. 5.4B vs. 5.4G), 
the presence of antigen resulted in a more homogenous lipid phase that is void of 
antigen-NAb binding. Large Ld areas fail to form, and the antigen is likely limited to the 
location of small (~30-60 nm in diameter) Ld pockets. This antigen distribution is in stark 
contrast to that in the POPC:MPER656 (Fig. 5.2E) and POPC:POPE:MPER656 (Fig. 5.3E) 
SLBs, where antigen is evenly distributed across the entire Ld phase. The NAb binding 
coverage is the lowest in the model HIV:MPER656 SLB (2 ± 0% for both 2F5 and 4E10) 
compared to that on POPC:MPER656 and POPC:POPE:MPER656 SLBs.  
SPR experiments confirmed that there is substantially less NAb-MPER656 binding 
when MPER656 is included in the highly ordered model HIV SLB when compared to the 
more fluid POPC SLB. Since both SLBs were prepared with an equal amount of MPER656, 
we believe that the reduced NAb binding to the model HIV:MPER656 SLB arises from the 
membrane structure and the organization of MPER656 in the SLB. AFM topography 
images suggest that an ordered phase dominates in the model HIV membrane (~97% 
surface coverage). Either this ordered phase is completely void of MPER656 or the antigen 
is buried in such an orientation that it cannot be detected by NAbs (or by the AFM 
cantilever during imaging). AFM images also show that MPER656 appears to be restricted 
to the small pockets in the SLB that contain the Ld phase (~3% surface coverage). Only a 
limited number of NAbs can bind MPER656 in these areas (Fig. 5.4H,I), before steric 
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restrictions likely prevent unbound NAbs from accessing unbound antigens, thus 
severely limiting NAb-antigen interactions.     
   
5.5 Conclusion 
Our results on SLBs demonstrate that NAbs 2F5/4E10 do not interact with the 
highly ordered gel or Lo phase but exclusively bind to the Ld phase. Using vaccine 
liposomes that mimic the high order of the HIV-1 envelope to induce antibodies that can 
recognize and bind to the viral envelope, may thus not be advantageous for 2F5/4E10 
based vaccine strategies. Rather, vaccine liposomes that contain an Ld phase may 
provide optimal selection of 2F5- and 4E10-like antibodies.  
In the context of liposomal antigen presentation, our results suggest that the 
presence of the MPER656 peptide may severely limit the Ld area available for antibody 
interactions. Subsequently, this reduces the amount of MPER656 that is accessible for 
2F5/4E10 binding, since MPER656 preferentially localizes to the Ld area. If Ld forming lipid 
components are used in vaccine liposomes, it is important to ensure that the presence of 
antigen does not inhibit large-scale Ld formation.       
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5.6 Materials and Methods 
5.6.1 Antibodies and Antigen  
Anti-HIV-1 gp41 (anti-membrane proximal) NAbs 4E10 and 2F5 were purchased 
from Polymun, Inc., Vienna, Austria. Mouse mAb 13H11 was produced from 
splenocytes from a mouse immunized with HIV Env oligomer CON-S [86], as described 
[84]. SLBs containing embedded HIV antigen, MPER656-GTH1 (CPC Scientific Inc., San 
Jose, CA) were prepared by first dissolving antigen in chloroform and then adding to 
lipid mixture before being dried under nitrogen.     
 
5.6.2 Lipid Preparation  
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphoethanolamine (POPE), 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
L-serine (POPS), brain sphingomyelin, and cholesterol in chloroform (Avanti Polar 
Lipids, Alabaster, AL) was brought to room temperature, dried under nitrogen, and 
then dried under vacuum for three hours. The lipid film was reconstituted in 37 °C PBS 
without Ca2+ and Mg2+, pH 7.4 (Gibco Invitrogen, Grand Island, NY), vortexed, 
sonicated, and extruded 11 times through a 0.4 μm filter (Whatman, Florham Park, NJ), 
and then through a 0.1 μm filter.[88] The concentrated lipid solution was then diluted to 
0.4 mg/mL in PBS buffer and vortexed immediately before use. After lipid extrusion, 
vesicle solutions were used within eight hours. 
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5.6.3 Atomic Force Microscopy  
The AFM images presented are the highest quality images that are representative 
of the observations obtained from image replicates (n=3 for SLBs containing antibodies 
and n≥4 for all other SLBs). In all AFM experiments, 2F5 and 4E10 were tested 
individually; however, no significant differences between the NAbs were observed. 
Unless otherwise noted, NAbs were added at approximately 4.7 µM for SLBs without 
MPER656 and 2.0 µM for SLBs with MPER656. Control antibody, 13H11 was added at 4.7 
µM for all membranes tested.  
AFM imaging was performed using a commercial AFM (Nanoscope IV, Digital 
Instruments/Bruker, Santa Barbara, CA) operating at room temperature. Images were 
obtained in buffer with tapping mode using triangular Si3N4 cantilevers (Bruker, SNL-
10) with a spring constant of 0.06 Nm-1. Between AFM experiments, cantilevers that were 
previously exposed to NAbs were soaked in ethanol in an attempt to remove NAbs that 
were adhered to the cantilever tip. This was necessary, because we observed that 
adhered NAbs from previous experiments could transfer from the cantilever tip to the 
SLB during AFM scanning.  
 Formation of SLBs for AFM imaging was achieved by α-helical (AH) peptide-
induced vesicle fusion.[60] First, 200 µL of 100 nm vesicle solution was added to a 
freshly cleaved mica surface taped to a Teflon puck. Samples were then washed with 
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buffer and incubated with AH peptide (Anaspec, San Jose, CA) at room temperature for 
at least 30 min. Stock AH peptide was prepared in dimethyl sulfoxide and diluted to 15 
mM in buffer. Prior to AFM imaging, surfaces were rinsed by successive 50 µL buffer 
exchanges. High resolution (512 x 512 points) topographical images were then collected. 
Antibodies were added to SLB samples between AFM scans by pipetting 20-50 µL of 
buffer containing antibodies to the water meniscus on the mica sample (ranging from 60-
120 µL). For experiments at 37 °C, a Thermal Applications Controller (Bruker, Santa 
Barbara, CA) was used to heat the sample. DI water was added to samples to 
compensate for water loss due to evaporation. Percent coverage of lipid domains and 
bound antibodies to SLB surfaces was calculated using height images analyzed with 
ImageJ software. Images were converted to grey scale and percent coverage was 
measured based on color thresholds. SLB RMS values (n=4) were calculated with 
NanoScope Analysis software. 
 
5.6.4 Surface Plasmon Resonance  
Surface plasmon resonance (SPR) measurements were performed on a BIAcore 
3000 (BIAcore Inc., Uppsala, Sweden) instrument. Antibody binding (100 ug/mL) was 
monitored in real-time at 25 oC with a continuous flow of PBS, pH 7.4 (Gibco Invitrogen, 
Grand Island, NY) at 20 μL/min for 2 min. For lipid surfaces, approximately 500 RU of 
liposomes were captured on a BIAcore SPR L1 chip. A blank in-line reference surface 
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was used to determine non-specific or bulk responses. Bound protein was removed from 
the liposome sensor surfaces following each cycle of antibody binding by octyl β-D 
glucopyranoside, and 5 s injections each of 5 mM HCl then 5 mM NaOH. BIAevaluation 
3.0 software (BIAcore Inc.) was used to determine Rmax values. A bivalent analyte model 
was used to fit the binding curves of 2F5/4E10-POPC:MPER interactions and a Langmuir 
1:1 model was used to fit the binding curves of all other antibody-membrane 
interactions. 
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Chapter 6. Conclusions and Future Research  
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6.1 Conclusions 
The research activities reported in this dissertation have advanced the design 
and synthesis of model membrane systems in an effort to contribute to HIV-1 vaccine 
development. By using substrates functionalized with thiol self-assembled monolayers 
(SAMs), we were able to mimic lipid surface chemistry, and identify functional groups 
that contribute to specific antibody-lipid interactions. We found that a hydrophobic 
SAM surface enables the distinction between neutralizing and non-neutralizing 
antibodies, both lipid reactive and non-lipid reactive, and thus is well suited as a 
screening platform for identifying antibodies that can replicate 2F5 and 4E10’s lipid 
reactivity. The unique hydrophobic reactivity of 2F5 and 4E10 supports the hypothesis 
that these NAbs embed into the hydrophobic membrane core, and suggests that 
immunogens designed to elicit 2F5/4E10-like antibodies may require an accessible 
hydrophobic lipid component.  
Since the accessibility of the hydrophobic membrane core is largely controlled by 
lipid type and membrane organization, we next tested NAb binding in the context of 
supported lipid bilayers (SLBs). To this end we developed a technique to create 
complex, high cholesterol-containing SLBs, using α-helical (AH) peptide-induced vesicle 
fusion. Specifically we used vesicles consisting of POPC:POPE:POPS:SM:CH (9.35 : 19.25 
: 8.25 : 18.15 : 45.00) to form a SLB that reflects the native composition of the human 
immunodeficiency virus-1 (HIV-1) lipid envelope. In the absence of AH peptides, these 
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biomimetic vesicles fail to form a complete SLB. We verified and characterized AH 
peptide-induced vesicle fusion by quartz crystal microbalance with dissipation 
monitoring (QCM-D), neutron reflectivity (NR), and atomic force microscopy (AFM). 
This vesicle fusion technique gives researchers access to complex SLB compositions with 
high cholesterol content and thus the ability to work with model systems that 
recapitulate the native HIV-1 lipid membrane. 
This SLB research platform was then used to visualize membrane domains, HIV 
antigen presentation, and HIV antibody-membrane interactions. Our results 
demonstrate that NAbs 2F5/4E10 do not interact with the highly ordered gel or Lo phase, 
but rather bind exclusively to the Ld phase. Thus, vaccine liposomes that contain a 
dominant Ld phase may provide improved selection of 2F5- and 4E10-like antibodies. 
However, our results also showed that the presence of vaccine antigen, MPER656 peptide, 
can severely limit the Ld area available for antibody interactions. Subsequently, this 
reduces the amount of MPER656 that is accessible for 2F5/4E10 binding, since MPER656 
preferentially localizes to the Ld area. If Ld forming lipid components are used in vaccine 
liposomes, it is important to ensure that the presence of antigen does not inhibit large-
scale Ld formation.       
In summary, this research has helped to advance the design and synthesis of 
model membrane systems, and has helped to gain a more complete, mechanistic 
understanding of the interaction of HIV-1 neutralizing antibodies 2F5 and 4E10 with 
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lipid membranes. Ultimately, this information can help guide HIV-1 vaccine 
development efforts. More broadly, this research contributes to the understanding of 
native lipid organization and progresses the understanding of more physiological 
relevant multi-component lipid membranes.  
 
6.2 Future Research  
There are two main areas of future work: (i) application and characterization of 
SLB model lipid systems, and (ii) continued HIV-1 vaccine related research.  
 
6.2.1 Application and Characterization of the SLB Model Lipid System  
There are many membrane properties and characteristics that have yet to be 
determined for phase-separated SLBs with multiple lipid types and high cholesterol 
content. Those of high importance include the effect of the membrane curvature on 
domain organization, and the effect of transmembrane proteins on lipid organization, 
and identifying physical properties of domains, including composition, thickness, and 
diffusivity.   
While planar SLBs are essential for quantitative surface-characterization 
techniques, they do not recapitulate the local and global curvature of the native HIV-1 
envelope, which could influence lipid organization.[199] To remedy this potential 
concern, it will be important to explore SLB formation on wrinkled oxidized 
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poly(dimethylsiloxane) (PDMS) surfaces.[200] The separation and height of the wrinkles 
can be precisely controlled from tens to hundreds of nanometers, which would allow the 
determination of protein-membrane interactions as a function of local substrate 
curvature. Such PDMS surfaces are ideally suited for SLB formation,[201] and are 
compatible with AFM imaging and fluorescence microscopy.[200]  
SLB research platforms often include important membrane proteins. As seen 
with the MPER antigen, inclusion of proteins in SLBs can have a dramatic effect on 
membrane organization. Although the SLBs used for this research were all formed on 
solid substrates (silica, gold, and mica), these substrates do not readily allow the 
inclusion of transmembrane proteins. A typical, solid-supported SLB has a hydration 
layer of 1–3 nm that separates the SLB from the substrate. This is often insufficient space 
for SLBs containing transmembrane proteins. The cytosolic domain of the protein could 
thus easily contact the substrate which would result in adhesion, deformation, and 
eventually denaturation. The use of polymer cushioned SLBs can overcome this problem 
by providing a low friction spacer layer that accommodates transmembrane proteins. To 
make the transition from complex solid supported SLBs to polymer supported SLBs it is 
necessary to first test the use of AH peptide-induced vesicle fusion on polymer 
substrates.    
With phase-separated SLBs is it important to understand the physical properties 
of each domain type. NanoSIMS, confocal microscopy in conjunction with fluorescently 
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tagged lipids, and force volume imaging using chemically functionalized AFM 
cantilevers, are important techniques that we have not yet utilized to provide structure-
function relationships. A high priority is also the identification of lipids within specific 
lipid domains when creating SLBs from multiple lipid types. While lipid domains 
inherently contain a composition different from that of the surrounding membrane, it is 
also likely that the lipid compositions in the upper and lower bilayer leaflet will 
differ.[161] This composition difference may be significant since only the upper leaflet is 
available to directly interact with antibodies. To detect asymmetry in our SLBs one can 
use sum frequency generation (SFG) spectroscopy, which is a highly surface sensitive 
characterization method.[202, 203] While the bulk phase of most materials does not emit 
sum frequency light, the asymmetry of a lipid bilayer will produce sum frequency 
signals. This inherent interface specificity can be used to probe the molecular leaflet 
arrangements in our SLBs. 
 
6.2.2 Continued HIV-1 Related Research 
There are many remaining questions on how lipid composition contributes to 
HIV neutralization and vaccine design. Open questions include: 
1. How does the density of MPER antigen contribute to domain 
organization? We observed that at 0.216 mol %, the presence of MPER 
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significantly reduced the Ld area in the model HIV SLB. Will this also 
occur at a lower concentration of antigen?   
2. Does the antigen disrupt domains in the model HIV SLB without 
cholesterol? If cholesterol is titrated into the SLB composition, at what 
concentration does MPER inhibit domain formation?    
3. Instead of localizing MPER to the Ld phase, can MPER’s membrane 
anchor be changed so it localizes to the Lo phase? Will NAbs then bind to 
MPER when it is surrounded by the Lo phase? What effect will CD4-
MPER binding have on domain localization?  
4. Can an SLB form large Ld areas while containing large amounts of 
cholesterol and antigen? Cholesterol is likely needed in vaccine liposomes 
to create sufficient liposome shelf-life and mechanical stability, while 
MPER antigen is required to elicit relevant antibodies. However, we 
showed that both cholesterol and antigen can inhibit Ld phase formation, 
the phase for which 2F5/4E10 exclusively bind. Thus, it should be a 
priority to discover a lipid composition that is able to contain cholesterol 
and antigen, but also large-scale Ld phase formation.  
5. Can SLB compositions be created that more accurately mimic current 
vaccine liposomes and the native HIV-1 envelope? Membrane 
components that could be added to our SLBs may include lipid A, native 
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lipid rafts, glycosylated lipids, and full length gp41 or gp160 peptides. To 
include, transmembrane HIV proteins within SLBs, it is likely that SLBs 
will need to be created on polymeric cushions. This provides further 
motivation to establish SLB formation techniques on polymer substrates.  
6. Neutralizing antibody, 10E8, interacts preferentially with the cholesterol-
rich, HIV-1-like membrane and has a weaker interaction to host 
membranes.[204] Will 10E8 interact with Lo domains?  
 
It is also a priority to use our research platform and methods to study not only 
2F5/4E10-viral membrane interactions but also other promising HIV-1 NAbs for which 
their epitopes are optimally expressed in the context of cell membranes.[205, 206] Potent 
neutralizing antibodies, VCRO1, PG9, and PG16, all have optimal antigen binding when 
their antigen is expressed within a cell membrane. Our SLB platform would allow us to 
extend our biophysical surface characterization techniques to help determine how and 
why these antibodies prefer membrane bound antigens. This information is significant 
for designing vaccine liposomes that could contain these membrane bound antigens for 
immunization studies.  
Finally, in order to validate current results and substantiate future research, it is 
essential to complete the following aim: Demonstrate that vaccine liposome 
compositions can contribute to antibody specificity.     
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This aim will validate that lipid compositions can dictate and contribute to 
antibody specificity. The research presented here provides the foundation for answering 
questions about which lipids should be used in vaccine liposomes for animal 
immunization studies, i.e., the transition from in vitro to in vivo experiments. 
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Appendix A. Membrane Screening Platforms Fabricated 
by Dip-Pen Nanolithography 
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A.1 Introduction  
Appendix A details progress towards fabricating a high-throughput 
phospholipid screening platforms using dip pen nanolithography (DPN). This research 
seeks to expand our SLB systems by writing lipid islands using DPN to generate a high-
throughput, array-based antibody screening platform. Currently, nanopatterned arrays 
of SLBs that contain different and complex lipid compositions cannot be achieved by 
vesicle fusion. The proposed screening platform will ultimately enable the efficient 
testing of multiple variables contributing to HIV-1 membrane organization, antigen 
distribution, and antibody binding in a single experiment under controlled conditions. 
Our approach is to first characterize high cholesterol containing lipid arrays 
prepared by lipid dip-pen nanolithography (DPN) in both liquid and in air. We also 
utilize α-helical (AH) fusion peptide to attempt to create HIV-1 mimetic domains within 
SLB islands created from dip pen nanolithography (DPN). This appendix will 
summarize progress achieved toward these objectives from research completed at 
Karlsruhe Institute of Technology under the guidance of Dr. Dr. Michael Hirtz. The 
results presented are preliminary and provide a basis for continuing these research 
objectives.  
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A.2 Background 
Dip pen nanolithography (DPN),[207] is a scanning probe based, parallel 
patterning technique. DPN can be used to pattern lipid bilayers and will thus enable the 
fabrication of combinatorial, high-throughput SLB screening platforms, amenable to 
testing membrane organization and NAb-lipid reactivity. Unlike other lithographic 
techniques, DPN is a direct-write “constructive” method that allows soft and hard 
materials to be printed from scanning probe tips on a surface from tens of nanometers to 
many micrometers in size. The technique works by delivering chemical or biological 
reagents (“inks”) to a substrate with nanometer precision. The tip, usually an AFM 
cantilever, is coated in ink and brought into contact with the substrate as a fluid 
meniscus forms between the tip and the surface. Ink molecules move through this 
meniscus to deposit onto the surface (depicted in Fig. A.1). Importantly, it is not 
necessary to modify the surface and DPN can be used to deposit multiple compounds, 
sequentially or in parallel, in a precise and exclusive manner. During the last decade, 
DPN has been developed to pattern a wide variety of inks, including small organic 
molecules[207, 208], polymers[209, 210], DNA[211, 212], proteins[212-214], 
antibodies[215], nanoparticles[216], and metal ions[217] which result in many diverse 
applications. The ability to pattern such biomolecules with nanometer precision is 
essential for a variety of biological applications including: studying cell surface binding 
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events[218], immobilizing antibodies for pathogen screening[215, 219], and deposition of 
therapeutic drugs on implantable biomaterials.[220] 
 
 
Figure A.1: Conventional dip-pen nanolithography. An AFM cantilever tip is coated 
with molecules in solution. As the tip travels across a substrate molecules are deposited 
through the fluid meniscus. Adapted with permission from reference [221]. Copyright 
(1999) Science. 
 
Our research will focus on using DPN’s ability to print lipids on substrates with 
nanoscale resolution to create monolayer and bilayer assemblies. Previous lipid 
DPN[222] research has mainly targeted applications toward biosensing[223-226] with a 
focus on analyte detection, functionalization, and quality control. This past research fails 
to characterize and control the structure and organization of lipid patterns in liquid. The 
ability of lipids to organize into domains and dictate membrane associated protein 
clustering is essential to the native cellular bilayer. Thus, it is crucial to create membrane 
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domains and achieve protein integration into SLBs upon DPN patterning if DPN is to be 
utilized as a research platform to model native membranes.  
SLBs formed from classical vesicle fusion are the standard for modeling cellular 
membranes. However, this classical SLB formation is inherently limited since it is 
difficult to control nanoscale patterning of the SLB or the ability to easily define different 
lipid composition on the same substrate. Thus, it is the focus of lipid DPN to be able to 
overcome those limitations. A DPN array-based lipid platform also eliminates 
experimental variations that typically arise when comparing results from substrates that 
use classical SLB formation. Since a DPN array of SLB compositions are tested on the 
same substrate, they are exposed to identical experimental variables such as 
temperature, protein concentrations, and washing conditions. SLBs are extremely 
sensitive to such experimental variations and the ability to eliminate these confounding 
variables insures any differences observed between tested variables are not influenced 
by experimental deviations.       
Although patterning domain-containing SLB islands with DPN is a relatively 
new concept, there are other, more established, methods of patterning SLBs. These 
techniques include robotic spotting,[227] ink-jet printing,[228] and microcontact 
printing.[201] While these techniques are established, they have many disadvantages 
compared to DPN, including limited reproducibility, residue transfer from stamps to 
substrates, molecular denaturation, and limited size resolutions. Importantly, these 
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techniques cannot obtain the lateral resolution of DPN. DPN lipid islands can range 
from tens of nanometers to micrometers in diameter. Spotting, ink-jet printing, and 
stamping can only achieve resolution on the order of tens of micrometers.[229] DPN’s 
nanometer resolution is essential since a major focus of lipid patterning is for cellular 
and viral interactions. Cell diameters are in the range of tens of micrometers and 
enveloped viruses are in the range of hundreds of nanometers. Thus, to target localized 
areas of cell and viral membranes, nanometer scale patterning of molecules (i.e., ligands) 
is required. Previous research has established that optimal spacing of cellular ligands 
that influence stress fiber formation, focal adhesion, cell motility, proliferation, and 
differentiation range from 10 nm to 500 nm.[230-232]  
To gain access to DPN capability and expertise, we have established a 
collaboration with Michael Hirtz (KIT, Karlsruhe, Germany). Dr. Hirtz is an expert in 
DPN and has already begun to focus on SLB formation from lipid DPN. Hirtz and 
colleagues have successfully patterned lipid islands consisting of a combination of an 
assembled lipid monolayer and bilayers (Fig. A.2). The schematic depiction of lipid 
assemblies in Figure A.2 can be seen in Figure A.3.     
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Figure A.2: Images of lipid stack structures in air with 20 mol % admixing of DNP Cap 
PE to DOPC as carrier ink obtained by AFM, FM, and SEEC microscopy (left to right, 
respectively). Scale bars = 20 µm. Adapted with permission from reference [233]. 
Copyright (2011) American Chemical Society.  
 
 
 
Figure A.3: Structural model for lipid membrane stacking. The three-layer membrane 
stack consists of a single monolayer as wetting layer and two bilayers. Adapted with 
permission from reference [233]. Copyright (2011) American Chemical Society. 
 
AFM, fluorescence microscopy (FM), and surface-enhanced ellipsometric 
contrast (SEEC) imaging revealed (i) a flat silicon oxide surface of the substrate, (ii) a 
first lipid layer approximating the height of a monolayer, (iii) a second lipid layer with a 
height of a single bilayer and (iv) a third lipid layer with a height of a single bilayer. The 
SEEC image profile shows optical thicknesses of 2.5 nm for the first layer, 5.0 nm for the 
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second layer, and 4.8 nm for the third layer. These images were taken in air, however, 
the dehydrated lipid structure is expected to be conserved upon exposure to water.[234, 
235] This research has initiated the effort to characterize and control the structure and 
organization of lipid DPN patterns. Further research is necessary, however, to enable 
lipid DPN to write biomimetic, domain containing SLBs in liquid.  
 
A.3 Results and Discussion 
To model the high concentration of sphingomyelin (SM) and cholesterol (CH) in 
the native HIV-1 envelope, the main lipid composition tested was DOPC:SM:CH with 
two different ratios of cholesterol, 18.25 and 30.00 molar %. The lipid ink wells and the 
multiplexed AFM cantilever array can be seen in Figure A.4. Sphingomyelin remained 
constant at 18.25 molar percent, which is the molar ratio recommended to mimic the 
amount of sphingomyelin in the native HIV-1 envelope. DOPC was used as a carrier ink 
and constituted the remaining molar percent of lipid. Thus, the molar ratios of lipid 
mixtures tested was DOPC:SM:CH (63.5 : 18.25 : 18.25) and DOPC:SM:CH (51.75 : 18.25 : 
30.00). All presented results are for these compositions unless specifically stated. 
Primary characterization of lipid DPN will be from atomic force microscopy (AFM) 
height and phase imaging in air and in liquid. Fluorescent imaging will be used to gain a 
macroscopic perspective on lipid DPN islands.  
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Figure A.4: Lipid ink well (lower half of image) and dip pen nanolithography cantilever 
array (upper half of image).  
 
A.3.1 Optimization of Lipid DPN Parameters 
Optimal lipid DPN writing on glass for both compositions occurs between 60 – 
70% writing humidity with 2.3 nm writing density for square patterns between 5-10 
micrometers in length.  These parameters helped achieve uniform pattern coverage 
while minimizing lipid spreading and maintaining as few lipid multilayers as possible.  
See the Methods section for complete details.  
Mica substrates were tested for lipid DPN in an attempt to minimize substrate 
effects on lipid organization (as seen with glass substrates, Fig. A.9), however, this was 
abandoned because, (i) it is difficult and time consuming to define an accurate plane 
when writing lipid patterns due to the highly curved mica samples, and (ii) the 
increased hydrophilicity of mica compared to glass requires different writing 
parameters to prevent mulitlayers and lipid spreading. Mica writing parameters for the 
lipid mixtures of interest have not been determined.     
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A.3.2 AFM Characterization of Lipid DPN in Air  
After imaging DOPC:SM:CH (63.50/51.75 : 18.25 : 18.25/30.00) islands in air there 
are three major results observed from AFM height and phase images; (i) height cross-
sections, (ii) halo effect, and (iii) the influence of cholesterol on lipid DPN writing.  
(i) Height Cross-sections:  Lipid DPN islands, in air, result in a base layer of lipids 
approximately 5 nm in height (Fig. A.5). Figure A.5 shows that there can be additional 
lipids on top of the base coverage that form a 5 nanometer height addition to the top of 
the base layer. When optimizing DPN writing parameters, it was the goal to achieve 
uniform coverage of only a 5 nm height difference between the lipids and the substrate. 
Within the base layer, small height differences, just less than 1 nm, can be observed at 
both the edges (Fig. A.6) and interior of the base layer (Fig. A.5D). It is possible that 
these areas indicate domain formation, however, this inference has not been proven or 
linked to the presence of sphingomyelin or cholesterol.  
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Height cross-section from C 
 
Height cross-section from D 
 
Figure A.5: AFM height images of lipid DPN islands in air. DOPC:SM:CH (51.75 : 18.25 : 
30.00) written at 60% humidity.  
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Figure A.6: AFM height image showing the height elevation on outer edge of DPN 
islands and patches of elevated lipids within the interior of DPN island. Height cross-
section given below the image.  
 
(ii) Halo effect: There is a presence of a faint circular ring, termed a halo, which 
appears to originate from DPN islands. This halo can be observed in both AFM height 
and phase images (Fig. A.7). This halo appears to be specific for islands that contain 
cholesterol since it is not observed in island containing solely phospholipids (images not 
shown). This halo may be important because if it contains cholesterol, then it suggests 
that the composition of the base layer lipid pattern contains less cholesterol then the 
original molar ratio of the lipid ink. The halo also appears to take the shape of the base 
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layer lipid island. In Figures A.7D,E the top of the island projects upwards into a small 
line of lipids. The phase image of Figure A.7E shows the halo wraps around this 
projection with the same width (lateral spread) as the main square island.   
 
 
Figure A.7: AFM height (A,B,D) and phase images (C,E), in air of lipid DPN islands 
demonstrating the halo effect.  
 
(iii) Influence of cholesterol on lipid DPN writing: As expected, the presence of 
cholesterol in lipid inks effects the transfer of lipids mixtures from the AFM tip to the 
substrate. As the molar ratio of cholesterol increases, the ink transfer from tip to the 
substrate decreases. This relationship can be observed in Figure A.8. 
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Figure A.8: AFM height images of DPN islands consisting of 30, 5, and 0 molar % of 
cholesterol (A,B, and C respectively). As the molar ratio of cholesterol increases, the lipid 
ink transfer from tip to the substrate decreases. All lipid compositions were written at 
60% humidity, on glass.  
 
Remaining questions to test and answer: Is the appearance of the 1 nm height 
differences due to domain formation? Is the presence of cholesterol in the lipid mixture 
responsible for the formation of this height difference? What is responsible for the 
appearance of the halo? Does the halo contain cholesterol?    
 
A.3.3 AFM Characterization of Lipid DPN in Liquid 
Characterization of lipid DPN islands in liquid resulted in eight major 
observations; (i) surface of bare glass in liquid, (ii) lipid smear from AFM imaging, (iii) 
dimples within base layer coverage, (iv) lipid DPN topography- with and without AH 
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fusion peptide, (v) blocking lipid DPN islands, (vi) antibody addition to DPN substrates, 
(vii) vesicle fusion versus DPN, and finally, (viii) lipid DPN island stability.  
(i) Clean, bare glass in liquid: AFM height images of bare glass substrates in liquid 
are first considered. As seen in Figure A.9, the glass surface results in patches with a 
height difference of approximately 1 nm. These patches resemble domains seen in 
planar supported lipid bilayers (SLBs), however, it is believed these patches do not 
contain lipids. Height images from a fresh AFM tip (Figs. A.9A,B) were compared to 
height images from a heavily used AFM tip (Figs. A.9C,D) which likely had lipids 
adhered to the surface of the tip. This comparison was made to confirm that lipid 
transfer from the tip to substrate was not responsible for creating the topography 
observed. Both test conditions give similar height images of bare glass. It should be 
noted that when clean, bare glass is imaged in air, a smooth surface is observed with no 
topographical features.    
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Figure A.9: (A,B) AFM height images from a fresh tip, imaging fresh glass in buffer 
(tapping mode). (C,D) AFM height images from a heavily used tip, imaging fresh glass 
in buffer (tapping mode). 
 
 (ii) Lipid smear from tapping mode: While imaging the edges of lipid DPN islands it 
was observed that lipids, with a very irregular height profile, occupied the area directly 
adjacent to the boundaries of the lipid DPN islands. It was determined that lipid 
smearing from the AFM tip contributed to the placement of these lipids adjacent to lipid 
islands. Using fluorescently tagged lipids (1 molar %) smearing could be observed only 
on islands imaged by the AFM (indicated by the red arrows in Fig. A.10). Lipids are 
transferred from the main DPN island to the surrounding glass substrate by the AFM 
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tip. There is no fluorescent smearing observed from islands that have not been imaged 
with the AFM (islands with no red arrow).  
 
 
Figure A.10: Fluorescent images of lipid DPN islands, DOPC:SM:CH (63.50 : 18.25 : 
18.25) with Rho-PE dye, taken at 63 x in liquid. The red arrows indicated islands that 
have been imaged by AFM tapping mode which results in lipid smearing. Lipids are 
transferred from the main DPN island to the surrounding glass substrate by the AFM 
tip.  
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(iii) Dimples within base layer coverage: Small holes, or dimples, about 20 nm in 
diameter regularly populate the base layer lipid coverage (Fig. A.11). Figure A.11A, is an 
image from a lipid mixture containing a 1:1 mixture of DOPC and POPE. Due to the 
small diameter of the holes, an accurate depth profile of the holes could not be 
determined. Currently, it is believed that these holes are a result of the underlying glass 
substrate. It is also noteworthy, that upon addition of AH fusion peptide, the holes still 
remained. Figure A.11B, was taken after AH fusion peptide was added and washed 
away.  
 
 
Figure A.11: (A) AFM height images showing regular arrangement of dimples on DPN 
island surfaces (DOPC:DOPE 1:1). (B) Height image of dimples after introduction and 
wash of AH fusion peptide.    
  
(iv) Lipid DPN topography- with and without AH fusion peptide: The topography of 
lipid DPN islands in liquid can be seen in Figures A.12 - A.15. Often the surface contains 
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holes from 5-15 nm deep, striations from the raster pattern of the AFM tip during 
written can be observed, and the area directly adjacent to the lipid DPN pattern often 
contains an irregular surface approximately the same height of the written DPN island. 
Upon addition of AH fusion peptide, the holes are closed and the irregular lipid 
organization adjacent to the written DPN island is merged with the main island to create 
a smoother, more uniform lipid surface (Fig. A.12). After AH peptide addition, patches 
within the main SLB are observed to be 1.5 nm tall (Fig. A.14).  
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Height cross-section from C 
 
 
Height cross-section from D 
 
Figure A.12: AFM height image of lipid DPN islands in buffer. DOPC:SM:CH (51.75 : 
18.25 : 30.00), 60% writing humidity.  Before and after images of AH fusion peptide 
addition from the zoomed in region from B. The corresponding height profiles are given 
below the height images. DOPC:SM:CH (51.75 : 18.25 : 30.00) 
 148 
 
Figure A.13: AFM height images before (A) and after (B) introduction of AH fusion 
peptide.  
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Height cross-section from B 
 
 
Height cross-section from D 
 
Figure A.14: (A-D) AFM height image of DPN islands in liquid after addition of AH 
fusion peptide, DOPC:SM:CH (51.75 : 18.25 : 30.00).  
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Height cross-section from A 
 
Figure A.15: AFM height images of lipid DPN islands in liquid. Height cross-section 
given below image.  
 
(v) Blocking lipid DPN islands: Blocking lipid DPN samples with bovine serum 
albumin (BSA) was performed to experiment with preventing lipid smearing and non 
specific binding of antibodies and AH fusion peptide to the glass substrate (Fig. A.16). 
While using height images to search for and image lipid DPN islands it was difficult to 
identify the location of the islands. The BSA blocking created a layer on the glass 
substrate that closely matched the height of the lipid DPN islands, thus, creating very 
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little height contrast between the lipid island and the background. The lipid islands 
could only be clearly identified in phase contrast (Fig. A.16B).  
 
 
Figure A.16: (A) AFM height image, and (B) phase image of lipid DPN islands that have 
been blocked with 5% bovine serum albumin (BSA).  
 
(vi) Antibody addition to DPN substrates: Figures A.17A-E shows the progression of 
added the AH fusion peptide, then 4E10 to DPN patterned surfaces. The image after the 
addition of AH fusion peptide (Fig. A.17B) has a reduced height contrast compared to 
the neat DPN island (Fig. A.17A) which suggests that the fusion peptide adheres to the 
glass substrate, raising the background height. Addition of 4E10 (Fig. A.17C) appears to 
adhere to the surrounding substrate since the image contrast is inverted when compared 
to the island with AH peptide (Fig. A.17B). As more 4E10 is added to the sample (Figs. 
A.17D,E), the height of the background grows taller and provided further height 
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contrast with the DPN island. No antibody addition to the DPN island can be detected 
(Fig. A.18). It should be noted that the concentration of antibody used in this experiment 
started at 4.6 µM, and raised to 46 µM, ten times the amount used to detect antibody-
lipid binding in SLBs created from vesicle fusion.   
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Figure A.17: AFM height images showing the result of AH fusion addition (A to B) and 
antibody, 4E10, addition. (C) one dose of 4E10 (0.3 mg/mL), and (D) after  three doses of 
4E10 (0.3 mg/mL). Each scan is about 15 minutes apart. Scan takes 8:30 minutes to 
complete, with about 7 minutes for the addition of antibody, incubation, and AFM setup 
to scan again.  DOPC:SM:CH (51.75 : 18.25 : 30.00), written at 70% humidity.  
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Height cross-section from A 
 
 
Height cross-section from C 
 
Figure A.18: Height image of the interior of DPN island before and after addition of 
antibody 4E10. Topography comparison of SLB created from vesicle fusion (left image) 
with lipid island created from DPN (Right image). Both techniques used a lipid 
composition of DOPC:SM:CH (63.50 : 18.25 : 18.25). Antibody was added in four dosages 
of 0.6 mg/mL each. The difference in color of the taller patches between the before and 
after image is due to a decreased set point (harder tapping force) when the “after” image 
was taken.  
 
Figure A.18 shows images of before and after 4E10 addition. No addition of 
antibody to the island can be detected. Antibody, 2F5, was also tested and the antibody 
was not detected on the DPN islands (images not shown). To confirm that the batch of 
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antibodies used had lipid reactivity, planar SLBs were created from vesicle fusion and 
screened for interactions with both 2F5 and 4E10. Both antibodies were observed to bind 
to the SLBs demonstrating the lipid reactivity of the antibodies.  
(vii) Vesicle fusion versus DPN: Figure A.18 compares the topology between 
supported lipid bilayers (SLBs) created from vesicle fusion (Fig. A.18C) and lipid islands 
created from DPN (Fig. A.18A). It is the goal of lipid DPN to create a lipid bilayer 
identical to the lipid bilayer created from vesicle fusion. However, major topological 
differences exist between the lipid structures resulting from each technique.    
(viii) Lipid DPN island stability: To test if the islands written from lipid DPN are 
stable and can resist washing (which occurs upon protein introduction to the sample) 
the interior region of a DPN patterned area was imaged, washed vigorously with a 
pipette, then re-imaged in the same location. No changes to the topology occurred, 
indicating that the patterned lipids are relatively stable in liquid.  
 
Remaining questions to test and answer:  
1) Is the regular appearance of the small holes, or dimples, in the base layer due 
to the glass substrate? Does a glass surface that is cleaned with a more 
aggressive technique (i.e., ozone or RCA solution) also result in these holes?    
2) Are the patches observed before/after AH peptide introduction domains? Are 
they dependent on the presence of sphingomyelin/cholesterol?  
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3) Can blocking with BSA prevent antibody adhesion to the glass substrate?  
4) Do antibodies adhere to a BSA substrate? 
5) Is there a more efficient way to correlate/identify which lipid islands were 
written with which AFM tips (pens) from the array of tips? 
6) What is the organizational structure of lipid DPN patterns? Why do they not 
resemble SLBs?  
7) What are diffusivities of lipid DPN patterns? - FRAP    
 
A.4 Conclusions  
While progress has been achieve towards understanding lipid DPN patterns in 
liquid, additional research needs to be completed to use lipid DPN platforms as an array 
platform for screening antibodies with lipid structures that mimic native cell 
membranes. Lipid DPN structures need to achieve a continuous bilayer formation and 
currently it is unclear what the resulting structures of lipid DPN patterns are. From 
these results, there are two major obstacles that must be overcome: (i) lipid DPN islands 
do not resemble the topology and domain formation of supported lipid bilayers (SLBs), 
a standard platform used for screening membrane-protein interactions, and (ii) lipid 
reactive antibodies that bind to SLBs have no detectable interactions with lipid DPN 
islands.  
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A.5 Materials and Methods 
For experiments using DPN, tip arrays were used to write lipid patterns ranging 
from 0.5 x 0.5 µm to 90 x 90 µm. Lipids were written on hydrophilic glass to facilitate 
SLB formation. Membrane components used for DPN ink included combinations of; 
POPC, DOPE, POPS, cholesterol, and sphingomyelin. Cholorform was used as a solvent 
to ink the DPN wells with lipids and antigen. Lipid DPN was written on glass samples 
using Nano Ink DPN 2000. DPN tips were inked at 70% humidity for 15 minutes. 
Optimal lipid DPN writing for both compositions occurs between 60 – 70% humidity 
with 2.3 um writing density for squares between 5-10 micrometers in length. Glass 
samples were cleaned by successive 5 minute sonication in chloroform, isopropanol, and 
water. Characterization of lipid DPN included fluorescent imaging, AFM imaging in air, 
and AFM imaging in liquid.  
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Appendix B. Protocols  
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B.1 AFM Parameters for Imaging Lipids Bilayers  
Imaging in Air:  
 Best cantilevers for tapping mode: Tap300 AI-G  (NSC 15 and AIBS from µmasch 
was recommended by KIT but were not tried.) 
 Spring constant: 40 N/m 
 Resonance: about 298 kHz  
 Set point: around 388 mV 
 Target amp: 500 mV 
 Nanoscope V controller 
 Mulitmode 8 with scan assist 
 J scanner   
 
Imaging in Liquid:  
 Best cantilevers for tapping mode: SNL-10 Bruker  
 Resonance: 33-34 kHz  
 Set point: 70-130 mV 
 Target Amp: 200 mV 
 Peak offset: 5% 
 Nanoscope V controller 
 Dimension Icon head with scan assist 
 
For SLB samples that will be used for both fluorescent and AFM analysis black 
double-sided tape must be used to secure glass samples to metal puck. When yellow 
double-sided tape was used the background illumination from the tape (Rhodamine) 
overpowered any fluorescent signal from the lipids.   
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B.2 AFM Fluid Cell and Sample Preparation  
This protocol is used to prepare samples being imaged in liquid. Take note that 
syringes, fluid ports, and o-ring assembly of the AFM liquid cell will not be used.   
1. Use a circlular Teflon puck, with an insert on the bottom to house metal disk 
(which is normally used for sample mounting).  
2. Clean Teflon puck in 2% SDS to maximize hydrophobicity of the Teflon surface.  
3. Use double sided sticky tape to mount the substrate (e.g., mica) to the Teflon 
surface. Insure the substrate is fully contained on the Teflon puck.  
4. Add sample (in liquid) to be imaged onto substrate surface. Add enough liquid 
(100-200 µL) to observe a rounded bead of liquid on the sample surface. The 
liquid should be contained to the substrate and should not spill onto the Teflon.  
5. Mount sample onto AFM scanner stage.  
6. Mount AFM cantilever to the fluid cell of the AFM. Place a small drop (20-50 uL) 
of liquid on the tip of the cantilever and mount inside the AFM head.  
7. Merge the liquid drop on the cantilever with the liquid on the sample by raising 
the sample until the liquid meniscus merge together. Continue to raise the 
sample until a stable liquid interface is formed.  
8. Locate laser and center on cantilever. Then tune the cantilever and approach 
surface to begin imaging.  
9. Due to the small amount of liquid, be aware of water loss due to evaporation, 
especially when the heater is used. Add distilled H2O (instead of buffer) to 
conserve salt concentrations.  
10. To add liquid (e.g., pure H2O or liquid containing proteins) separate the 
cantilever and sample surface without breaking the water meniscus. Then add 
liquid using a standard pipette. Monitor the total volume and be sure the liquid 
is not spilled off the substrate surface and onto/over the Teflon surface. Large 
Teflon surfaces better protect from spills.  
  
 161 
B.3 Quartz Crystal Cleaning 
This protocol was used to prepare quartz crystals for QCM-D experiments with 
bilayers (silica) and monolayers (hydrophobic gold). It was adapted from the Q-Sense 
D300 cleaning methods. 
 
New SiO2 crystal: 
1. UV/ozone 5 min 
2. Incubate in 2 wt % SDS for 30 min 
3. Sonicate in SDS for 3 min, power 3 
4. Rinse with ultrapure H2O, dry with N2 
5. UV/Ozone 10 min 
6. Sonicate in acetone 3 min, power 3 
7. Rinse excessively in ultrapure H2O, dry with N2. Use immediately. 
 
Used SiO2 Crystal: 
1. Start at step 2 in cleaning procedure above. 
 
Au Crystal: 
1.   Clean as per SiO2 crystals.  
2. Place cleaned crystals in heated solution of 5:1:1 ultrapure H2O: NH3OH:H2O2 (14 
ml in a beaker on a hot plate set to 190 °C to reach 70-75 °C in beaker). (5 parts 
H2O : 1 part Hydrogen Peroxide : 1 part Ammonium Hydroxide) for 5 minutes.  
- Rinse with DI H2O, dry with N2 
3. UV/Ozone 5 minutes. Rinse with acetone and ultrapure H2O. Dry under N2. 
4. Submerge immediately into 1 mM solution of octadecanethiol in ethanol. 
Incubate at least 12 hours in the dark. 
5. Sonicate 3 min at power 3 in thiol solution. 
6. Rinse with ethanol, dry under N2, and mount immediately into QCM-D chamber. 
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B.4 Lipid Film and Vesicle Preparation 
This protocol was adapted from David Boren (Duke Human Vaccine Institute). It 
was used to prepare lipid films and extruded lipid solutions for SLB experiments.  
 
Lipid Film Preparation: 
1. Take lipids out of -20 °C freezer for 45 minutes to equilibrate to room 
temperature (lipids should be clear when at room temperature). 
2. Pipette solutions in desired ratio into new test tube.  
3. Place test tube in holder in hood, and flow nitrogen over top until there is no 
visible liquid in vial. N2 pipette should not touch lipid solution. 
4. Fill ice bucket with dry ice. 
5. Submerge Erlenmeyer flask in dry ice and hook up to vacuum. 
6. When chloroform is mostly evaporated, turn off N2 flow and place lipid vial in 
vacuum spinner. Place balance vial opposite. 
7. Start rotation, then turn on spinner. 
8. Turn on vacuum pump. 
9. Wait at least 3 hours for lipids to dry. 
10. Turn off centrifuge and vacuum pump, then pull plug from flask to release 
vacuum seal on centrifuge. 
11. Remove lipid vial, cap with N2, and store at 4 °C. Use within a few weeks. 
 
Lipid Extrusion: 
1. Turn on water bath to 37°C, and place vial of lipid film filled with buffer in the 
water bath for 30 minutes. 
2. Vortex to help dissolve lipids. Sonicate for 2 minutes (without probe). Vortex. 
3. Dip 2 pieces of filter support in PBS, and place inside each of two O-rings on 
extruder. 
4. Place 0.4 µm filter film atop one O-ring, and close extruder capsule. 
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5. Place 1 mL PBS in “in” syringe, and pump through 4 times to saturate supports 
and film. 
6. Discard PBS. Pipette transfer lipid solution to a 15 mL centrifuge tube and then 
fill extruder syringe with lipid solution.  
7. Extrude 11 times, or more, insuring to end at an odd number of extrusion so the 
lipid solution is finished in the “out” syringe. 
8. Discard filter supports and membrane, and replace with fresh filter supports and 
0.08 µm membrane. 
9. The previous “out” syringe containing the 0.04 um vesicles becomes the new 
“in” syringe. Repeat step 7. 
10. Transfer lipid solution to clean screw-cap vial and use as soon as possible, within 
8 hours.  
11. To clean extruder, rinse thoroughly with degassed, filtered deionized H2O, and 
leave to dry in air. Rinse syringes 5 times with water, then 2 times with ethanol. 
Leave disassembled to air dry. 
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